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Pancreatic cancer is a dismal malignancy with a 5-year survival rate of 7-9%, one 
of the worst among all cancer types. Patients with pancreatic ductal 
adenocarcinoma (PDAC) usually present an advanced stage of the disease upon 
diagnosis and often develop chemotherapy resistance. As the disease progresses, 
patients are commonly administered a gemcitabine-based therapy, which is known 
for its clinical benefits, but also low response and concomitant high resistance rates. 
For this reason, the mechanism driving gemcitabine resistance has been 
extensively studied in pancreatic cancer. In fact, several gemcitabine metabolizing 
enzymes have been identified as prognostic, correlating with gemcitabine response 
rates in patient biopsies. Still, the molecular consequences of gemcitabine 
resistance in tumors remain elusive. Chemotherapeutic agents are known to not 
only act on their targets, but to also elicit stress and therefore trigger stress-induced 
apoptosis. Thus, it is plausible that chemotherapy resistance is not only mediated 
by a bypass of the pathway directly targeted by the chemotherapeutic agent, but 
also by an altered response to stress cues.  
In this study we investigated the molecular consequences of gemcitabine resistance 
in PDAC tumors. For this, a gemcitabine resistant cell line was established by 
treating treatment-naïve PDAC cells with increasing concentrations of gemcitabine. 
By studying the genomic, epigenomic and transcriptomic changes associated with 
acquired gemcitabine resistance, we identified a main driver of gemcitabine 
resistance and unraveled a novel mechanism employed by these tumors to 
overcome stress and activate alternative pathways. Copy number variation analyses 
revealed an amplification of a segment of chromosome 11, which included genes 
previously associated with gemcitabine resistance, such as Ribonucleotide 
Reductase Catalytic Subunit M1 (RRM1) as well as other genes, like Stromal 
Interaction Molecule 1 (STIM1). RRM1 is a known target of gemcitabine and 
proliferation studies confirmed that its amplification and upregulation drove 
gemcitabine resistance in our system. 
In order to elucidate further molecular mechanisms affected by acquired 
gemcitabine resistance, an epigenetic profiling of the cells was traced. This led to 
the identification of a dampened ER stress response in gemcitabine resistant 




responsive transcription factors, such as Activating Transcription Factor 4 (ATF4), 
while also displaying a drop in active transcription histone marks around ATF4 
binding sites and target genes. Interestingly, the stress response is tightly coupled 
to calcium signaling and an important ER calcium sensor, STIM1, was identified to 
be co-amplified with RRM1 in gemcitabine resistant cells. In fact, the co-
amplification of the neighboring genes, RRM1 and STIM1, was shown to have a 
high co-occurrence rate in different treatment naïve cancer cell lines as well as 
several primary tumors, suggesting it may also spontaneously occur in tumors.  
STIM1 is an ER calcium sensor, which upon ER calcium depletion interacts with the 
calcium channel ORAI calcium release-activated calcium modulator 1 (ORAI1). This 
stimulates the influx of calcium from the extracellular matrix into the cytosol, a 
process referred to as Store Operated Calcium Entry (SOCE). Interestingly, calcium 
measurements revealed that STIM1-amplifying cells displayed an increased SOCE, 
which in turn led to a dampened ER stress response. Moreover, this increase in 
SOCE elicited an aberrant activation of the Nuclear Factor of Activated T cells 
(NFAT) family of transcription factors. Finally, analysis of primary tumors as well as 
treatment-naïve and gemcitabine treated Patient-Derived Xenografts (PDXs) 
corroborated our findings in vivo.  
Taken together, our study characterizes molecular mechanisms driving gemcitabine 
resistance in PDAC and unravels the role of calcium signaling in these tumors.  
While the amplification of RRM1 drove gemcitabine resistance, the upregulation of 
STIM1 elicited a heightened SOCE leading to ER stress resistance and aberrant 
NFAT activation. Thus, STIM1 was identified as a rheostat balancing between ER 
stress-responsive and NFAT-driven epigenetic programs upon stress. Finally, we 
propose STIM1 as a novel therapeutic target for the treatment of gemcitabine 







1.1. PDAC incidence and prognosis 
Among all cancer types, pancreatic ductal adenocarcinoma (PDAC) patients face 
one of the worst prognoses with a 7-9% 5-year survival rate, mainly due to late 
diagnosis and chemotherapy resistance (American Cancer Society, 2020). While 
53% of the patients are diagnosed with a metastatic tumor, those patients who can 
undergo a tumor resection usually face a relapse in 1-2 years (American Cancer 
Society, 2020; Oettle et al., 2013). Thus, the understanding of PDAC and the study 
of alternative diagnostic and treatment options is of ultimate importance. 
1.1.1. Development of PDAC 
Several external risk factors, which include smoking, type 2 diabetes, obesity and a 
history of chronic pancreatitis, are associated with PDAC development (American 
Cancer Society, 2020; Kirkegård et al., 2018; Malka et al., 2002). After Vogelstein’s 
model for the development of colorectal cancer (Faeron and Vogelstein, 1990), 
Hruban et. al proposed a model for PDAC development. In this model, the pancreas 
first presents ductal lesions, pancreatic intraepithelial neoplasms (PanINs), which 
evolve from a low-grade lesion, with minimal atypia to high-grade lesions with severe 
cytological and architectural atypia. These lesions are initially non-invasive, but later 
develop into adenocarcinoma as they accumulate mutations over time (Fig. 1) 
(Distler et al., 2014; Hruban et al., 2000). Low grade PanINs are characterized by 
K-RAS mutations, which lead to a constitutively active signaling cascade and only 
progress to invasive pancreatic cancers when followed by silencing of tumor 
suppressors (Buscail et al., 2020; Di Magliano and Logsdon, 2013). After K-RAS 
mutation, 90% of the lesions present a loss of heterozygosity or silencing of the 
tumor suppressor, CDKN2A (Rozenblum et al., 1997). It was suggested that the K-
RAS mutation alone leads to senescence, but upon silencing of CDKN2A, a key 
regulator of the G1/S-phase transition in cell cycle, the cells are able to overcome 
this and undergo cell cycle. This allows for a fast cell proliferation and further 
promotes tumor formation (Tu et al., 2018).  
Later in PDAC development, the tumor suppressor genes TP53 and SMAD4 are lost 





of mutations, shortening of telomeres and increased reactive oxygen species (ROS) 
levels, which would normally trigger a p53 dependent DNA-damage response, cell 
cycle arrest and apoptosis. Thus, the loss of TP53 allows cells to proliferate even 
under aberrant events (Hezel et al., 2006). While the ablation of TP53 is essential 
for cell cycle progression, the consequences of SMAD4 loss are still under 
investigation. Some studies propose that in the presence of a mutated K-RAS, loss 
of SMAD4 leads to accelerated fibrosis, loss of acinar cells and neoplastic changes 
(Bardeesy et al., 2006; Kojima et al., 2007). Taken together, the loss of tumor 
suppressor genes together with mutations in oncogenes allow PanIN lesions to 
develop into carcinomas.  
Furthermore, it has been shown that misregulation of several other transcriptional 
regulators drive the development of lesions and initiation of carcinomas. One such 
example is KLF4, which together with K-RAS stimulates the formation of PanINs 
promoting their reprogramming and plasticity (Wei et al., 2016). GLI1 is also required 
for K-RAS driven PanINs and accelerates tumor formation by activating NF-κB 
signaling (Nolan-Stevaux et al., 2009; Rajurkar et al., 2012). PRRX1B has been 
shown to be upregulated in PanINs being associated with increased proliferation 
and a first de-differentiation step from epithelial cells to more invasive carcinoma 
cells. While PRRX1B was not found to promote metastasis and a more aggressive 
oncogenic phenotype, the other isoform, PRRX1A, has been shown to promote EMT 
in PDAC and was found to be upregulated in metastatic cancer cells (Reichert et al., 
2013; Takano et al., 2016). In conclusion, genetic aberrations accompanied by 
transcriptional misregulation drive PDAC initiation and development, while also 





















1.1.2. PDAC heterogeneity and subtypes 
Transcriptomic analysis of PDAC revealed the tumors’ high heterogeneity and 
context dependency. In an attempt to first classify adenocarcinomas for a better 
targeted therapy, Collisson et al. microdissected and profiled 27 resected PDAC 
tumors. The authors identified 62 genes, which were intrinsically variably expressed 
and conferred different properties to these tumors. This gave rise to three molecular 
subtypes termed: classical, quasimesenchymal (QM) and exocrine-like. While the 
classical subtype was characterized for being more dependent on the transcription 
factor GATA6 and having higher expression of epithelial and cell adhesion genes, 
the QM subtype enriched for mesenchymal genes. The exocrine-like subtype 
comprised digestive enzyme genes and could not be verified in further cell culture 
and mice studies, raising the possibility that it originates from contaminating tissues, 
from the stroma or normal pancreatic cells (Collisson et al., 2011). 
A further study by Moffitt et al. not only subtyped PDAC tumors, but also 
characterized the tumor stroma and metastases. PDAC was classified into classical 
and basal-like, where the classical signature greatly overlapped with the classical 
signature defined by Collisson et al. The basal-like subtype showed a more 
aggressive phenotype and was found to be enriched in metastases. The stroma was 
classified into activated and normal stroma, characterized by a more inflammatory 
environment and better prognosis, respectively. Interestingly, the basal-like, normal 
Fig. 1 PDAC development model. The scheme shows the progression of a normal 
pancreas into a low grade PanIN to a high grade one and finally to PDAC. The mutation 
of K-RAS and silencing of CDKN2A, p53 and SMAD4 are essential for the development 


















and activated stroma signatures included genes comprised in QM signature defined 
by Collisson et al. (Moffitt et al., 2015). 
A third classification based on gene expression and tumor histology identified the 
following subtypes: squamous, pancreatic progenitor, immunogenic and aberrantly 
differentiated endocrine exocrine (ADEX). The squamous subtype showed the worst 
prognosis and was characterized by the upregulation of the transcription factor 
ΔNp63, while early development transcription factors were enriched in the 
pancreatic progenitor subtype. The ADEX subtype comprised genes involved in 
exocrine and endocrine differentiation and the immunogenic subtype upregulated 
genes involved in immune suppression. When compared to the Collisson et al. 
classification, the squamous signature correlated with the QM subtype, while the 
classical signature comprised the ADEX and pancreatic progenitor subtypes. The 
immunogenic signature did not correlate with any previously reported subtype 
(Bailey et al., 2016).  
In an attempt to validate the several subtype classifications, Raphael et al. 
molecularly characterized and classified 146 resected tumors as low or high purity 
samples. Low purity tumors comprised the exocrine-like, QM, ADEX and 
immunogenic subtypes, suggesting that these arise mainly due to impurities, such 
as high stroma content, present in the microdissection samples. High purity samples 
comprised the squamous/basal-like and the classical/pancreatic progenitor 
subtypes, further validating these classifications (The Cancer Genome Atlas 
Research Network et al., 2017). 
Chan-Seng-Yue et al. further stratified the basal-like and classical signatures into 5 
subtypes: basal-like A and B, classical A and B and hybrid. The signatures of basal-
like A and B overlapped with the previously defined basal-like signature from Moffit 
et al. The same is true for the classical A and B signatures and the published 
classical subtype by Moffitt et al. The hybrid subtype comprised several distinct 
expression profiles and was most likely a mixture of basal-like and classical tumor 
cells. Generally, classical A and B signatures were found in early stage PDAC, and 
late stage PDAC was mainly composed of basal-like A tumors. Basal-like B and 





Interestingly, several independent studies have observed that even though 
intratumor heterogeneity may be high, such that one tumor may be comprised of 
several subtypes, metastatic tumors were mainly comprised of one specific subtype 
and that chemotherapy response was also highly subtype dependent. There is a 
consensus that most liver metastases are basal-like even if originating from a tumor, 
which is of a different subtype (Chan-Seng-Yue et al., 2020; Ligorio et al., 2019; 
Makohon-Moore et al., 2017; Moffitt et al., 2015). This suggests that metastatic cells 
face a higher selective pressure imposed by extrinsic factors than primary tumors. 
Very limited data is available on the subtype of metastases after chemotherapy. 
Chan-Seng-Yun were the first to report the switch of a basal-like B metastasis to the 
classical A subtype after adjuvant treatment (Chan-Seng-Yue et al., 2020). 
Regarding chemotherapy response, Collisson et al. reported that QM cell lines were 
more sensitive to gemcitabine, while erlotinib was more effective in classical 
carcinomas in vitro (Collisson et al., 2011). Moffitt et al. further showed that patients 
with basal-like tumors presented a better response to adjuvant therapy, while Chan-
Seng-Yun found that basal-like A tumors were more chemoresistant and basal-like 
B, classical A and B and hybrid carcinomas more sensitive to chemotherapy (Chan-
Seng-Yue et al., 2020; Moffitt et al., 2015). In accordance with that, Aung et al. 
reported that patients with classical PDAC responded better to FOLFIRINOX (Aung 
et al., 2018) and Kloesch et al. showed that a loss of the classical driver GATA6 
confers tumor resistance to 5-FU and gemcitabine (Kloesch et al., 2020). Taken 
together, PDAC tumors are composed of several subtypes, which can be selected 
for during disease progression as well as by chemotherapy treatment. Still, currently, 
the same chemotherapeutic agent is applied to all subtypes, regardless of their 
specific vulnerabilities. 
1.1.3. Standard PDAC treatment 
PDAC treatment includes tumor resection, radiation and chemotherapy. While 40% 
of the patients present a locally advanced tumor without metastases, less than 20% 
classify for tumor resection and 30-40% of the patients display metastatic tumors 
(American Cancer Society, 2020; Ryan and Mamon, 2020a). Patients qualifying for 
resection present relatively small tumors, without metastases and distant major 





tumor is local, but does not entirely fulfill all of these requirements or is too big, it is 
classified as borderline resectable. Recently, more and more patients with locally 
advanced and borderline resectable tumors are administered neodjuvant therapy 
with or without chemoradiotherapy prior to surgical reevaluation (Ryan and Mamon, 
2020b). 
Neodjuvant treatment consists of combination treatments including gemcitabine with 
nab-paclitaxel and FOLFIRINOX (5-FU, leucovin, irinotecan and oxaliplatin). The 
treatment lasts for six months and can be followed by an additional round of 
radiochemotherapy. Afterwards, the patient’s health condition and tumor are re-
evaluated and tumors may be resected. After surgery, patients receive another six 
months of adjuvant therapy. In this case, patients displaying good health conditions 
are administered FOLFIRINOX, while secondary treatment options include 
gemcitabine with capecitabine, gemcitabine alone or S-1 (tegafur, gimeracil and 
oteracil) alone. Following, patients who previously received gemcitabine-based 
therapies are recommended to undergo an additional six months of 
chemoradiotherapy. This is not recommended in the case of adjuvant FOLFIRINOX 
treatment, as it is unknown, whether the patients can handle chemoradiotherapy 
following FOLFIRINOX treatment (Ryan and Mamon, 2020b). If, after neoadjuvant 
treatment, locally advanced and borderline resectable tumors do not qualify for 
surgical removal, patients may continue chemotherapy, receive alternative 
chemotherapeutic agents or enter clinical trials (Ryan and Mamon, 2020a). 
For patients facing a relapse and/or a metastatic tumor and an Eastern Cooperative 
Oncology Group (ECOG) Performance Status (PS) of 0-1, first-line therapy options 
include FOLFIRINOX, FOLFOX (5-FU, leucovin and oxaliplatin) or gemcitabine in 
combination with nab-paclitaxel (Conroy et al., 2011). In fact, FOLFIRINOX and 
FOLFOX are preferred over gemcitabine and nab-paclitaxel as gemcitabine is 
metabolized in the liver and thus presents higher hepatic toxicity. Still, patients 
presenting an ECOG PS of 2 qualify for second-line therapy options such as S-1 
alone, gemcitabine alone, gemcitabine with S-1 or gemcitabine with capecitabine. 
Even though the response rate to gemcitabine treatment is low and the hepatic 
toxicity high, gemcitabine-based therapies are preferred in this case, due to the 
clinical benefit to patients (Rothenberg et al., 1996). Furthermore, although 





have shown worse side effects and no changes in overall survival, the response rate 
was significantly increased when compared to gemcitabine treatment alone 
(Cunningham et al., 2009; Herrmann et al., 2007; Nakai et al., 2012; Ueno et al., 
2013). S-1 treatment alone is currently emerging as an alternative to gemcitabine-
based therapies. It is particularly attractive due to lower hematologic toxicity, better 
objective response rate and similar overall survival when compared to gemcitabine 
(Ueno et al., 2013). Still, availability to S-1 is limited to Japan and Europe, as it 
remains unavailable in the US (Ryan, 2020a). Thus, as PDAC progresses, patients 
are likely administered gemcitabine-based therapies, which present low response 











1.1.4. Gemcitabine metabolism and mechanism of action 
As described previously, most PDAC patients receive a gemcitabine-based therapy 
during cancer treatment. Gemcitabine is a deoxycytidine analog (2’,2’-
difluorodeoxycytidine, dFdC), which is transported into the cell and metabolized 
analogously to deoxycytidine. Its metabolic intermediates affect DNA replication by 
stalling DNA Polymerase and interfere with de novo deoxynucleotide synthesis (Fig. 
3) (De Sousa Cavalcante and Monteiro, 2014; Wong et al., 2009).  
First gemcitabine is actively transported into the cell, as it is highly hydrophilic and, 
for this reason, cannot diffuse through the plasma membrane. Two different types 
Fig. 2 PDAC treatment options. Scheme depicting standard PDAC treatments. Tumors 
qualifying for resection are removed and adjuvant therapy is employed. For locally 
advanced and borderline resectable tumors, patients undergo neoadjuvant and adjuvant 
therapy prior and after resection, respectively. Metastatic and recurrent tumors are treated 
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of transporters, the concentrative and equilibrative nucleoside transporters (NT) 
import gemcitabine. While the concentrative NT (CNT) depends on transporting the 
nucleoside against the concentration gradient at the exchange of sodium ions, the 
equilibrative NT (ENT) is bidirectional and transports nucleosides following the intra- 
and extracellular nucleoside concentrations (Mackey et al., 1998a). Most of 
gemcitabine is taken up by the human equilibrative nucleoside transporter 1 
(hENT1) and to a lesser extent by the human equilibrative nucleoside transporter 2 
(hENT2) and the human concentrative nucleoside transporters 1 and 3 (hCNT1 and 
hCNT3) (García-Manteiga et al., 2003; Mackey et al., 1998b, 1999; Ritzel et al., 
2001). 
Once inside the cell, gemcitabine is mono- (dFdCMP), di- (dFdCDP) and 
triphosphorylated (dFdCTP) by deoxycytidine kinase (dCK), pyrimidine nucleoside 
monophosphate kinase (CMPK) and possibly by nucleoside diphosphate kinase 
(NDPK), respectively. The monophosphorylation of gemcitabine by dCK being the 
rate-limiting step in gemcitabine anabolism (Bouffard et al., 1993; Hatzis et al., 1998; 
Heinemann et al., 1988; Van Rompay et al., 1999; Wong et al., 2009). This opens a 
window of opportunity for the cell to mitigate the effects of gemcitabine, by 
employing cytosolic 5’-nucleotidase 1A (NT5C1A) to dephosphorylate 
monophosphorylated gemcitabine. As the dephosphorylation is much faster than the 
monophosphorylation step by dCK, the amount of metabolized and cytotoxic 
gemcitabine products is reduced (Hunsucker et al., 2001, 2005). Furthermore, 
gemcitabine can be deaminated by cytidine deaminase (CDA) into 2’,2’-
difluorodeoxyuridine (dFdU) becoming inactivated in the cell (Heinemann et al., 
1992; Xu and Plunkett, 1992). 
Regarding targets, gemcitabine affects nucleotide metabolism as well as DNA 
replication. Monophosphorylated gemcitabine can be deaminated by 
deoxycytidylate deaminase (DCTD) being converted into 2’,2’-difluorodeoxyuridine 
monophosphate (dFdUMP). This compound inhibits thymidylate synthase (TS) 
affecting deoxynucleotide triphosphate (dNTP) pools (Bergman et al., 2000; 
Heinemann et al., 1992; Xu and Plunkett, 1992). Diphosphorylated gemcitabine 
further affects deoxynucleotide metabolism by inhibiting ribonucleotide reductase 
(RNR) and preventing the enzyme from reducing ribonucleotide diphosphates 





key enzyme in dNTP synthesis and is composed by two homodimeric subunits. The 
dimer formed by ribonucleotide reductase catalytic subunit M1 (RRM1) contains the 
catalytic subunits and binds a second smaller dimer formed by either ribonucleotide 
reductase regulatory subunits M2 (RRM2) or ribonucleotide reductase regulatory 
TP53 inducible subunit M2B (RRM2B) subunits. RRM2 and RRM2B contain an iron-
sulfur cluster, which stores the reducing equivalents used during catalysis by RRM1. 
They are also highly allosterically regulated by ATP and all dNTPs (Reichard, 1997; 
Stubbe, 2003; Uhlin and Eklund, 1994). The inhibition of RNR by diphosphorylated 
gemcitabine has severe consequences for the cell, as dNTP pools are drastically 
reduced, while, in a compensatory mechanism, available deoxynucleosides and 
gemcitabine are increasingly triphosphorylated (Heinemann et al., 1990). This then 
intensifies the cytotoxic effects of gemcitabine in the cell increasing the pools of 
triphosphorylated gemcitabine and thus its chances of being incorporated into DNA. 
Upon incorporation of triphosphorylated gemcitabine into DNA, DNA Polymerase is 
able to incorporate one additional dNTP before stalling. DNA repair mechanisms are 
unable to remove triphosphorylated gemcitabine at the internal as well as at the 3’ 
end position, triggering cell cycle arrest and finally apoptosis (Huang et al., 1991). 
This way, gemcitabine not only impairs DNA replication, but also inhibits key 



































1.1.5. Gemcitabine resistance in PDAC 
Even though chemotherapy, specially gemcitabine, is widely administered to PDAC 
patients, a very small fraction of these patients responds to treatment. When first 
undergoing clinical trials, gemcitabine was extremely attractive compared to 5-FU 
as 24% of gemcitabine-treated PDAC patients profited from clinical benefits 
compared to 5% of 5-FU-treated patients. The median survival rate for gemcitabine-
treated patients also slightly increased to 5.65 months compared to 4.41 months for 
5-FU-treated patients (Burris et al., 1997). Unfortunately, response rates to 
gemcitabine were low, with 89% of the patients not responding to gemcitabine 
treatment and facing chemotherapy resistance (Casper et al., 1994). Gemcitabine 
resistance is suggested to arise due to extrinsic and intrinsic factors, these being 
the tumor stroma and the rewiring of gemcitabine metabolism in cancer cells, 
respectively (Amrutkar and Gladhaug, 2017; De Sousa Cavalcante and Monteiro, 
2014).  
Regarding extrinsic factors, the exact role of the tumor stroma in chemotherapy 
resistance is still under investigation. The stroma of pancreatic cancer is known to 
account for up to 90% of the tumor volume and is suggested to hamper drug delivery 
and/or scavenge chemotherapy. It is composed of an extracellular matrix rich in 
hyaluronic acid, fibronectin, secreted protein acidic and rich in cysteine (SPARC) 
and collagens, cancer-associated fibroblasts (CAFs), inflammatory cells and blood 
vessels. Key signaling pathways, such as TGFβ and Hedgehog, foster tumor as well 
as stromal growth and tumor differentiation (Ligorio et al., 2019; Neesse et al., 
2011).  
In fact, combinatory targeting of the Hedgehog pathway with gemcitabine 
administration has shown very promising results. In a mouse model, Olive et al. 
Fig. 3 Gemcitabine metabolism and targets. Gemcitabine is mainly imported by hENT1, 
but also by hENT2, hCNT1 and hCNT3. It is later monophosphorylated (dFdCMP) by dCK, 
diphosphorylated (dFdCDP) by CMPK and finally triphosphorylated (dFdCTP) possibly by 
nucleoside diphosphate kinase. Gemcitabine is deaminated by CDA being inactivated in 
the cell in the form of dFdU. dFdCMP is also deaminated by CDTD and its product inhibits 
thymidylate synthase (TS). dFdCDP inhibits ribonucleotide reductase, significantly lowering 
the dNTP pool in the cell. dFdCTP stalls DNA Polymerase shortly after being incorporated 






showed that by inhibiting the Hedgehog pathway and co-treating with gemcitabine, 
the stroma was reduced, while the tumor showed a higher vascularization. This 
allowed for a better drug delivery and chemotherapy response. Unfortunately, the 
stroma quickly became resistant to Hedgehog inhibition, growing back and impeding 
gemcitabine delivery after 2 weeks of co-treatment (Olive et al., 2009). Reduced 
fibrosis upon Vitamin-D receptor activation and depletion of hyaluronic acid and 
collagen have also led to increased drug delivery and response in mouse models 
(Chauhan et al., 2013; Jacobetz et al., 2013; Provenzano et al., 2012; Sherman et 
al., 2014). Still, in a different study, SPARC levels did not correlate with overall 
survival and response to gemcitabine or gemcitabine and nab-Paclitaxel treatment 
in patients (Hidalgo et al., 2015). Furthermore, the stroma volume was only 
indicative of chemotherapy response rates in patients after accounting for the 
expression of gemcitabine transporters, such as hENT1, in tumors (Koay et al., 
2014a, 2014b). Thus, whether the tumor stroma provides an effective physical 
barrier to gemcitabine is still under debate. Still, another role has been accredited to 
the stroma, this being that of scavenging gemcitabine. Higher levels of active, 
triphosphorylated gemcitabine (dFdCTP) were found in CAFs compared to tumor 
cells, while the opposite was true for levels of inactive, deaminated gemcitabine 
(dFdU). Stromal cells also expressed lower levels of gemcitabine inactivating 
enzymes, suggesting that they, rather than tumor cells, are more affected by 
gemcitabine treatment (Hessmann et al., 2018). 
Even though the role of the stroma in chemotherapy resistance is still under debate, 
it is clear that the expression levels of gemcitabine targets and metabolic enzymes 
are key in gemcitabine resistance. Levels of the nucleotide transporter proteins, 
hENT1 and hCNT1, in naïve as well as gemcitabine treated patients and cell lines 
correlated with gemcitabine response (Bhutia et al., 2011; Farrell et al., 2009; Mori 
et al., 2007; Spratlin et al., 2004). High dCK levels have also been associated with 
better overall survival and gemcitabine responsiveness in patients (Kroep et al., 
2002; Maréchal et al., 2010; Sebastiani et al., 2006). This indicates that the rate-
limiting steps of gemcitabine uptake and metabolism are key for patients’ response 
to gemcitabine-based therapy. Taken together, dCK and hENT1 have been 





Gemcitabine inactivating enzymes, such as CDA and NT5C1A, have also been 
shown to play an important role in gemcitabine resistance. In neuroblastoma, CDA 
levels have been shown to negatively correlate with gemcitabine response, while in 
ovarian cancer, this observation did not hold (Ferrandina et al., 2010; Ogawa et al., 
2005). Furthermore, CDA levels varied greatly in human tumor xenografts of 
pancreatic, lung, colorectal, ovarian and head and neck tumors upon gemcitabine 
treatment (Kroep et al., 2002). More recently, a study has shown that tumor 
associated macrophages induce the upregulation of CDA in PDAC cells, conferring 
gemcitabine resistance to the tumor (Weizman et al., 2014). NT5C1A is also robustly 
expressed by PDAC patients and its overexpression in PDAC mouse models as well 
as HEK293T cells resulted in increased gemcitabine resistance (Hunsucker et al., 
2001; Patzak et al., 2019). 
Ribonucleotide reductase levels have also been associated with gemcitabine 
resistance, although its prognostic value is still under debate. In gemcitabine 
resistant cell lines, an overexpression of RRM1 has been reported to drive 
gemcitabine resistance (Nakahira et al., 2007; Nakano et al., 2007; Wang et al., 
2015; Zhou et al., 2019). In vivo studies confirmed this finding, identifying RRM1 as 
the most highly overexpressed gene in gemcitabine resistant tumors, being 
upregulated by 25-fold (Bergman et al., 2005). Still, the prognostic value of RRM1 
remains under debate, as one study reported a negative correlation between RRM1 
levels and gemcitabine responsiveness in patients, another study described  a 
positive correlation and a third patient study did not corroborate any of these findings 
(Akita et al., 2009; Aoyama et al., 2017; Maréchal et al., 2012). Taken together, 
gemcitabine resistance in PDAC is primarily driven by the up- and downregulation 
of target and metabolic genes, while also being modulated by the stroma’s 
scavenging ability and physical barrier. 
1.2. The Integrated Stress Response (ISR) 
Many chemotherapeutic drugs are known to not only act on their specific targets, 
but to also trigger a more general cellular stress response. Furthermore, due to the 
hypoxic and nutrient deprived environment of tumors, cancer cells experience 
chronic stress (Avril et al., 2017). The integrated stress response (ISR) is activated 





deprivation and the accumulation of unfolded proteins in the endoplasmic reticulum 
(ER) signaling ER stress. It converges at the halt of global cap-dependent 
translation, achieved by the phosphorylation of the eukaryotic translation initiation 
factor 2 alpha subunit (eIF2α). This leads to the cap-independent translation of the 
activating transcription factor 4 (ATF4), which can then fine-tune the stress 
response, triggering the transcription of pro-survival genes and, if the cell fails to 
respond, of apoptotic genes (Fig. 4) (Pakos‐Zebrucka et al., 2016).  
 
1.2.1. ISR in pancreatic diseases 
The ISR is of great importance in the pancreas, playing a role in insulin-secreting 
pancreatic β cells, acute and chronic pancreatitis and possibly in pancreatic cancer. 
It is the main trigger of type I diabetes, where the pancreas produces little or no pro-
insulin. Because glucose levels are constantly fluctuating in pancreatic β cells, pro-
insulin production in the ER is accordingly highly variable. This can cause an acute 
accumulation of unfolded pro-insulin in the ER, triggering ER stress. Furthermore, 
Fig. 4 An overview of the integrated stress response. Different sources of stress activate 
their respective stress kinase, which phosphorylates eIF2α, shutting down cap-dependent 
translation and activating ATF4. ATF4 promotes the transcription of stress responsive pro-





mutations in the insulin coding region can prevent proper protein folding in the ER, 
also leading to the accumulation of unfolded pro-insulin and ER stress. For these 
reasons, it is crucial that pancreatic β cells express robust amounts of ISR sensors 
and mediators to properly cope with such stresses; activating the pro-survival 
branch of the ISR and, only if needed, undergoing apoptosis. Several studies have 
shown that mutations in ISR components can lead to a failure in the stress response, 
increased apoptosis of pancreatic β cells and, consequently, to type I diabetes 
(Harding et al., 2001; Ladiges et al., 2005; Wang et al., 1999).  
A very similar phenomenon is found in pancreatic acinar cells that produce and 
secrete digestive enzymes, such as trypsinogen and chymotrypsinogen, and, when 
malfunctioning, can trigger acute and chronic pancreatitis. In pancreatitis, acinar 
cells fail to properly fold, post-translationally modify, package and/or secrete 
digestive enzymes. This leads to an early intrapancreatic activation of these 
enzymes and consequently to the digestion of the pancreas followed by 
inflammation (Gukovskaya et al., 2019; Habtezion, 2015; Pandol et al., 2007). 
Several studies have shown that in the early stages of pancreatitis development, 
mice presented an increase in the stress response, more specifically in ER stress 
response (Kubisch et al., 2006; Logsdon and Ji, 2013; Lugea et al., 2012; Sah et 
al., 2014; Waldron et al., 2018) . Thus, again, the correct folding of digestive 
enzymes is crucial for proper functioning of acinar cells and a robust and functional 
ER stress response is critical to resolve this. Mutations in trypsinogen and 
trypsinogen inhibitor proteins have been shown to lead to an accumulation of 
unfolded proteins in the ER, triggering ER stress and predisposing people to 
pancreatitis (Hegyi and Sahin-Tóth, 2019; Teich et al., 2006).  
The role of the ISR in pancreatic cancer is not as well characterized as in pancreatitis 
and diabetes, but the ISR is commonly hijacked in several cancer types and there 
are some suggestions that ER stress may contribute to gemcitabine resistance. In 
general, the tumor microenvironment is highly deprived of nutrients and oxygen, 
thus it is common that cancer cells activate the ISR. In fact, during nutrient 
starvation, tumors activate the ISR and are able to, this way, maintain amino acid 
homeostasis. Furthermore, nutrient starvation promotes a metabolic plasticity 
triggered by the ISR, which is crucial for cancer cells to quickly adapt to changing 





triggering ER stress and inhibiting cap-dependent translation with the aim of 
reducing energy consuming processes (Blais et al., 2004; Koritzinsky et al., 2006). 
Interestingly, it was shown that some solid tumors even rely on hypoxia and ER 
stress to activate LAMP3, a gene tightly associated with metastasis (Mujcic et al., 
2013). Thus, even though some cancer cells undergo apoptosis due to ISR 
activation, tumors usually adapt and use the pro-survival branch of the ISR to thrive 
in stressful environments. Furthermore, although these studies were conducted 
mainly in solid tumors other than pancreatic cancer, it is very plausible that the ISR 
has similar effects in PDAC, as the latter also presents high levels of hypoxia and 
nutrient deprivation.  
Regarding ISR in pancreatic cancer specifically, very recently a study described that 
ER stress activation results in quiescent and immune evading pancreatic cancer 
cells. Furthermore, these cells were shown to constitute the bulk of 
macrometastases found in the liver, linking ER stress to metastasis (Pommier et al., 
2018). ER stress has also been implicated in gemcitabine resistance, in two 
opposite ways. In one study, gemcitabine resistant tumors were sensitized by ER 
stress inducers, such as Orlistat and Thapsigargin, while in another study ER stress 
promoted gemcitabine resistance in PDAC (Palam et al., 2015; Tadros et al., 2017). 
In conclusion, many processes in pancreatic cancer and in the pancreas in general 
are highly dependent on the ISR and more specifically on ER stress and on the fine-
tuning between its pro-survival and pro-apoptotic branches. 
1.2.2. The ISR balance – pro-survival or apoptotic? 
As seen in the previous section, the ISR helps many systems cope with stresses 
and survive them. Still, when failing to resolve the stress, the ISR may lead to 
apoptosis and cell death. The exact mechanisms behind this switch between pro-
survival and apoptotic pathways remains under investigation. It is believed that the 
ISR signal duration and the levels of phosphorylated eIF2α (peIF2α) and translated 
ATF4 highly influence the cell’s decision to survive the stress or not (Fig. 5).   
The pro-survival branch is mainly characterized by an initial alleviation of translation, 
a highly energy consuming process, and by the upregulation of autophagy and anti-





dependent translation, viral mRNA and globin translation is reduced, thus instantly 
counteracting viral infections and adjusting globin to heme levels, while preventing 
the accumulation of globin aggregates (Balachandran et al., 2000; Han et al., 2001). 
Less translation also leads to a diminished consumption of amino acids helping the 
cells cope with nutrient deprivation (Vazquez de Aldana et al., 1994). The ER is also 
less overwhelmed with proteins to be folded, thereby, alleviating ER stress (Guan 
et al., 2017; Ron, 2002). This immediate response is followed by the translation and 
activation of ATF4. Several studies have shown that upon different kinds of stresses, 
ATF4 can upregulate the expression of several autophagy genes, such as 
MAP1LC3, ATG5 and SQSTM1 (B’Chir et al., 2013; Rouschop et al., 2010). 
Autophagy is, thus, initially activated in the cells, as it helps catabolize proteins, 
replenishing the pool of amino acids, while also lowering the amount of unfolded 
and viral proteins, therefore further alleviating stress (Kroemer et al., 2010; Ye et al., 
2010). Interestingly, a study has shown that the early activation of autophagy does 
not necessarily mean that all cells undergo autophagy to survive stress. In fact, what 
Suraweera et al. noticed is that upon proteasome inhibition, a depleted amino acid, 
such as cysteine, triggers the ISR and consequently autophagy. But, once this 
critical amino acid is replenished by the cell, peIF2α is dephosphorylated and 
autophagy is suppressed (Suraweera et al., 2012). Another mechanism employed 
by the cell to overcome stress is the upregulation of anti-apoptotic genes, such as 
MCL-1 and cIAP1 and cIAP2 by ATF4 (Hamanaka et al., 2009; Hu et al., 2012, 
2004).  
It is important to note that the termination of the ISR is crucial for cell survival, as 
the synthesis of essential proteins has to resume. This is achieved by the 
dephosphorylation of peIF2α by the phosphatase GADD34, an ATF4 target, thereby 
restoring cap-dependent translation (Ma and Hendershot, 2003; Novoa et al., 2001). 
Thus, a timely termination of the ISR can also influence the cell’s ability to survive 
or not in response to stress (Tabas and Ron, 2011). In fact, upon prolonged stress, 
ATF4 upregulates DNA damage inducible transcript 3 (DDIT3), which encodes for 
the transcription factor CHOP. In response to ER stress, ATF4 and CHOP have 
been shown to promote the transcription of several pro-apoptotic genes, such as 
the BCL2 family members, PUMA and BIM (Galehdar et al., 2010; Puthalakath et 





environment in the ER into a hyperoxidizing environment. This has severe 
consequences as reactive oxygen species accumulate in the ER and proteins 
cannot be properly folded, aggravating ER stress and promoting apoptosis 
(Marciniak et al., 2004). Another important target gene of ATF4 and CHOP is tribbles 
pseudokinase 3 (TRIB3), which was shown to repress tumorigenesis and promote 
apoptosis by inhibiting AKT activation (Ohoka et al., 2005; Salazar et al., 2015). 
TRIB3 was also shown to negatively regulate ATF4, dampening the stress response 
and its own expression (Jousse et al., 2007; Liew et al., 2010). Furthermore, Liew 
et al. showed that pancreatic β cells that have the TRIB3 Q43R polymorphism have 
a greater stabilization of TRIB3 and thus are much more prone to stress-induced 
apoptosis. As a consequence, these cells fail to cope with the normal ER stress 
associated with pro-insulin production undergoing cell death at a higher frequency, 
failing to secrete insulin and leading to type I diabetes (Liew et al., 2010). In 
conclusion, peIF2α and ATF4 are key mediators of the stress response, instantly 
relieving the cells from the energy consuming process of translation, while activating 
autophagy, anti-apoptotic and pro-apoptotic genes. The activation intensity and 
duration of peIF2α and ATF4 are key determinants of the cellular ability to thrive 




















1.2.3. ER stress 
ER stress response, as shown in the previous sections, is essential for the proper 
functioning of the pancreas, while its role in pancreatic cancer and chemotherapy 
response is still being studied. The accumulation of unfolded proteins signals ER 
stress, triggering the unfolded protein response (UPR). In this process, different ER 
protein chaperones act as sensors, which, upon disturbances, activate ER stress 
mediators. These relay the signal activating several transcription factors and 
responsive genes, while also stimulating the ISR by phosphorylating eIF2α (Urra et 
al., 2016; Walter and Ron, 2011). As the ER is a central organelle for several cellular 
processes, the UPR is tightly coupled to and can be further activated by changes in 
the oxidizing environment and perturbations in calcium levels in the ER as well as 
by variations in ATP and glucose levels in the cell (Rutkowski and Hegde, 2010).  
1.2.3.1. ER stress mediators 
ER stress mediators are the bridge between ER homeostasis and the stress 
response, phosphorylating eIF2α and activating b-ZIP transcription factors: 
activating transcription factor 6 (ATF6), X-box binding protein 1 (XBP1) and ATF4. 
The ER stress mediators are comprised of three transmembrane ER proteins: ATF6, 
inositol requiring enzyme 1 (IRE1), and PKR-like ER kinase (PERK). While ATF6 
activates UPR-responsive genes including mainly protein chaperone genes, IRE1 
leads to the upregulation of protein chaperone, lipid synthesis and ER-associated 
protein degradation (ERAD) genes (Hetz, 2012; Hillary and Fitzgerald, 2018; Vekich 
et al., 2012). PERK leads to the activation of the transcription factor nuclear factor 
erythroid 2-related factor 2 (NRF2) and of the ISR by phosphorylating eIF2α and 
triggering ATF4 accumulation. Consequently PERK stimulates the transcription of 
CHOP, GADD34, pro-survival, apoptotic and antioxidant genes (Fig. 6) (Maas and 
Diehl, 2015; Pakos‐Zebrucka et al., 2016).  
Fig. 5 Activation of pro-survival and apoptotic pathways by the ISR. The 
phosphorylation of eIF2α by stress kinases inhibits cap-dependent translation, which 
relieves the cell from consuming amino acids and from accumulating unfolded proteins in 
the ER. Still, if translation is not resumed, vital proteins become scarce potentiating stress 
and triggering apoptosis. The activation of ATF4 leads to the upregulation of autophagy, 
anti-apoptotic and apoptotic genes. GADD34 provides a feedback mechanism by 
dephosphorylating peIF2α, while CHOP dimerizes with ATF4 to regulate apoptotic genes. 





ATF6 is an ER-transmembrane protein, which upon ER stress, is vesicle transported 
by COPII to the Golgi apparatus. There, site-1 protease (S1P) cleaves off the luminal 
domain of ATF6 and site-2 protease (S2P) removes the transmembrane anchor of 
ATF6. The N-terminus of ATF6 is then released in the cytosol translocating into the 
nucleus and activating several ER protein chaperone genes, such as heat shock 
protein family A (Hsp70) member 5 (GRP78) and protein disulfide isomerase family 
A member 6 (PDIA6) (Haze et al., 1999; Schindler and Schekman, 2009; Vekich et 
al., 2012; Ye et al., 2000). Furthermore, ATF6 can upregulate XBP1, the substrate 
of another ER stress mediator, IRE1 (Yoshida et al., 2001). Thus, ATF6 not only 
senses ER stress, but also activates responsive genes to cope with stress and 
potentiates ER stress response by upregulating ER stress mediator targets.  
IRE1 is a kinase, but also has RNase activity, splicing the XBP1 mRNA. Upon ER 
stress, IRE1 autophosphorylates in trans, oligomerizing and stabilizing its RNase 
active site. Oligomerized IRE1 binds TRAF2, fostering the mitogen-activated protein 
kinase (MAPK) signaling pathway. This leads to the activation of JNK, which, in turn, 
stimulates the pro-apoptotic protein BIM and inhibits the anti-apoptotic protein 
BCL2, promoting apoptosis (Urano et al., 2000; Xu et al., 2005). Still, IRE1 also 
fosters pro-survival pathways, by promoting the accumulation of XBP1. IRE1 splices 
out an intron of the XBP1 mRNA by using its RNase activity to cut the XBP1 
transcript at two different positions. This leads to the shifting of the open reading 
frame, such that the mRNA can be properly translated (Ali et al., 2011; Shamu and 
Walter, 1996; Yoshida et al., 2001). XBP1 then translocates into the nucleus 
activating mainly pro-survival genes, such as protein chaperones, ERAD subunits 
and lipid synthesis protein coding genes. Thus, XBP1 promotes the proper folding 
of newly synthesized proteins and the degradation of unfolded proteins, while also 
stimulating the production of phospholipids for ER membrane expansion (Hetz, 
2012; Lee et al., 2003). The negative regulation of XBP1 involves the destabilization 
of IRE1 oligomers due to an accumulation of phosphates and charge repulsion or 
by the action of receptor of activated C kinase 1 (RACK1) and protein phosphatase 
2A (PP2A), which dephosphorylate IRE1 oligomers. As a consequence, less XBP1 
mRNA is spliced and translated, dampening the stress response (Qiu et al., 2010; 





The third ER stress mediator is PERK, which senses unfolded proteins in the ER 
and undergoes oligomerization and autophosphorylation. PERK does not only 
phosphorylate itself, but also has NRF2 and eIF2α as substrates (Carrara et al., 
2015; Cullinan et al., 2003; Harding et al., 2009; Mukaigasa et al., 2018; Wang et 
al., 2018). NRF2 is a transcription factor, which upon phosphorylation by PERK, 
translocates into the nucleus and activates metabolic enzymes and antioxidant 
protein coding genes (Cullinan et al., 2003; Hayes and Dinkova-Kostova, 2014; 
Mukaigasa et al., 2018). Thus, upon ER stress, PERK and consequently NRF2 
activation lead to an antioxidant response, protecting the cell and the ER from 
reactive oxygen species.  
PERK also phosphorylates eIF2α leading to an inhibition of global cap-dependent 
translation and a cap-independent translation of ATF4, triggering the transcription 
of the aforementioned pro-survival and apoptotic genes. Furthermore, ATF4 
together with CHOP promote the transcription of GADD34, a phosphatase whose 
main substrate is peIF2α and which negatively regulates PERK-dependent ER 
stress response (Harding et al., 2009; Marciniak et al., 2004). Interestingly, ATF4 
was also shown to upregulate endoplasmic reticulum to nucleus signaling 1 (ERN1), 
the gene coding for IRE1, thus fostering the splicing of XBP1 and positively 
regulating the stress response (Tsuru et al., 2016). XBP1, in turn, was proven to 
upregulate DnaJ homolog subfamily C member 3 (DBAJC3), which binds to the 
kinase domain of PERK inhibiting it and lowering pNRF2 and peIF2α levels (Lee et 
al., 2003; Yan et al., 2002). Thus, PERK directly links ER stress to the ISR and is 







1.2.3.2. ER stress sensors 
ER stress is a result from protein chaperones in the ER responding to the 
accumulation of unfolded proteins triggered by environmental changes. These 
changes encompass disturbances in the oxidizing environment and calcium levels 
in the ER as well as overall cellular ATP levels and culminate in the accumulation of 
unfolded proteins. Proteins being folded in the ER contain several disulfide bonds, 
Fig. 6 The ER stress mediators ATF6, IRE1 and PERK trigger the ER stress response. 
Upon ER stress, ATF6 is transported to the Golgi apparatus, where it is cut by S1P and S2P 
and released in the cytoplasm. Active ATF6 then translocates into the nucleus upregulating 
protein chaperone genes and XBP1. Following ER stress, IRE1 autophosphorylates, 
activating JNK and promoting apoptosis. It also splices the mRNA of XBP1, which then 
translocates into the nucleus activating protein chaperones, ERAD subunit and lipid 
synthesis protein coding genes. It also upregulates DBAJC3. IRE1 is negatively regulated 
by the destabilization of its oligomers through charge repulsion or by the phosphatase 
complex RACK-1-PP2A. PERK is the third ER stress mediator, which dimerizes and 
autophosphorylates upon stress. PERK phosphorylates NRF2, which becomes active 
upregulating antioxidant genes. The ISR is also triggered by PERK, which phosphorylates 
eIF2α leading to a global shut down of translation and ATF4 activation. As ATF4 translocates 
into the nucleus, GADD34, ERN1, pro-survival and apoptotic genes are upregulated. The 





requiring an oxidizing environment. Thus, failure to recycle protein disulfide 
isomerases upon oxidative stress, leads to an accumulation of misfolded proteins, 
which lack disulfide bonds. Furthermore, protein chaperones need ATP to bind and 
release proteins, coupling protein folding to overall energy levels in the cell. Calcium 
is a second messenger, which is stored in the ER and released upon distinct signals, 
including ER stress. It is buffered and used as a co-factor by protein chaperones, 
linking the UPR to several cellular processes such as apoptosis, oxidative 
phosphorylation and transcriptional activation (Fig. 7) (Carreras-Sureda et al., 2018; 
Ma and Hendershot, 2004; Zhang et al., 2019b).  
The general protein chaperone, GRP78, is the main sensor of unfolded proteins and 
direct regulator of ER stress mediators. Under unstressed conditions, GRP78 
inhibits the ER stress mediators by directly interacting with their luminal domains, 
which in turn hinder the ATPase activity of GRP78. Upon stress, GRP78 binds 
unfolded proteins and hydrolyzes ATP to ADP trapping the unfolded protein and 
dissociating from ER stress mediators triggering ER stress. Only after successfully 
folding of the protein and exchanging ADP for ATP is GRP78 able to inhibit ER 
stress mediators again (Bertolotti et al., 2000; Kopp et al., 2019). Thus, GRP78 is 
the major sensor of accumulated unfolded proteins in the ER and of cellular ATP 
levels, while being the main activator of the stress response.  
Further protein chaperones, such as protein disulfide isomerases, which catalyze 
the formation of disulfide bonds and are thus direct readouts of the ER redox state, 
have also been shown to regulate specific ER stress mediators. Upon 
oligomerization of IRE1 under stress, two intermolecular disulfide bonds form, 
stabilizing the complex (Liu et al., 2003). The protein disulfide isomerase, PDIA6, 
can in turn break these disulfide bonds, destabilizing the complex and dampening 
the ER stress response (Eletto et al., 2014). ATF6 also presents inter- and 
intramolecular disulfide bonds, which can be resolved by the protein disulfide 
isomerase PDIA5 upon stress. This facilitates the trafficking of ATF6 to the Golgi 
apparatus, but is not sufficient to promote ATF6 activation (Higa et al., 2014; 
Nadanaka et al., 2007). Taken together, protein disulfide isomerases regulate ER 






Calcium has also been tightly associated with protein chaperones, modulating the 
ER stress response by affecting chaperoning activity, while also providing a link 
between ER protein chaperones and other processes in the cell (Carreras-Sureda 
et al., 2018; Gutiérrez and Simmen, 2018). ER protein chaperones buffer almost all 
calcium in the ER, while also using it as a co-factor. One such example is GRP78, 
which alone buffers about 25% of ER calcium (Lièvremont et al., 1997). 
Furthermore, the glycoprotein chaperones, calnexin (CNX) and calreticulin (CRT), 
also bind calcium and, in fact, the structure of the C-terminal domain of CRT is highly 
dependent on how many calcium ions it binds and overall calcium levels in the ER 
(Giraldo et al., 2010). Calcium buffering in the ER and in the cell is essential, as it 
controls the amount of calcium which can be released upon a stimulus, fine tuning 
the cellular response to stimuli (Smith and Eisner, 2019). Furthermore, the 
chaperoning activity of GRP78, CNX and CRT depends on calcium and is reduced 
upon low calcium levels in the ER. Thus, calcium levels directly influence protein 
chaperoning, the UPR and ER stress activation (Ivessa et al., 1995; Prins and 
Michalak, 2011; Vassilakos et al., 1998).  
Recent studies have shown that ER protein chaperones can also directly regulate 
ER calcium levels by controlling ER calcium influx and efflux. The protein disulfide 
isomerase PDIA19 has been shown to activate the sarco/endoplasmic reticulum 
ATPase (SERCA) pump under stress, promoting an influx of calcium in the ER 
(Ushioda et al., 2016). GRP78 has also been implicated in promoting the efflux of 
calcium from the ER by inhibiting endoplasmic reticulum protein 44 (ERp44) under 
normal, but not stressed conditions. ERp44, in turn, inhibits calcium efflux through 
the inositol 1,4,5-triphosphate receptor (IP3R). Thus, under normal conditions 
GRP78 prevents ERp44 from inhibiting IP3R leading to calcium efflux. Upon stress, 
ERp44 can successfully obstruct IP3R, hindering further calcium release from the 
ER (Higo et al., 2010). Thus, several protein chaperones try to restore calcium levels 
in the ER in order to facilitate protein folding. Furthermore, by regulating ATP 
dependent calcium pumps and calcium efflux, protein chaperones affect oxidative 
phosphorylation and calcium dependent apoptosis in the mitochondria (Carreras-
Sureda et al., 2018; Gutiérrez and Simmen, 2018). This way, calcium allows protein 
chaperones to not only fine tune their activity and trigger the ISR, but also to 






















1.3  Calcium signaling 
As seen in the previous section, calcium is one of the major players during ER 
stress, modulating protein chaperone activity, while also integrating the ER stress 
response with other cellular processes. Calcium homeostasis is achieved by several 
channels, exchangers and pumps in the ER, mitochondrial and cytoplasmic 
membrane. Ion gradients and ATP are consumed in order to maintain low cytosolic 
and high ER calcium levels. Upon stimuli, calcium is released from storage 
organelles, such as the ER, activating transcription factors in the cytoplasm, while 
also affecting mitochondrial activity. 
Fig. 7 ER stress is triggered by the dissociation of protein chaperones from ER stress 
mediators upon accumulation of unfolded proteins. During resting conditions, GRP78 
inhibits the activation of ER stress mediators, which in turn hinder the ATPase activity of 
GRP78. Furthermore, GRP78 buffers 25% of ER calcium and regulates Calcium efflux by 
inhibiting ERp44. ATF6 is further stabilized by disulfide bonds sensing the redox state in the 
ER. Upon stress, GRP78 dissociates from ER stress mediators as it hydrolyzes ATP and 
starts folding proteins. Calcium levels highly modulate the protein folding activity of GRP78 
and other protein chaperones. Thus, in an attempt to restore calcium levels and increase its 
folding activity, GRP78 no longer inhibits ERp44 allowing it to obstruct IP3R and hinder 
calcium efflux. At the same time calcium influx is stimulated by further activation of SERCA. 
Furthermore, IRE1 oligomers are stabilized by disulfide bonds, which are only resolved once 
the oxidizing environment in the ER is restored. Thus, once protein disulfide isomerases are 
functioning normally again, IRE1 oligomers are reduced and destabilized, dampening the 
ER stress response. The figure was based on and adapted from Carreras-Sureda et al. and 





1.2.4. Calcium homeostasis 
Under resting conditions, the cytoplasmic free calcium concentration is 100nM, 
being 10,000 times lower than the extracellular calcium concentration (1mM) 
(Monteith et al., 2017). The free calcium levels in the ER are, in turn, higher and 
range between 100-800µM, while total ER calcium concentrations range between 
1-3mM (Carreras-Sureda et al., 2018). Calcium pumps and calcium ion exchangers 
create these gradients, allowing calcium to flow through channels flooding the 
cytoplasm upon stimuli (Fig. 8A, B). 
In the cytoplasmic membrane, plasma membrane Ca2+-transporting ATPase 
(PMCA) pumps calcium from the cytoplasm into the extracellular matrix at the cost 
of ATP hydrolysis (Strehler and Zacharias, 2001). The plasmalemmal sodium 
Na+/Ca2+ exchangers (NCXs) also export calcium from the cytoplasm by allowing 
sodium ions go down the concentration gradient (Blaustein et al., 2008). Calcium 
influx is facilitated by calcium channels, which open in response to different stimuli. 
Voltage-gated calcium channels respond to electric stimuli, promoting an influx of 
calcium mainly in neurons, endocrine, smooth muscle and cardiac cells (Catterall, 
2011). The transient receptor potential (TRP) family of calcium channels are 
responsible for responding to other environmental stimuli such as light, temperature, 
chemicals and mechanical stress. Only two TRP channels are known to be 
constitutively active, that being TRPV5 and TRPV6, which are expressed in the 
kidney and gastrointestinal tract and are responsible for absorbing calcium (den 
Dekker et al., 2003). It has been shown that stimuli can also promote the opening of 
both voltage-gated and TRP channels at the same time. One such example is that 
of insulin secretion by pancreatic β cells, which relies on voltage gated as well as 
TRP proteins. The hormone glucagon-like peptide 1 (GLP-1), promotes the opening 
of voltage-gated channels, TRPM4 and TRPM5 leading to a depolarization of the 
cytoplasmic membrane and thus stimulating the secretion of insulin in pancreatic β 
cells (Shigeto et al., 2015; Uchida et al., 2011). 
Another calcium channel family in the cytoplasmic membrane is the calcium release-
activated calcium channel (ORAI) family, which comprises ORAI calcium release-
activated calcium modulators 1, 2 and 3 (ORAI1, ORAI2 and ORAI3), ORAI1 being 





promoting the increase of cytoplasmic calcium levels in a process called store 
operated calcium entry (SOCE) (Prakriya and Lewis, 2015a). Thus, ORAI has a 
unique function, by which it can promote calcium influx in a depolarized cell as well 
as in response to internal signals and changes in cellular microdomains (Berridge 
et al., 2000; Parekh, 2011). Stromal interaction molecules (STIMs) are ER 
transmembrane proteins, which sense the drop in ER calcium levels, undergoing 
conformational changes, oligomerizing and activating ORAI at ER-cytoplasmic 
membrane junctions (Jing et al., 2015; Prakriya and Lewis, 2015a). ORAI channel 
activity is further modulated by the number of STIM it interacts with, being highest 
in a ratio of 2-8 STIM per ORAI. Thus, the stoichiometric ratio of STIM to ORAI 
determines the rate of calcium influx and the total calcium levels imported by the cell 
(Hoover and Lewis, 2011; Li et al., 2011). The STIM protein family is comprised by 
stromal interaction molecule 1 (STIM1) and stromal interaction molecule 2 (STIM2). 
STIM1 has a high affinity for calcium ions, thus, sensing big changes in ER calcium 
levels due to stimuli and rapidly activating SOCE (Luik et al., 2008). STIM2, on the 
other hand, has a lower affinity for calcium, being more susceptible to small calcium 
changes and activating SOCE to control resting calcium levels (Brandman et al., 
2007). SOCE is further regulated by phosphorylation and redox modulation of STIM, 
pH and temperature (Bogeski et al., 2010; Lopez et al., 2012; Prakriya and Lewis, 
2015a; Saul et al., 2016). Furthermore, the ER transmembrane protein SOCE-
associated regulatory factor (SARAF) senses ER calcium levels and upon 
replenishing of the stores, promotes the dissociation of STIM1 and STIM2 from 
ORAI (Jha et al., 2013; Palty et al., 2012). Calcium has also been proven to regulate 
SOCE, but the exact mechanism is still under investigation (Prakriya and Lewis, 
2015a). Thus, ORAI and STIM bridge changes in ER calcium levels and calcium 
influx in the cytoplasm (Fig. 8B). 
ER calcium levels are further monitored and maintained by the IP3R, which releases 
ER calcium into the cytosol upon inositol 1,4,5-triphosphate (IP3) binding. G-protein 
coupled receptors (GPCRs) and receptor tyrosine kinases (RTK) lead to the 
production of IP3 , which activates IP3R triggering ER calcium efflux upon several 
external signals (Berridge et al., 2000). In turn, ER calcium levels are restored by 
SERCA, which hydrolyze ATP in order to transport calcium ions against the 





in the absence of stimuli, calcium leaks from the ER counteracting SERCA by means 
which are still being elucidated (Lomax et al., 2002; Mogami et al., 1998). Recently, 
transmembrane and coiled-coil domains 1 (TMCO1) has been described to 
homotetramerize, forming a calcium channel and allowing ER leakage upon calcium 
overload in the ER by SERCA (Wang et al., 2016).   
Calcium levels are further controlled in the mitochondria. Calcium is imported into 
the mitochondria by the mitochondrial calcium uniporter (MCU), at the cost of 
protons and the electrochemical gradient (Perocchi et al., 2010; De Stefani et al., 
2016). Whereas sodium ions are exchanged during the  efflux of calcium from the 
mitochondria by the Na+/Ca2+ Li+-permeable exchanger (NCLX), a protein highly 
homologous to NCX in the plasma membrane (Palty et al., 2010). Calcium regulation 
in the mitochondria is tightly coupled to ER calcium levels and changes in 
mitochondrial calcium levels can rewire metabolism or trigger apoptosis (Carreras-
Sureda et al., 2018; Gutiérrez and Simmen, 2018). Taken together, calcium 
homeostasis is achieved by calcium pumps, channels and exchangers, which 





















Fig. 8 Pumps, channels and exchangers ensure Calcium homeostasis in the cell. A. 
ATP- driven pumps, sodium exchangers and inducible channels are responsible for calcium 
homeostasis in the cell. B. Under resting conditions, STIM binds and buffers calcium and 
does not interact with ORAI. When ER calcium levels drop, STIM oligomerizes, activating 
ORAI and promoting an influx of calcium into the cytoplasm. In blue, yellow, orange and 
green are calcium channels, pumps, exchangers and SOCE members, respectively. Even 
though MCU is not an exchanger, its activity is directly influenced by the proton gradient in 





1.2.5. Calcium-dependent signaling  
The importance of calcium in mediating cellular responses to environmental stimuli 
has been first reported in 1883, where electrolytes were described to be essential 
for muscle contraction (Ringer, 1883). Since then, great advances in calcium 
signaling have been made and its importance in the most distinct cellular processes 
recognized. The intensity of calcium uptake by the cell and its organelles together 
with the amount of calcium released by cellular stores determine the kinetics and 
intensity of the response to a stimulus. Furthermore, changes in calcium levels in 
different cellular compartments can have drastic consequences. Increases in 
mitochondrial calcium levels upon stimuli can lead to metabolic changes or 
apoptosis. Meanwhile, higher cytoplasmic calcium levels can trigger the activation 
of several calmodulin-dependent proteins culminating in the activation of a diverse 
range of transcription factors (Fig. 9) (Berridge et al., 2000, 2003; Carreras-Sureda 
et al., 2018; Giorgi et al., 2018). 
In non-excitable cell systems, G-protein coupled receptors (GPCRs) and receptor 
tyrosine kinases (RTKs) relay external events to the cell often by activating calcium-
dependent signaling cascades in the cell. Upon substrate binding, GPCRs and 
RTKs are activated, phosphorylating phospholipase C (PLC). Once activate, PLC 
hydrolyzes phosphatidylinositol 4,5-bisphosphate (PIP2) into inositol 1,4,5-
triphosphate (IP3) and diacylglycerol (DAG) (Hanlon and Andrew, 2015; Lemmon 
and Schlessinger, 2010). IP3 then interacts with the IP3R in the ER, promoting the 
release of calcium from the ER into the cytoplasm. As cytoplasmic calcium 
increases, protein kinase C (PKC) binds calcium and DAG, thereby, being activated. 
PKC then phosphorylates several targets, such as components of the MAPK 
pathway, amplifying the stimulus sensed by GPCRs and RTKs (Lipp and Reither, 
2011; VanRenterghem et al., 1994). This way, PKC activity and the overall signaling 
intensity are directly modulated by cytoplasmic calcium levels. Consequently, 
several calcium channels, pumps and exchangers modulate PKC activity. STIM1 
and ORAI1 positively regulate PKC, by sensing the calcium depletion from the ER 
and promoting SOCE, leading to a further increase in cytosolic calcium levels. Still, 
PKC activity itself and SOCE are negatively regulated by PMCA, NCX and SERCA, 





restoring resting calcium levels (Lipp and Reither, 2011). Mitochondrial pumps and 
exchangers can also affect signal intensity and SOCE, as they can significantly 
buffer cytoplasmic calcium. Depending on MCU levels, more or less calcium is 
pumped from the cytoplasm into the mitochondria. This leads to a fast depletion of 
calcium from the cytoplasm and a slow replenishment of the ER with calcium, 
modulating PKC and SOCE, respectively (Giorgi et al., 2018). Thus, GPCRs and 
RTKs rely on an increase in cytosolic calcium levels to activate PKC and the MAPK 
pathway. Consequently, the kinetics of the response are highly regulated by calcium 
pumps, channels and exchangers in all cellular compartments, as these are closely 
interconnected. 
In fact, there is a tight coupling between ER and mitochondrial calcium levels. Upon 
several stimuli, such as ER stress, calcium is released through the IP3R channel 
and taken up by the mitochondrial MCU. A significant, but relatively low, increase in 
mitochondrial calcium boosts oxidative phosphorylation and thus ATP production. 
Still, an overflow of calcium in the mitochondria can trigger apoptosis (Giorgi et al., 
2018; Monteith et al., 2017). Thus, by regulating IP3R and SERCA, as discussed  in 
the previous section, ER protein chaperones are not only regulating their 
chaperoning activity, but are also modulating the mitochondrial response to ER 
stress (Carreras-Sureda et al., 2018; Gutiérrez and Simmen, 2018). Taken together, 
calcium allows the ER to easily communicate with the mitochondria, influencing 
energy production and cell death initiation based on external and internal cues.  
Moreover, increased cytoplasmic calcium levels due to stress or any other signal 
also lead to the activation of calmodulin-dependent proteins, such as kinases and 
phosphatases. These, in turn, promote the activation and/or de-repression of 
several other transcription factors (Dewenter et al., 2017; Feske, 2007). 
Calcium/calmodulin-dependent protein kinase II (CAMKII) is activated upon 
calmodulin binding and autophosphorylation, being able to then translocate to the 
nucleus and phosphorylate Calcium/calmodulin-dependent protein kinase IV 
(CAMKIV). CAMKII and CAMKIV further phosphorylate and activate several 
transcription factors in the cytoplasm and in the nucleus (Ma et al., 2014). Still in the 
cytoplasm, CAMKII releases NFκB from an inhibitory complex by activating inhibitor 
of nuclear factor kappa B kinase subunit beta (IKK2) (Gray et al., 2017; Kashiwase 





protein (CREB) is activated upon Ser133 phosphorylation by CAMKIV, while 
CAMKII phosphorylates CREB at Ser133 or at Ser142 activating or inhibiting it, 
respectively (Cruzalegui and Means, 1993; Sun et al., 1994). Another common 
target of CAMKII and CAMKIV is the serum response factor (SRF), which is 
activated upon phosphorylation by both enzymes (Flück et al., 2000; Miranti et al., 
1995). CAMKII, in turn, is also linked to stress, as it phosphorylates and activates 
the stress responsive transcription factor heat shock factor 1 (HSF1) at Ser230 
(Holmberg et al., 2001; Peng et al., 2010). Protein C-ets-1 (ETS1) is also 
phosphorylated by CAMKII, but in this case leading to an inhibition of ETS-1 (Cowley 
and Graves, 2000; Pognonec et al., 1988). Interestingly, CAMKII and CAMKIV can 
also phosphorylate histone deacetylase 4 (HDAC4) promoting its nuclear export. 
HDAC4 is known to not only deacetylate histones, but also to repress SRF and 
myocyte enhancer factor 2 (MEF2). This way, CAMKII and CAMKIV indirectly further 
activate SRF, while also promoting MEF2 activity (Backs et al., 2006, 2011; Davis 
et al., 2003). 
The phosphatase calcineurin (CaN) also becomes active upon calmodulin binding, 
dephosphorylating transcription factors, which are usually kept inactive by 
phosphorylation in the cytoplasm. The main substrate of CaN is the family of nuclear 
factor of activated T cells (NFATs), which is crucial for T cell activation, 
differentiation and development, while also promoting cancer development (Macian, 
2005; Monteith et al., 2017). Upon dephosphorylation of NFATs by CaN, the nuclear 
import signal is unmasked, allowing NFATs to translocate into the nucleus and 
activate target genes (Macian, 2005). Additionally, CaN is suggested to activate 
MEF2, although the exact mechanism is still under investigation (Van Oort et al., 
2006). Furthermore, CaN can be inhibited upon phosphorylation by CAMKII, 
decreasing NFAT translocation (Kreusser et al., 2014; MacDonnell et al., 2009).  
Transcriptional changes are further fine-tuned by the activity of their activators, 
which is modulated by their affinity for calmodulin and calcium levels. CAMKII has a 
much lower affinity for calmodulin than CaN, thus CaN activation is more robust and 
faster compared to CAMKII activation (Dewenter et al., 2017). Thus, local calcium 
levels directly influence the amount of calcium-bound calmodulin and consequently 
the intensity of CaN and CAMKII activation. Local calcium levels have also been 





Upon SOCE, a local increase in calcium levels is sufficient to activate nuclear factor 
of activated T cells 2 (NFATc2), while nuclear factor of activated T cells 3 (NFATc3) 
requires higher levels of nuclear calcium to be activated (Kar and Parekh, 2015). 
Taken together, disturbances in calcium levels upon stimuli can lead to the activation 
of several signaling cascades and calmodulin-dependent kinases, culminating in the 
activation, de-repression and inhibition of a diverse range of transcription factors. 
These effects on transcription factor activity are further directly modulated by 
calcium levels in different cellular compartments, the kinetics by which these levels 







1.3. Epigenetics and transcriptional regulation 
As shown in the last section, calcium can trigger the activation of several different 
families of transcription factors. This induces changes in the transcriptome and 
proteome of the cell, ultimately creating a response to the original stimulus. The 
changes in transcriptome are extremely fast, starting to be detected already minutes 
after the original signal. This is only possible, because epigenetic proteins allow for 
a very plastic and adaptive gene regulation by quickly de-repressing and repressing 
genes. Upon binding of a transcription factor to DNA, epigenetic readers, writers 
and erasers are recruited, leading to chromatin re-arrangements and ultimately to 
the activation or inhibition of transcription. 
1.3.1. Transcription factors and gene regulation 
Transcriptional regulation is crucial for a proper stimulus response and for the 
maintenance of the cell and its identity. Cancer cells very often hijack pathways or 
reprogram their identity by aberrantly activating transcription factors and thus 
changing their overall transcriptome. Examples of such activities are the activation 
of ATF4 and ISR in many cancers and of ΔNp63 and NFAT in pancreatic cancer. 
By dimerizing with various transcription factors, acting on promoter regions as well 
as distal regulatory elements and recruiting different epigenetic regulators, ATF4, 
ΔNp63 and NFAT activate pro-survival and apoptotic genes, drive the basal subtype 
of pancreatic cancer and regulate tumor growth in PDAC, respectively (Baumgart et 
al., 2013; Hamdan and Johnsen, 2018; Pakos‐Zebrucka et al., 2016) (Fig. 10A, B). 
Fig. 9 Calcium signaling scheme. Upon a stimulus, GPCRs or RTKs are activated, 
phosphorylating PLC and promoting the breakdown of PIP2 to DAG and IP3. The latter 
promotes the opening of the channel IP3R, raising cytosolic calcium levels. While calcium 
pumps and MCU1 try to restore cytosolic calcium levels, SOCE further promotes the influx 
of calcium into the cytoplasm. DAG and calcium activate PKC and consequently the MAPK 
pathway. Calmodulin (CaM) binds calcium, activating CaN and CAMKII. CaN 
dephoshorylates NFATs promoting its translocation into the nucleus and activity. In the 
cytosol, CAMKII activates NFκB by activating IKK. CAMKII further activates HSF1, while 
repressing ETS1. CREB1 can be phosphorylated by CAMKII at two sites, one repressive 
(Ser142) and one activating (Ser133). Upon the inhibition of HDAC4 by CAMKII, MEF2 and 
SRF are de-repressed and activated. In yellow are calcium pumps, in orange MCU1, in blue 
calcium channels and in green the components of SOCE, STIM and ORAI. Concerning 
signaling components, receptors are in purple and their downstream effectors in pink/red. 
Factors activated by CaN in green and factors activated and/or repressed by CAMKII in 





Transcription factors (TFs) are proteins which regulate transcription upon DNA 
binding in a sequence-specific manner and recruiting co-factors for gene activation 
or repression (Reiter et al., 2017). DNA sequences recognized by TFs range 
between 6-12bp and are spread across the genome. Thus, there are millions of gene 
regulatory regions for TFs to bind and the likelihood of it binding one site over 
another is influenced by their interaction partners and the environment (Wunderlich 
and Mirny, 2009). TFs can bind DNA as homo- and heterodimers or as trimers 
having their binding affinity altered according to their binding partners (Jolma et al., 
2013, 2015). As TFs bind in a complex, their sequence specificity may change due 
to stereochemical requirements (Slattery et al., 2011). Furthermore, TFs, as many 
other proteins, are more stable in a complex, thus, binding to DNA is stronger and 
lasts longer (Chen et al., 2014; Gebhardt et al., 2013). Taken together, cooperativity 
between TFs can highly affect their activity and targets (Fig. 10A).  
A great example of this is ATF4 and its binding partners. As discussed previously, 
ATF4 is the major transcription factor activated by the ISR and can modulate the 
cellular response to stress regulating pro-survival and apoptotic genes. ATF4 
heterodimerizes with a wide range of TFs, activating a different set of genes, 
depending on its binding partner. It is proposed that heterodimers of ATF4 and 
CHOP rather activate apoptotic genes, such as PUMA and BIM, while also 
regulating the negative feedback loop of the ISR by upregulating GADD34 (Pakos‐
Zebrucka et al., 2016). Interestingly, ATF4 can also dimerize with the CAAT 
box/enhancer-binding proteins (C/EBPs), binding CCAAT-enhancer binding protein-
activating transcription factor (C/EBP-ATF) response elements (CAREs). CAREs 
comprise half of the ATF binding sequence and half of the C/EBP binding sequence, 
thus being only recognized by ATF-C/EBP dimers. Genes regulated by ATF4-
C/EBP dimers encompass amino acid deprivation responsive genes and other 
stress-dependent transcription factors, such as ATF3 and CHOP (Kilberg et al., 
2009; Vallejo et al., 1993). Other dimerization partners of ATF4 include the activator 
protein 1 (AP1), FOS and JUN, even though their effects in activating pro-survival 
and apoptotic genes are not well defined (Chevray and Nathans, 1992; Hai and 
Curran, 1991). 
The calcium-dependent family of TFs, NFAT, also heterodimerizes with different 





et al., 2010a). Interestingly, NFATc1 and NFATc2 can displace SMAD3 repressors 
complexes from c-MYC regulatory regions upon TGFβ signaling, while also binding 
to the c-MYC promoter as NFATc1/NFATc2-ELK1 dimers in response to serum in 
PDAC (König et al., 2010b; Singh et al., 2010). More generally, NFATc1/NFATc2-
STAT3 dimers promote inflammation-driven pancreatic cancer development and 
proliferation (Baumgart et al., 2014, 2016). NFATc2-STAT3 dimers are further 
stabilized by glycogen synthase kinase 3β (GSK-3β), which is implicated in the 
inflammatory response of tumors (Baumgart et al., 2016). Taken together, upon 
dimerization with different factors, NFATs promote the development and growth of 
PDAC by activating growth promoting protein coding genes. 
Furthermore, TFs can regulate gene expression by binding regulatory elements, 
which are proximal or distal to the target gene’s transcriptional start site (TSS). Distal 
regulatory elements, enhancers, can be further classified into typical enhancers and 
super-enhancers (SE), the latter being characterized by a much higher density of 
TFs and co-factors than the former (Lovén et al., 2013). While typical enhancers 
modulate the expression of a wide range of genes, SEs are mainly associated with 
the regulation of lineage-specific programs (Whyte et al., 2013). Interestingly, 
NFATc1-STAT3 dimers have been shown to rather bind typical enhancer elements, 
while ΔNp63 has been associated with SE regions to regulate and drive the basal 
subtype in PDAC (Baumgart et al., 2014; Hamdan and Johnsen, 2018) (Fig. 10B). 
The bridging between typical enhancers and SEs and promoters is mediated by co-
factors. In fact, TFs regulate gene expression by binding to very specific regulatory 
elements and recruiting different co-factors to these regions. Co-factors modify 
chromatin by post-translationally modifying histone tails and DNA itself and, thus, 
creating new binding sites for further proteins (discussed in the next section). 
Ultimately, the co-factors recruit or block recruitment of RNA Polymerase to the 
promoter region, activating or repressing gene expression, respectively (Reiter et 
al., 2017). Taken together, TFs bind typical enhancers, SEs and promoter regions, 
recruiting co-factors and regulating target gene expression. The binding of TFs to a 
regulatory element is highly dependent on sequence specific binding and their 
dimerization partners. This way, TFs ensure a fast and specific response to stimuli, 






1.3.2. Active and repressive histone marks 
As seen previously, TFs can regulate genes by recruiting co-factors that add, 
remove and recognize post-translational modifications on histone tails and 
ultimately promote or block RNA Polymerase recruitment to the promoter region. 
DNA is wrapped around nucleosomes, which are composed of histone octamers 
consisting of four homodimers of histones 2A, 2B, 3 and 4 (H2A, H2B, H3 and H4, 
respectively). Each histone has a tail, which can be, among others, acetylated, 
methylated and ubiquitinated by different epigenetic writers. The type and position 
of the histone modification is crucial as it can signal gene activation or silencing upon 
recognition by different epigenetic readers. Furthermore, epigenetic erasers can 
remove histone modifications further affecting transcription by preventing epigenetic 
readers to bind to these modifications and promote the activation or repression of 
genes (Allis and Jenuwein, 2016). Thus, epigenetic writers, erasers and readers 
Fig. 10 Transcription factor cooperative binding and localization at TSS proximal and 
distal regulatory elements. A. Transcription factor binding to DNA depends on its 
recognition sequence and binding partner. As TFs heterodimerize, they activate a different 
set of genes. For example, while CHOP-ATF4 dimers activate mainly apoptotic genes, 
ATF4-C/EBP dimers promote the transcription of amino acid (aa) deprivation responsive 
genes. Furthermore, ATF4-C/EBP dimers bind CAREs rather than the normal ATF4 or 
C/EBP recognition sequences, thus activating a very specific set of genes. NFATc1 and 
NFATc2 dimerize with ELK1 or STAT3 upon different stimuli to promote cell proliferation in 
both cases. B. TFs bind promoter as well as typical enhancer and super-enhancer regions, 
interacting with several co-factors (COF) and promoting or also blocking transcription. The 





confer plasticity to gene regulation by quickly adding, removing and recognizing 
active and repressive histone modifications, respectively (Fig. 11).  
Histone marks associated with transcriptional repression include trimethylated Lys9 
and Lys27 on H3 (H3K9me3 and H3K27me3, respectively), together with 
monoubiquitinated Lys119 on H2A (H2AK119ub). Interestingly, regions marked by 
H3K27me3 in the genome are still accessible for TFs and RNA Polymerase to bind, 
even though RNA Polymerase cannot progress into the gene, whereas areas with 
H3K9me3 are so densely packed with nucleosomes that binding of any TF is 
impaired (Breiling et al., 2001; Dellino et al., 2004; Soufi et al., 2012). Furthermore, 
H2AK119ub has been proposed to block transcription initiation, most likely by 
preventing the deposition of active histone marks, while also affecting transcription 
elongation (Weake and Workman, 2008; Zhou et al., 2008).  
The writers, polycomb repressor complex 1 and 2 (PRC1 and PRC2, respectively), 
catalyze the ubiquitination of H2AK119 and methylation of H3K27, respectively, 
while PRC1 can also function as a reader, recognizing H3K27me3 and then 
catalyzing the ubiquitination of H2AK119 (Laugesen et al., 2016; Weake and 
Workman, 2008). Interestingly, PRC2 has also been reported to recognize 
H3K27me3, further promoting the spread and maintenance of this histone mark 
(Hansen et al., 2008; Margueron et al., 2009). The mono-, di- and trimethylation of 
H3K9 is catalyzed by histone lysine methyltransferases (KMT) including suppressor 
of variegation 3-9 homolog 1 and 2 (SUV39H1 and SUV39H2, respectively) (Becker 
et al., 2016). The reader of methylated H3K9 is heterochromatin protein 1 (HP1), 
which upon recognizing H3K9me2 and H3K9me3, recruits SUV39H1 to these sites, 
further promoting the spread of H3K9me3 (Lachner et al., 2001; Schotta et al., 
2002). Interestingly, NFATc2 has been shown to promote the silencing of the tumor 
suppressor CDKN2B by recruiting SUV39H1 and promoting a first local H3K9me3. 
The mark is then extended as HP1 recognizes H3K9me3 and further recruits H3K9-
specific methyltransferases (Baumgart et al., 2012).  
Thus, the removal of these modifications by histone deubiquitinases (DUBs) and 
lysine demethylases (KDMs) is essential to restore transcription. Interestingly, ATF4 
has been shown to recruit lysine demethylase 4C (KDM4C) to ISR responsive 





repression of pro-survival genes (Zhao et al., 2016). Furthermore, PRC2 has been 
proven to silence NFATc1 in pancreatic acinar cells, but not pancreatic cancer. Upon 
the activation of K-RAS in pancreatic cancer, PRC2’s activity has been shown to be 
reversed, de-repressing NFATc1 (Chen et al., 2017). 
Concerning active histone marks, the best characterized ones are acetylated Lys27 
on H3 (H3K27ac), acetylated Lys5, Lys8, Lys12 and Lys16 on H4 (H4K5ac, 
H4K8ac, H4K12ac and H4K16ac, respectively), monomethylated Lys4 on H3 
(H3K4me1), trimethylated Lys4 on H3 (H3K4me3) and monoubiquitinated Lys120 
on H2B (H2BK120ub). All marks have been correlated with active transcription, but 
their location suggests that each mark affects a different step of transcription. 
H3K27ac, H4K5ac, H4K8ac, H4K12ac and H4K16ac are found in enhancer, as well 
as promoter, regions, while H3K4me1 mainly occupies enhancer regions and 
H3K4me3 is largely found at promoters (Li et al., 2019; Nagarajan et al., 2015; 
Taylor et al., 2013; Zhao and Garcia, 2015). H2BK120ub mainly occupies the gene 
body correlating with active transcriptional elongation (Weake and Workman, 2008).  
E1A binding protein p300 and cAMP-response element-binding CREB-binding 
protein (p300/CBP) recognize transcription factors on chromatin, being recruited to 
such sites and acetylating neighboring nucleosomes on H3K27 (Chan and La 
Thangue, 2001). In fact, NFATs have been proven to recruit p300/CBP to the c-
MYC promoter, leading  to a hyperacetylation of the promoter region and, thus, 
further activating c-MYC (König et al., 2010b). p300/CBP together with lysine 
acetyltransferase (KAT) also acetylate H4 giving rise to H4K5ac, H4K8ac, H4K12ac 
and H4K16ac (Nicholson et al., 2015). Furthermore, H3K4me1 has been shown to 
be linked to H3K27ac. The mono-, di- and trimethylations of H3K4 are catalyzed by 
the mixed lineage leukemia complexes (MLLs) and by the SET domain containing 
1A and 1B, histone lysine methyltransferases (SETD1A and SETD1B, respectively) 
(Nicholson et al., 2015). MLL3 and MLL4 have been suggested to be recruited to 
determined sites by recognizing H3K27ac and methylating neighboring H3K4 
(Wang et al., 2017). Furthermore, H2BK120ub stimulates SETD1A and SETD1B 
activity, promoting the deposition of H3K4me3 (Holt et al., 2015). Consequently, the 
ubiquitination of H2BK120 by Ring finger protein 20 and 40 (RNF20 and RNF40, 
respectively) has been shown to be a pre-requisite for the trimethylation of H3K4 





and enhancers laying the ground for readers to facilitate transcription. Bromo- and 
extraterminal domain proteins (BETs) are key in mediating this, as they recognize 
H4K5ac, H4K8ac, H4K12ac and H4K16ac, while BET bromodomain containing 4 
(BRD4) recruits cyclin-dependent kinase 9 (CDK9) to these sites, fostering the 
release of promoter proximally paused RNA Polymerase II, and thereby promoting 
transcriptional elongation (Filippakopoulos et al., 2012; Moon et al., 2005). This way 
the removal of these modifications by DUBs, histone deacetylases (HDACs) and 
KDMs also affects transcription. In fact, during amino acid deprivation, ATF4 knock-
out cells are only able to activate some ISR responsive genes upon HDAC inhibition. 
This suggests that the recruitment of histone acetyltransferases (HATs) by ATF4 is 
crucial for transcription and its removal can de-activate genes (Shan et al., 2012). 
In conclusion, epigenetic writers, readers and erasers mediate gene activation and 
repression by adding or removing and by recognizing active and repressive histone 
marks. This process is mediated by transcription factors, which recruit different 
epigenetic writers and erasers to regulatory elements of their target genes.  
 
1.3.3. Chromatin and genome organization 
The recruitment of co-factors by TFs and histone modifications leads to major 
chromatin rearrangements in the cell. Repression of transcription is often 
Fig. 11 Active and repressive histone marks. The scheme depicts the active histone 
marks (H3K27ac, H3K4me1, H3K4me3, H4K5ac, H4K8ac, H4K12ac, H4K16ac and 





accompanied by chromatin condensation, while transcriptional activity is associated 
with a more accessible chromatin. Condensed and silenced regions are typically 
located close to the nuclear lamina, whereas more accessible and active regions 
are brought together by a multitude of co-factors and are centrally located in the 
nucleus. Furthermore, bridging between enhancers and promoters takes place as 
chromatin regions are brought together and co-factors from both regions cooperate, 
potentiating gene regulation (Fig. 12) (Plank and Dean, 2014; Pombo and Dillon, 
2015).  
Two chromatin regions are brought together through looping, where CCCTC-binding 
factor (CTCF) and cohesin form a ring extruding a chromatin loop, consequently 
bringing two regions of chromatin in close proximity. This allows for distal regulatory 
elements, typical enhancers and SEs, to interact with promoter regions (Dixon et al., 
2012; Lupiáñez et al., 2015). This interaction is supposed to be very dynamic and 
further facilitated by co-factors, such as the mediator and BRD4. The mediator is a 
complex known to bridge enhancers to promoters by interacting with TFs and other 
co-activators on enhancers and recruiting the pre-initiation complex of RNA 
Polymerase II to promoter regions. Transcription initiation is also triggered by the 
mediator, as it phosphorylates the C-terminal domain (CTD) of RNA Polymerase II 
on Ser5 (Soutourina, 2018). The mediator can also bind cohesin further promoting 
the contact between two chromatin regions through looping, bridging enhancers to 
promoters (Kagey et al., 2010). Furthermore, upon promoter-enhancer looping, the 
local concentration of co-activators, such as BRD4, the mediator complex, and RNA 
Polymerase II increases, favoring and augmenting transcription (Reiter et al., 2017; 
Sabari et al., 2018). Taken together, TFs are recruited to promoters, typical 
enhancers and SEs upon stimuli or for cellular homeostasis, leading to a change in 
histone modifications and consequently chromatin structure. Chromatin looping and 
TFs together with co-activators favor an interaction between promoters, typical 






1.4  Objectives of this study 
PDAC patients face a 5-7% 5-year survival rate, mainly due to late diagnosis and 
chemotherapy resistance, where 77% of the patients do not respond to the 
commonly used therapy agent, gemcitabine (American Cancer Society, 2020; Burris 
et al., 1997). Thus, it is of utmost importance to understand the traits acquired upon 
and the mechanisms driving gemcitabine resistance in order to monitor resistance 
development and to give a more suitable treatment to patients, improving their 
response to chemotherapy and increasing their lifespan.  
Many correlative studies have pointed at several gemcitabine metabolizing proteins 
as being indicative of the responsiveness of patients to gemcitabine (Farrell et al., 
2009; Kroep et al., 2002; Maréchal et al., 2012; Spratlin et al., 2004). Furthermore, 
the prognostic value of the gemcitabine target, ribonucleotide reductase, in 
gemcitabine resistance has been of debate. While several cell line studies and one 
in vivo study have shown that resistant cells and tumors rely on an upregulation of 
Fig. 12 Enhancers and promoters interact promoting transcription. Transcription 
factors bind promoters and enhancers, recruiting several histone modifiers. Epigenetic 
readers recognize histone marks and interact with co-activators. The mediator complex 
bridges enhancers to promoters and phosphorylates the CTD of RNA Polymerase II 
promoting transcription initiation. CTCF and cohesin bring distal chromatin regions in close 
proximity, further facilitating the interactions between factors on enhancers and promoters. 





RRM1 to overcome gemcitabine toxicity, studies on patient biopsies have not been 
as straightforward (Nakahira et al., 2007; Nakano et al., 2007; Wang et al., 2015; 
Zhou et al., 2019). Three patient studies came to different conclusions as to whether 
RRM1 levels are of prognostic value for gemcitabine responsiveness in PDAC (Akita 
et al., 2009; Aoyama et al., 2017; Maréchal et al., 2012). A hurdle of these studies 
is that they have analyzed the expression levels of putative markers in naïve patient 
biopsies, as biopsies from treated patients are rare. Therefore, these studies did not 
consider that the expression of many of these markers may change during the 
establishment of resistance. Furthermore, even though the cell line and in vivo 
studies are more consistent, they mainly focused on transcriptomic changes, not 
tracing an entire profile of gemcitabine resistance.  
Gemcitabine, as any chemotherapeutic drug, apart from inhibiting ribonucleotide 
reductase and DNA Polymerase, induces cellular stress, such that resistant cells, 
most likely, have to adapt to a highly stressful environment (Avril et al., 2017). The 
ISR is a major mechanism for the cell to cope with different kinds of stresses 
activating pro-survival and apoptotic genes (Pakos‐Zebrucka et al., 2016). In fact, 
various cancers hijack the pro-survival branch of the ISR to cope with their stressful 
environment (Avril et al., 2017; Mujcic et al., 2013; Rouschop et al., 2010; Sun et 
al., 2015; Ye et al., 2010). Thus, it is plausible that gemcitabine resistant cells adapt 
and perceive stress differently, possibly heavily relying on the ISR to survive the 
stress induced by gemcitabine. This would further imply that resistant cells would be 
selected for not only overcoming gemcitabine’s toxicity, but for also thriving under 
general stress. 
The fact that cancer cells are highly susceptible to the accumulation of genetic 
mutations, amplifications and deletions would be a form to adapt to gemcitabine and 
stress. It is possible that upon the selective pressure of continuous gemcitabine 
treatments, tumors with certain genetic backgrounds thrive better and are selected 
for. Epigenetics also poses a highly plastic system, which can be modulated by 
tumors in response to gemcitabine and stress. In fact, the ISR relies on the 
epigenetic plasticity of the cell, being highly dependent on the activity of transcription 
factors, such as ATF4 (Pakos‐Zebrucka et al., 2016; Wortel et al., 2017). Branches 
of the ISR are also tightly linked to calcium signaling in the cell, which can 





regulation (Carreras-Sureda et al., 2018; Dewenter et al., 2017; Gutiérrez and 
Simmen, 2018). Thus, in order to survive gemcitabine and general stress, resistant 
cells may adopt a different genetic and epigenetic landscape and respond differently 
to stress and other stimuli compared to naïve cells. In this case, not only would the 
activation of certain transcription factors be affected, but also the histone marks and 
target genes be different before and after the establishment of gemcitabine 
resistance.  
Taken together, we hypothesize that gemcitabine resistance leads to genetic, 
epigenetic and transcriptomic changes, which allow gemcitabine resistant tumors to 
not only thrive under gemcitabine, but also under general stress stimuli. We, 
therefore, aim to compare treatment-naïve with gemcitabine resistant tumors on a 
transcriptional, epigenetic and genetic level. With these approaches, we plan to 
further characterize cellular traits acquired upon gemcitabine resistance. Finally, we 
intend to propose novel targets for precision oncology and alternative treatment 
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Pancreatic Ductal Adenocarcinoma (PDAC) displays a dismal prognosis due to late 
diagnosis and high chemoresistance incidence. For advanced disease stages or 
patients with comorbidities, treatment options are limited to gemcitabine alone or in 
combination with other drugs. While gemcitabine resistance has been widely 
attributed to the levels of one of its targets, RRM1, the molecular consequences of 
gemcitabine resistance in PDAC remain largely elusive. Here we sought to identify 
genomic, epigenomic, and transcriptomic events associated with gemcitabine 
resistance in PDAC and their potential clinical relevance. We found that 
gemcitabine-resistant cells displayed a co-amplification of the adjacent RRM1 and 
STIM1 genes. Interestingly, RRM1, but not STIM1, was required for gemcitabine 
resistance, while high STIM1 levels caused an increase in cytosolic calcium 
concentration. Higher STIM1-dependent calcium influx led to an impaired ER stress 
response and a heightened NFAT activity. Importantly, these findings were 
confirmed in patient and patient-derived xenograft samples. Taken together, our 
study uncovers previously unknown biologically relevant molecular properties of 
gemcitabine-resistant tumors, revealing an undescribed function of STIM1 as a 
rheostat directing the effects of calcium signaling and controlling epigenetic cell fate 
determination. It further reveals the potential benefit of targeting STIM1-controlled 
calcium signaling and its downstream effectors in PDAC. 
2.2 Statement of significance 
Gemcitabine-resistant and some naïve tumors co-amplify RRM1 and STIM1, which 
elicit gemcitabine resistance and induce a calcium signaling shift, promoting ER 







Pancreatic ductal adenocarcinoma (PDAC) patients display a dismal 7-9% 5-year 
survival rate due to late diagnosis and therapeutic resistance (American Cancer 
Society, 2020). The current first-line treatment includes FOLFIRINOX (5-
fluorouracil-oxaliplatin-irinotecan) with the combination of gemcitabine and nab-
paclitaxel as an alternative. Still, patients displaying a more advanced disease or 
comorbidities that preclude intensive therapy generally receive either gemcitabine 
alone or in combination with either capecitabine or S-1 (tegafur-gimeracil-oteracil) 
(Ryan, 2020b; Sohal et al., 2018). Thus, inevitably, with disease progression, 
gemcitabine-based treatment is administered to most patients. Unfortunately, the 
response to such therapy is low and variable, establishing gemcitabine resistance 
as a major hurdle in PDAC treatment (Cunningham et al., 2009; Hamada et al., 
2017; Scheithauer et al., 2003). Therefore, it is of utmost importance to understand 
the effects of gemcitabine treatment on PDAC. 
Many studies attribute gemcitabine resistance to the upregulation of one of its main 
targets, ribonucleotide reductase (Akita et al., 2009; Bergman et al., 2005; Nakahira 
et al., 2007; Nakano et al., 2007; Wang et al., 2015; Zhou et al., 2019), while also 
identifying differential expression of gemcitabine metabolizing enzymes as 
predictive of treatment response (Farrell et al., 2009; Maréchal et al., 2012). Still, 
the broader effects of gemcitabine on tumors remain elusive. Previous studies 
suggested that gemcitabine sensitivity highly depends on genetic changes in the 
tumor and the cellular response to chemotherapeutic-induced stress (Tiriac et al., 
2018). In addition to or as a result from acting on its primary target, many 
chemotherapies induce apoptosis through cell stress. The integrated stress 
response pathway is activated upon ER stress, amino acid deprivation, heme 
deprivation or viral infection and elicits two responses. First, cells attempt to resolve 
the stress source by inducing pro-survival genes and, if failing to do so, activating 
apoptotic genes (Pakos‐Zebrucka et al., 2016). Consequently, cells heavily rely on 
the transcription factor ATF4, which is translated and translocates to the nucleus 
upon stress mediating the activation of stress-induced genes (Harding et al., 2000; 
Lu et al., 2004). Furthermore, stress conditions, such as ER or oxidative stress, are 
tightly coupled to calcium signaling. This stress-calcium interplay controls the 





alter cellular phenotype (Monteith et al., 2017; Zhang et al., 2019a). The cellular 
stress response is highly variable and depends on the molecular and epigenetic 
context of the cell. Therefore, chemotherapy-resistant cells may present an altered 
dependency on the integrated stress response, rendering the targeting of the latter 
potentially useful in certain contexts. Thus, a better understanding of the molecular 
mechanisms affected by gemcitabine resistance and their response to cellular 
stress is of great importance.  
Here we investigated gemcitabine resistance in PDAC by characterizing 
gemcitabine-resistant cells and validated our results in patient samples as well as in 
naïve and gemcitabine-treated patient-derived xenografts. We identified an 
amplification in chromosome 11 harboring genes involved in resistance and genes 
whose functions were elusive in this context. Among them is STIM1, whose 
overexpression provokes an aberrant calcium signaling program, eliciting ER stress-
resistance, a rewiring of several transcription factors and widespread epigenetic 
reprogramming in resistant cells. Taken together, our data provide new insights into 
mechanisms accompanying gemcitabine-resistance in PDAC and reveal a novel 







2.4.1 Amplification in chromosome 11 confers gemcitabine resistance 
To study chemoresistance in PDAC, a gemcitabine-resistant human cell line 
(GemR) was established by treating parental L3.6pl (Par) cells with increasing 
gemcitabine concentrations (Fig. 13A). Cells were considered resistant once the half 
maximal inhibitory concentration (IC50) was 50-fold higher in GemR (IC50:223.70 nM 
± 26.45 nM) compared to Par (IC50:3.70 nM ± 0.11 nM) (Fig. 13B-C). 
 
Fig. 13 Establishment of gemcitabine resistant L3.6pl (GemR). (A) Scheme depicting 
the establishment of GemR. Images of Par and GemR. Scale=1.36mm. (B) Crystal violet 
staining of a 7 days proliferation assay of Par and GemR treated with gemcitabine (Gem). 
(C) Proliferation assay of Par and GemR treated with gemcitabine for 7 days. The 
absorbance of cell titer blue was normalized to the respective vehicle absorbance. Mean 
±SD, n=2. IC50 values ±SD, n=2. 
Transcriptome-wide mRNA sequencing and low coverage whole genome 
sequencing was performed on GemR and Par to identify acquired traits upon 
resistance. Gene Set Enrichment Analysis (GSEA) showed an enrichment for the 
“Gemcitabine Resistance UP" signature in GemR. Surprisingly, 11 out of 16 of the 
significantly enriched genes identified were located on chromosome 11 (Fig. 14A 
and Table S1). Copy number variation analysis revealed that a region of 
chromosome 11 (chr11: 3,810,838-10,012,224), encompassing most of the genes 
contained within this signature, was amplified in GemR compared to Par. RRM1 was 





whose association with gemcitabine resistance are unknown (Fig. 14B-D and Table 
S2).  
 
Fig. 14 GemR amplify a portion of chromosome 11. (A) GSEA showing an enrichment 
of the gemcitabine resistance signature in GemR. Significantly enriched genes are listed 
and classified into amplified genes on chr11 (in red). (B) Genome-wide copy number 
variation analysis of GemR compared to Par. Highlighted in a red box is the identified 
amplification in chr11. (C) Copy number variation analysis of GemR compared to Par in 
chr11 and highest amplified genes. (D) Volcano plot of differentially regulated, amplified and 
deleted genes in GemR compared to Par. 
RRM1 is a ribonucleotide reductase subunit and one of the main targets of 
gemcitabine (De Sousa Cavalcante and Monteiro, 2014). Its upregulation has also 
been tightly associated with this chemotherapeutic agent, being reported to drive 
gemcitabine resistance in vitro and in vivo (Bergman et al., 2005; Nakahira et al., 
2007; Nakano et al., 2007; Wang et al., 2015; Zhou et al., 2019). Consistently, we 
found that RRM1 levels correlate with gemcitabine resistance in vitro and that RRM1 
depletion restores gemcitabine sensitivity in GemR (Fig. 15A-C). Interestingly, the 
amplified region not only includes RRM1, but extends for over 6 Mb. While the role 
of RRM1 in gemcitabine resistance has been established, the effects of the co-
amplification of the various other genes remain elusive. It is therefore plausible that 







Fig. 15 RRM1 amplification drives gemcitabine resistance. (A) Crystal violet staining of 
a 7 days proliferation assay upon RRM1 knockdown and treatment with gemcitabine (Gem) 
in Par and GemR. (B) GemR proliferation assay upon RRM1 knockdown and treatment with 
gemcitabine for 7 days. The absorbance of solubilized crystal violet was normalized to the 
respective vehicle absorbance. Mean ±SD, n=2. IC50 values ±SD, n=2. (C) Western blot 
validation of RRM1 knockdown in Par and GemR. 
2.4.2 GemR display attenuated ATF4 activity and diminished ER-stress 
response 
We hypothesized that additional genes co-amplified on chromosome 11 may 
influence the cellular phenotype. As the epigenetic landscape can shape the cellular 
response to external stimuli and provides an excellent readout for transcription factor 
and upstream signaling activity, we compared the epigenomic profiles of Par and 
GemR. For this, we performed chromatin immunoprecipitation followed by next-
generation sequencing (ChIP-seq) for the active transcription mark H3K27ac. 
Despite the identified amplification, about an equal number of acetylated regions 
were lost and gained in GemR compared to Par (Fig. 16A). Bioinformatic 
characterization of these regions revealed that sequence motifs for AP1 
transcription factors were enriched in both gained and lost regions. Motifs for the 
transcription factor ATF3 were also enriched in the gained regions, likely due to the 
sequence similarity to AP1 motifs. Interestingly, regions displaying decreased 
H3K27ac levels showed an enrichment for the motifs of the stress-responsive 







Given the reported importance of ATF4 in mediating stress response, we performed 
ChIP-seq for ATF4 in Par following induction of ER stress by thapsigargin. 
Interestingly, 24% of the lost H3K27ac regions in GemR overlapped with ATF4 
peaks. Consistently, lower H3K27ac signal intensity was observed at those sites in 
GemR compared to Par (Fig. 17A). Accordingly, ATF4 target genes displayed 
decreased H3K27ac occupancy near their transcriptional start site (TSS) in GemR 
(Fig. 17B). 
To investigate whether ATF4 activity and the stress response were affected in 
GemR compared to Par, we induced ER stress in Par and GemR. Strikingly, upon 
ER stress, ATF4 protein levels, which dramatically increased in Par, were not 
detectable in GemR (Fig. 17C). Consistently, GemR failed to activate ATF4 target 
genes, such as TRIB3, ERN1 and DDIT3 (encoding CHOP) (Fig. 17D). In 
conclusion, GemR are unable to activate ATF4 translation and induce downstream 
ER stress responsive genes. 
Fig. 16 Motifs of stress responsive transcription factors are enriched in H3K27ac lost 
regions in GemR. (A) MA plot and pie chart of differentially occupied H3K27ac regions in 
GemR and Par. (B) Top three hits of motif analysis in H3K27ac gained regions in GemR 







Fig. 17 ATF4 activity and ER stress response are dampened in GemR. (A) Venn 
diagram of ATF4 peaks in Par after thapsigargin (Thap) treatment and H3K27ac lost regions 
in GemR. Aggregate plot and heatmaps of H3K27ac on ATF4 summits of overlapping 
regions. (B) ATF4 and H3K27ac profiles around the TSS of stress responsive genes. (C) 
Western blot of ATF4 in Par and GemR treated with thapsigargin (Thap). (D) Expression of 
stress responsive genes upon thapsigargin (Thap) treatment in Par and GemR. Mean ±SD, 
n=3. *P≤0.05, **P≤0.01, ***P≤0.001, ns=not significant. 
2.4.3 STIM1 amplification elicits a higher store-operated calcium entry 
driving ER stress resistance 
Long-term thapsigargin treatment inhibits cell proliferation via induction of the ER 
stress response pathway. Therefore, we examined whether GemR displayed 
differential responsiveness to thapsigargin compared to Par. Indeed, GemR were 
significantly more resistant to the anti-proliferative effects of thapsigargin (IC50: 
>819.2 nM) compared to Par (IC50: 5.09 nM ± 0.20 nM) (Fig. 18A-B). Consistently, 
analysis of DepMap data revealed that thapsigargin sensitivity highly correlated with 





triggered by the accumulation of unfolded proteins or changes in redox, calcium, or 
nutrient levels in the ER (Carreras-Sureda et al., 2018; Pakos‐Zebrucka et al., 
2016). Furthermore, thapsigargin is a SERCA-pump inhibitor, which affects ER 
calcium storage. Therefore, we examined whether protein-coding genes involved in 
these processes were aberrantly regulated and amplified in GemR. Interestingly, 
STIM1, an ER calcium sensor coding gene, was among the most amplified and 
highly upregulated genes in GemR, being co-amplified with RRM1 in a focal 
amplification within the larger amplified region on chr11. Previous studies have also 
reported the upregulation of STIM1 and RRM1 upon gemcitabine treatment and 
gemcitabine resistance in pancreatic cancer cells (Kondratska et al., 2014; Zhou et 
al., 2019). Notably, analysis of DepMap data revealed that RRM1 and STIM1 
amplifications are highly correlated in cancer cell lines, including pancreatic cancer. 
Additionally, analysis of TCGA data revealed that 5% of pancreatic cancer patients 
display a gain of both genes irrespective of treatment modality (Fig. 18D). 
Consistently, we were able to identify several established cell lines that displayed 
an amplification and an increased expression of STIM1. For example, the pancreatic 
and colorectal cancer cell lines Panc1 and DLD1, respectively, highly co-expressed 
RRM1 and STIM1, while the osteosarcoma cell line SJSA only expressed high levels 





Fig. 18 Amplification of STIM1 leads to increased SOCE. (A) Crystal violet staining of a 
7 days proliferation assay of Par and GemR treated with thapsigargin (Thap). (B) 
Proliferation assay of Par and GemR treated with thapsigargin for 7 days. The absorbance 
of cell titer blue was normalized to the respective vehicle absorbance. Mean ±SD, n=2. IC50 
values ±SD, n=2. (C) Scatter plot showing the Spearman correlation of gemcitabine and 
thapsigargin sensitivity in pancreatic cancer cell lines obtained from DepMap. r=0.644, 
P=5.45e-5. (D) Density scatter plot showing the Spearman correlation of the copy number 
of RRM1 and STIM1 in pancreatic and other cancer cell lines obtained from DepMap. 
rpancreas=0.994, P=1.83e-39; rother=0.992, P=0.00. Oncoprint and co-occurence probability of 
a gain of STIM1 and RRM1 in pancreatic cancer patients from TCGA PanCancer Atlas 
Studies data (cBioportal). (E) Western blot of STIM1 and RRM1 levels in pancreatic, 
colorectal and osteosarcoma cell lines. 
STIM1 is an ER calcium sensor that interacts with and activates ORAI calcium 
channels in the plasma membrane following ER calcium store depletion. This leads 
to ORAI channel opening, allowing extracellular calcium to enter the cytosol in a 
process termed store-operated calcium entry (SOCE) (Prakriya and Lewis, 2015b; 
Soboloff et al., 2012). Fluorescence calcium measurements revealed comparable 
calcium levels at resting conditions and upon thapsigargin-induced ER calcium store 
depletion in Par and GemR. However, GemR displayed a highly increased SOCE 





recent studies have pointed at the effects of STIM1 on ER stress response 
(Conceicao et al., 2020; Gilon et al., 2018), no such correlation has been reported 
in cancer. Moreover, the possible effects elicited by increased SOCE on ER stress 
response remain elusive. Thus, we investigated whether higher STIM1 levels, and 
consequently increased SOCE, could lead to ER stress resistance in GemR. To 
address this, SOCE was prevented by either treating with the SOCE inhibitor, 
CM4620, or by chelating extracellular calcium from the media with EGTA before the 
induction of ER stress by thapsigargin. Notably, as assessed via ATF4 
accumulation, treatment with either CM4620 or EGTA restored the stress response 
to thapsigargin in GemR to levels comparable to thapsigargin treatment alone in Par 
(Fig. 19B and D). This confirms that ER stress resistance in GemR is conferred by 
elevated SOCE elicited by STIM1. This conclusion was further supported by the 
ability of combined CM4620 or EGTA and thapsigargin treatment to rescue the 





Moreover, overexpression of STIM1 in Par cells was sufficient to lower ATF4 levels 
and impair the induction of stress responsive genes upon thapsigargin treatment 
(Fig. 20A-B). Similarly, STIM1 overexpression in other pancreatic cancer cell lines, 
namely BxPC-3 and CFPAC-1, decreased ATF4 accumulation and dampened the 
induction of stress-responsive genes following thapsigargin treatment (Fig. 20C-H).  
Fig. 20 STIM1 overexpression leads to a dampened ER stress response in PDAC. (A) 
Western blot of STIM1 and ATF4 levels upon STIM1 overexpression and thapsigargin 
(Thap) treatment in Par. (B) Expression of stress responsive genes upon STIM1 
overexpression and thapsigargin (Thap) treatment in Par. Mean ±SD, n=3. (C) Western blot 
of STIM1 and ATF4 levels upon STIM1 overexpression and thapsigargin (Thap) treatment 
in BxPC-3. (D) Validation of STIM1 overexpression in BxPC-3. Mean ±SD, n=3. (E) 
Expression of stress responsive genes upon STIM1 overexpression and thapsigargin 
(Thap) treatment in BxPC-3. Mean ±SD, n=3. (F) Western blot of STIM1 and ATF4 levels 
upon STIM1 overexpression and thapsigargin (Thap) treatment in CFPAC-1. (G) Validation 
of STIM1 overexpression in CFPAC-1. Mean ±SD, n=3.  (H) Expression of stress responsive 
genes upon STIM1 overexpression and thapsigargin (Thap) treatment in CFPAC-1. Mean 
±SD, n=3. *P≤0.05, **P≤0.01, ***P≤0.001, ns=not significant. 
Fig. 19 Increased SOCE elicits ER stress resistance in GemR. (A) Fura-2 based cytosolic 
calcium imaging and quantification of ΔSOCEmax. Mean ±SEM, n=334 (Par siCont), 143 (Par 
siSTIM1), 347 (GemR siCont), 243 (GemR siSTIM1). (B) Western blot showing ATF4 levels 
upon SOCE inhibition by CM4620 and thapsigargin (Thap) treatment in Par and GemR. (C) 
Expression of stress responsive genes upon SOCE inhibition by CM4620 and thapsigargin 
(Thap) treatment in Par and GemR. Mean ±SD, n=3. (D) Western blot depicting ATF4 levels 
upon EGTA and thapsigargin (Thap) treatments in Par and GemR. (E) Expression of stress 
responsive genes upon EGTA and thapsigargin (Thap) treatment in Par and GemR. Mean 





Consistent with these effects, inhibition of SOCE with CM4620 (Fig. 21A-D) or 







This was further validated in the colorectal cancer cell line DLD1, which expressed 
higher levels of both STIM1 and RRM1 and was more resistant to the anti-
proliferative effects of thapsigargin compared to HCT116. Consistently, SOCE 
inhibition restored the sensitivity of DLD1 to thapsigargin to levels similar to HCT116 
(Fig. 22A-D). Thus, higher levels of STIM1, and thereby SOCE, in GemR as well as 
other tumor cell lines provide a survival advantage under ER stress conditions. 
Fig. 21 SOCE impairment sensitizes GemR to ER stress. (A) Crystal violet staining of a 
7 days proliferation assay in Par upon CM4620 and thapsigargin (Thap) treatments. In a red 
box are the thapsigargin (Thap) only treated Par, also shown in Fig. 6A. (B) Proliferation 
assay of Par treated with CM4620 and thapsigargin (Thap) for 7 days. The absorbance of 
cell titer blue was normalized to the respective vehicle absorbance. Mean ±SD, n=2. IC50 
values ±SD, n=2. The profile of Par treated with thapsigargin (Thap) only was previously 
depicted in Fig. 6B. (C) Crystal violet staining of a 7 days proliferation assay in GemR upon 
SOCE inhibition by CM4620 and thapsigargin (Thap) treatment. In a red box are the 
thapsigargin (Thap) only treated GemR, also shown in Fig. 6A. (D) Proliferation assay of 
GemR treated with thapsigargin and the SOCE inhibitor CM4620 for 7 days. The 
absorbance of cell titer blue was normalized to the respective vehicle absorbance. Mean 
±SD, n=2. IC50 values ±SD, n=2. The profile of GemR treated with thapsigargin (Thap) only 
was previously shown in Fig. 6B. (E) Crystal violet staining of a 7 days proliferation assay 
in Par upon STIM1 depletion and treatment with thapsigargin (Thap). Highlighted in a red 
box is the control, vehicle-treated Par, which was previously shown in Fig. 3A. (F) 
Proliferation assay of Par depleted from STIM1 and treated with thapsigargin (Thap) for 7 
days. The absorbance of solubilized crystal violet was normalized to the respective vehicle 
absorbance. Mean ±SD, n=2. IC50 values ±SD, n=2. (G) Crystal violet staining of a 7 days 
proliferation assay in GemR upon STIM1 and/or RRM1 knockdown and treatment with 
thapsigargin (Thap). Highlighted in a red box are the control, vehicle-treated GemR and 
vehicle-treated RRM1-depleted GemR, which were previously shown in Fig. 3A. (H) 
Proliferation assay of GemR depleted from STIM1 and/or RRM1 and treated with 
thapsigargin (Thap) for 7 days. The absorbance of solubilized crystal violet was normalized 
to the respective vehicle absorbance. Mean ±SD, n=2. IC50 values ±SD, n=2. (I) Western 






Fig. 22 STIM1 levels correlate with ER stress resistance in colorectal cancer. (A) 
Crystal violet staining of a 7 days proliferation assay in DLD1 upon SOCE inhibition by 
CM4620 and thapsigargin (Thap) treatment. (B) Proliferation assay of DLD1 treated with 
CM4620 and thapsigargin (Thap) for 7 days. The absorbance of cell titer blue was 
normalized to the respective vehicle absorbance. Mean ±SD, n=2. IC50 values ±SD, n=2. 
(C) Crystal violet staining of a 7 days proliferation assay in HCT116 upon SOCE inhibition 
by CM4620 and thapsigargin (Thap) treatment. (D) Proliferation assay of HCT116 treated 
with CM4620 and thapsigargin (Thap) for 7 days. The absorbance of cell titer blue was 
normalized to the respective vehicle absorbance. Mean ±SD, n=2. IC50 values ±SD, n=2. 
Since STIM1 and RRM1 are commonly co-amplified and have important 
physiological functions, we tested whether they act synergistically. For this, we 
monitored cell proliferation upon STIM1 and/or RRM1 depletion and thapsigargin or 
gemcitabine treatment. RRM1 levels did not influence cell growth upon thapsigargin 
treatment and the depletion of both RRM1 and STIM1 was not synergistic (Fig. 21G-
I). Similarly, while RRM1 depletion restored gemcitabine responsiveness, STIM1 
knockdown did not appreciably influence GemR growth upon gemcitabine treatment 
nor did it synergize with RRM1 depletion (Fig. 13A, Fig. 21I and Fig. 23A-B). 
Furthermore, SOCE inhibition did not influence the effects of gemcitabine treatment 
on cell proliferation in either GemR or Par cells (Fig. 1A-B and Fig. 23C-D). 
Together, these findings confirm that while STIM1 and RRM1 are co-amplified in 
human tumors and cancer cell lines, they independently affect calcium-associated 





Fig. 23 STIM1 amplification does not affect gemcitabine resistance in GemR. (A) 
Crystal violet staining of a 7 days proliferation assay of STIM1 and/or RRM1 depleted GemR 
treated with gemcitabine (Gem). In red boxes are the vehicle-treated and STIM1 or STIM1 
and RRM1 depleted GemR, also shown in Fig. 9G. (B) Proliferation assay of GemR 
depleted from STIM1 and/or RRM1 and treated with gemcitabine (Gem) for 7 days. The 
absorbance of solubilized crystal violet was normalized to the respective vehicle 
absorbance. Mean ±SD, n=2. IC50 values ±SD, n=2. The profiles of GemR siCont and GemR 
siRRM1 were previously depicted in Fig. 1C. (C) Crystal violet staining of a 7 days 
proliferation assay in Par and GemR upon CM4620 and gemcitabine (Gem) treatments. The 
crystal violet staining of a 7 days proliferation of Par and GemR treated with gemcitabine 
(Gem) only can be found in Fig. 1B. (D) Proliferation assay of Par and GemR treated with 
CM4620 and gemcitabine (Gem) for 7 days. The absorbance of cell titer blue was 
normalized to the respective vehicle absorbance. Mean ±SD, n=2. IC50 values ±SD, n=2. 
The profiles of Par and GemR treated with gemcitabine (Gem) only can be found in Fig. 1C. 
2.4.4 STIM1 depletion restores ER stress-induced transcriptomic and 
epigenomic changes 
To further characterize the role of STIM1 in ER stress resistance, we performed 
mRNA sequencing in Par, GemR, and STIM1-depleted GemR treated with 
thapsigargin. Consistent with GemR being resistant to ER stress, gene set 
enrichment analysis (GSEA) displayed an enrichment of the “Unfolded Protein 
Response” in Par compared to GemR following treatment with thapsigargin (Fig. 
24A and Table S3). Hierarchical clustering revealed two gene clusters whose 
expression was influenced by STIM1 (Fig. 24B). Genes within cluster 1 were 
upregulated in thapsigargin-treated Par, but failed to be activated in GemR. 





thus referred to as “down (DN-)reversed” genes. Cluster 2 genes were not induced 
in Par, but upregulated in GemR in response to thapsigargin. Notably, STIM1 
depletion in GemR reversed their induction by thapsigargin and were therefore 
referred to as “UP-reversed” genes (Table S4). Consistent with our observations, 
the DN-reversed cluster includes the ER-stress responsive genes TRIB3, ERN1 and 
DDIT3, whose induction by thapsigargin was rescued upon STIM1 depletion in 
GemR (Fig. 24C). Moreover, STIM1-depletion restored ATF4 accumulation in 
response to thapsigargin treatment in GemR (Fig. 24D). To validate our findings in 
another pancreatic cancer cell line, we assessed the induction of DN-reversed 
genes in STIM1-amplified Panc1 cells. Here we observed low levels of induction of 
DN-reversed genes and ATF4 upon thapsigargin treatment, which were rescued by 
STIM1 depletion (Fig. 24E-F). 
 
Fig. 24 STIM1 depletion sensitizes GemR to ER stress. (A) GSEA showing an 
enrichment for the unfolded protein response upon thapsigargin (Thap) treatment in Par. 
(B) Heatmap showing the Z-score of each gene ordered into 4 clusters identified by 
hierarchical clustering highlighting gene clusters: DN-reversed and UP-reversed. (C) 
Expression of DN-reversed genes upon thapsigargin (Thap) treatment in Par, GemR and 
STIM1-depleted GemR. Mean ±SD, n=3. (D) Western Blot of ATF4 and STIM1 levels upon 
a STIM1 knockdown and thapsigargin (Thap) treatment in Par and GemR. (E) Expression 
of DN-reversed genes upon thapsigargin (Thap) treatment in Panc1 and STIM1-depleted 
Panc1. Mean ±SD, n=3. (F) Western Blot of ATF4 and STIM1 levels upon a STIM1 






We next sought to uncover the molecular and transcriptional mechanisms 
responsible for the differential gene regulation observed in GemR. Based on our 
initial epigenome mapping studies, we rationalized that ER stress-induced gene 
expression changes may be coupled to epigenetic reprogramming. Indeed, in 
accordance with the gene expression data, H3K27ac occupancy increased near the 
TSS of DN-reversed genes in Par, but not in GemR upon thapsigargin treatment. 
STIM1 depletion as well as SOCE inhibition by CM4620 in GemR partially rescued 





Fig. 25 SOCE impairment partially rescues H3K27ac profile around ER stress 
responsive genes in GemR. (A) ATF4 profile in Par treated with thapsigargin (Thap) and 
H3K27ac profile in Par and GemR upon thapsigargin (Thap) treatment and STIM1 
depletion. Black boxes indicate the regions used for ChIP qPCR. (B) ChIP qPCR of positive 
and negative H3K27ac sites around the TSS of TRIB3, ERN1 and DDIT3 in Par and GemR 
upon SOCE inhibition by CM4620 and thapsigargin (Thap) treatment. Each condition is 
depicted as a percentage of its corresponding input. Mean ±SD, n=3. (C) ChIP qPCR of 
positive ATF4 sites around the TSS of TRIB3, ERN1 and DDIT3 in Par treated with 
thapsigargin (Thap). The average ATF4 signal on the negative sites around TRIB3, ERN1 





condition is depicted as a percentage of its corresponding input. Mean ±SD, n=2. *P≤0.05, 
**P≤0.01, ***P≤0.001, ns=not significant. 
Consistent with our earlier findings, STIM1-depletion in GemR restored an 
enrichment of ATF4 and CHOP motifs in H3K27ac gained regions upon thapsigargin 
treatment in a manner similar to what we observed following thapsigargin treatment 
in Par cells (Fig. 26A), where 53% of ATF4 peaks overlapped with H3K27ac gained 
regions in Par (thapsigargin vs vehicle). On these regions, a significant increase in 
H3K27ac was only observed in Par and STIM1-depleted GemR, but not in GemR 
upon thapsigargin treatment (Fig. 26B-D). This confirms that GemR cells fail to 
recruit epigenetic factors to DN-reversed genes in a STIM1-dependent manner, 
indicating that STIM1-dependent SOCE rewires the cellular epigenome and 






2.4.5 NFAT is aberrantly activated in STIM1-amplified cells 
After characterizing the effects of STIM1 amplification on ER stress-induced gene 
expression, we examined genes that were specifically induced by thapsigargin in 
the presence of STIM1 amplification (UP-reversed cluster), which included KDM7A, 
KRT14 and KLF4. These genes were upregulated upon thapsigargin treatment in 
GemR, but less induced in Par and STIM1-depleted GemR (Fig. 27A). Similarly, 
SOCE inhibition diminished the induction of these genes by thapsigargin in GemR 
(Fig. 27B). These effects were not limited to GemR since STIM1-amplified Panc1 
cells also displayed an upregulation of KDM7A and KLF4 upon thapsigargin 
treatment in a STIM1-dependent manner (Fig. 27C). Moreover, H3K27ac signal 
intensity on the TSS of UP-reversed genes displayed a significant increase in GemR 
compared to Par and STIM1-depleted GemR upon thapsigargin treatment (Fig. 
27D).  
Fig. 26 STIM1 knockdown rescues H3K27ac profile around ATF4-occupied regions in 
GemR. (A) Top most significantly enriched motifs on gained H3K27ac regions in 
thapsigargin-treated (Thap) STIM1-depleted GemR compared to vehicle-treated STIM1-
depleted GemR (top) and on gained H3K27ac regions in Par treated with thapsigargin 
(Thap) compared to vehicle-treated Par (bottom). (B) Venn diagram of ATF4 peaks in Par 
treated with thapsigargin (Thap) and gained H3K27ac regions in Par treated with 
thapsigargin (Thap) compared to vehicle-treated Par. Aggregate plot of H3K27ac on ATF4 
summits of overlapping regions. (C) Heatmaps of H3K27ac and ATF4 on ATF4 summits of 
overlapping regions from Fig. 14B. (D) Bigwig compare of Par (left) and STIM1-depleted 
GemR (right) upon thapsigargin (Thap) treatment both compared to GemR treated with 






Fig. 27 Upon ER stress, STIM1-amplified cells upregulate and gain H3K27ac around 
the TSS of UP-reversed genes. (A) Gene expression of UP-reversed genes upon 
thapsigargin (Thap) treatment and STIM1 depletion in Par and GemR. Mean ±SD, n=3. (B) 
Gene expression of UP-reversed genes upon thapsigargin (Thap) treatment and SOCE 
inhibition by CM4620 in GemR. Mean ±SD, n=3. (C) Gene expression of UP-reversed 
genes upon thapsigargin (Thap) treatment and STIM1 depletion in Panc1. Mean ±SD, n=3. 
(D) H3K27ac profile around the TSS of UP-reversed genes in Par, GemR and STIM1-






To uncover the underlying mechanisms by which this subset of genes was 
specifically induced in response to ER stress in GemR cells, we employed EnrichR 
and GSEA. NFAT-related pathways were identified by EnrichR, while GSEA 
displayed an enrichment for the “NFAT transcription factor pathway” in thapsigargin-
treated GemR cells (siCont vs siSTIM1) (Fig. 28A-B and Table S5). Consistently, 
NFAT and NFAT-AP1 motifs were enriched in genomic regions displaying increased 
H3K27ac in the same comparison (Fig. 28C). NFAT activation by calcium signaling 
promotes its translocation to the nucleus, thereby enabling target gene activation. 
Consistent with our findings that GemR cells display pronounced SOCE, NFAT 
nuclear translocation was increased in thapsigargin-treated GemR and decreased 








To confirm the importance of NFAT in driving the expression of UP-reversed genes, 
we treated GemR with the calcineurin inhibitor cyclosporine A (CSA) to attenuate 
NFAT activation. We observed that the induction of UP-reversed genes by 
thapsigargin was dampened upon CSA treatment (Fig. 29A). Among the various 
NFAT proteins, NFATc2 is more tightly linked to STIM1 and SOCE (Kar and Parekh, 
2015; Kar et al., 2011). NFATc2 is also the only NFAT family member contained in 
the UP-reversed gene cluster. Consistent with a critical role in mediating the effects 
of altered calcium signaling in STIM1-amplified cells, NFATc2 depletion significantly 
dampened the induction of UP-reversed genes in thapsigargin-treated GemR (Fig. 
29B-C). Overexpression of STIM1 in Par, BxPC-3 and CFPAC-1 further confirmed 
that the upregulation of these genes by thapsigargin was due to increased SOCE 
elicited by higher STIM1 (Fig. 29D-F). Notably, the overexpression of NFATc2 in Par 
did not affect ATF4 levels and the ER stress response (Fig. 29G). This suggests 
that heightened SOCE independently leads to a dampened ER stress response and 
an aberrant NFATc2 activation. In conclusion, STIM1 amplification facilitates and 
increased SOCE, thereby promoting the upregulation of NFATc2 and calcium-
mediated activation of NFATc2-dependent gene expression. 
Fig. 28 GemR aberrantly activate NFAT upon ER stress. (A) NCI-2016 signature of UP-
reversed genes from EnrichR showing an enrichment for Calcineurin-dependent NFAT 
signaling.  (B) GSEA showing an enrichment for the NFAT TF pathway in GemR compared 
to STIM1-depleted GemR both treated with thapsigargin (Thap). (C) Motif analysis showing 
a significant enrichment for NFAT motifs on gained H3K27ac regions in GemR compared 
to STIM1-depleted GemR both treated with thapsigargin (Thap). (D) NFATc2 
immunofluorescence and average nuclear signal intensity in Par. Scale=5µm. Mean ±SEM, 
n=47 (Par siCont Veh), 34 (Par siCont Thap), 34 (Par siSTIM1 Veh), 41 (Par siSTIM1 Thap). 
(E) NFATc2 immunofluorescence and average nuclear signal intensity in GemR. 
Scale=5µm. Mean ±SEM, n=68 (GemR siCont Veh), 57 (GemR siCont Thap), 30 (GemR 






Fig. 29 NFATs drive the expression of UP-reversed genes in a STIM1-dependent 
manner. (A) Expression of UP-reversed genes upon cyclosporine A (CSA) and thapsigargin 
(Thap) treatments in GemR. Mean ±SD, n=3. (B) Expression of UP-reversed genes upon 
NFATc2 knockdown and thapsigargin (Thap) treatment in GemR. Mean ±SD, n=2. (C) 
NFATc2 knockdown validation. Mean ±SD, n=2. (D) Expression of UP-reversed genes upon 
STIM1 overexpression and thapsigargin (Thap) treatment in Par. Mean ±SD, n=3. (E) 
Expression of UP-reversed genes upon STIM1 overexpression and thapsigargin (Thap) 
treatment in BxPC-3. Mean ±SD, n=3. (F) Expression of UP-reversed genes upon STIM1 
overexpression and thapsigargin (Thap) treatment in CFPAC-1. Mean ±SD, n=3.  (G) 
Western blot of HA and ATF4 levels upon NFATc2 overexpression and thapsigargin (Thap) 
treatment in Par. *P≤0.05, **P≤0.01, ***P≤0.001, ns=not significant. 
2.4.6 STIM1 levels correlate with ATF4 and NFAT activity in primary PDAC 
and patient-derived xenografts 
To examine the in vivo relevance of our findings, we performed 
immunohistochemistry for STIM1, KRT14, and ATF4 in naïve primary tumor tissue 
derived from resected PDAC patients and in corresponding PDX-models derived 
from these specimens (Fig. 30A). Remarkably, in one patient tumor (GöPat15: Fig. 





expression was low, we observed readily detectable nuclear ATF4, but only low 
levels of KRT14 expression. In contrast, another patient tumor (GöPat4; Fig. 30B 
and D) and its corresponding PDX sample (GöPDX4; Fig. 30C-D) displayed higher 
STIM1 and correspondingly high KRT14 levels, but only cytoplasmic ATF4 
expression.  
 
Fig. 30 ATF4 and KRT14 expression correlate with STIM1 levels in treatment-naïve 
PDAC patients and PDXs. (A) Scheme depicting the generation of PDXs and the treatment 
schedule of mice with vehicle (Veh), gemcitabine (Gem) or a combination of gemcitabine 
and nab-paclitaxel (Gem/Pac). (B & C) Immunohistochemistry for STIM1, ATF4 and KRT14 
in naïve patient tumor material (Pat) (C) and in the respective naïve PDX. (D) Quantification 
of STIM1, ATF4 and KRT14 staining in naïve patient samples and PDXs. For all 






Next, we tested the effects of chemotherapy by treating PDXs with gemcitabine 
alone or in combination with nab-paclitaxel (Fig. 30A) and subsequently explored 
the expression of the aforementioned proteins. Notably, treatment of GöPDX13 with 
gemcitabine alone, or co-treatment with gemcitabine and nab-paclitaxel, resulted in 
increased STIM1 and KRT14 expression and lower nuclear ATF4 levels compared 
to the vehicle-treated GöPDX13 (Fig. 31A-C). Furthermore, mRNA-seq and GSEA 
analysis revealed an enrichment for UP-reversed genes in GöPDX13 co-treated 
with gemcitabine and nab-paclitaxel compared to untreated (Fig. 31D). Taken 
together, STIM1 is not only positively and negatively correlated with KRT14 
expression and ATF4 nuclear localization, respectively, in naïve patient tumors, but 
is also altered in response to treatment both in vitro and in vivo. Thus, STIM1 levels 
could be exploited as a potential biomarker and/or therapeutic target for naïve and 





















Fig. 31 STIM1 levels increase upon chemotherapy treatment in PDXs. (A) STIM1, ATF4 
and KRT14 staining in vehicle (Veh) as well as in gemcitabine (Gem) treated PDXs. (B) 
Immunohistochemistry for STIM1, ATF4 and KRT14 in vehicle (Veh) and gemcitabine and 
nab-paclitaxel (Gem/Pac) co-treated PDXs. (C) Quantification of STIM1, ATF4 and KRT14 
staining in gemcitabine and gemcitabine and nab-paclitaxel co-treated PDXs. (D) GSEA 
showing an enrichment for the UP-reversed genes in GöPDX13 co-treated with gemcitabine 
and nab-paclitaxel (Gem/Pac) compared to vehicle-treated GöPDX13. For all 






In this study, we examined molecular alterations resulting from prolonged 
gemcitabine treatment of PDAC and identified the co-amplification of RRM1 and 
STIM1 as responsible for gemcitabine resistance and for altered calcium signaling, 
downstream transcriptomic and epigenomic alterations, respectively. While STIM1 
amplification does not augment RRM1-driven gemcitabine resistance, it shifts 
calcium signaling via increased SOCE, thereby reciprocally dampening the ER 
stress response and increasing NFAT activity (Fig. 32A). 
 
Fig. 32 STIM1 acts as rheostat balancing between ATF4 and NFAT-dependent 
transcriptional programs. (A) Scheme depicting the amplification of RRM1 and STIM1 
upon gemcitabine resistance. While the upregulation of RRM1 drives gemcitabine 
resistance, increased STIM1 levels elicit a calcium signaling shift, leading to a dampened 
ER stress response and an aberrant NFAT activation. 
RRM1, one of the main targets of gemcitabine, was found to be amplified in GemR 
and to drive gemcitabine resistance. To date, studies have failed to show that RRM1 
levels are prognostic since its expression in naïve patients did not correlate with 
therapeutic response to gemcitabine (Ashida et al., 2009; Maréchal et al., 2012). 





response only in patient tumors after selective pressure caused by treatment. Thus, 
examining patient samples after treatment would help address this. 
Gene amplifications are common in tumors, and their overexpression is known to 
drive cancer progression. Recently, studies have revealed the importance of co-
amplified neighboring genes in tumorigenesis. For example, in HER2-positive breast 
cancer, the amplified region encompasses not only the oncogenic driver ERBB2, 
but also GRB7, MIEN1, PNMT, PGAP3, and TCAP (Ferrari et al., 2016). While 
HER2 overexpression drives HER2-positive breast cancer, GRB7 and MIEN1 affect 
tumorigenesis downstream and independent of HER-2, respectively (Chu et al., 
2010; Janes et al., 1997; Katz et al., 2010). Similarly, the co-amplification of RRM1 
and STIM1 elicits independent effects, where RRM1 does not affect ER stress 
resistance and NFAT activation, while STIM1 does not influence gemcitabine 
resistance. This suggests that the co-amplification of these genes endows tumor 
cells with distinct molecular properties, thereby potentially providing multiple survival 
advantages. Moreover, it is plausible that persistent ER stress or perturbed SOCE 
stimulation may elicit a selective pressure to amplify STIM1, which could result in 
the co-amplification of RRM1 and elicit gemcitabine resistance. This is supported by 
our finding that many treatment-naïve tumors display a co-amplification of STIM1 
and RRM1. It is also possible that the upregulation of STIM1 may help promote or 
facilitate the emergence gemcitabine resistance by promoting cell survival upon 
gemcitabine treatment during resistance acquisition. In support of this, STIM1 
depletion was shown to promote the pro-apoptotic effects of gemcitabine in 
pancreatic cancer cells (Kondratska et al., 2014). Furthermore, STIM1, and thereby 
SOCE, are known to regulate various metabolic processes (Maus et al., 2017; Vaeth 
et al., 2017), and could thereby help tumor cells adapt to metabolic changes which 
could arise as a consequence of RRM1 upregulation during the acquisition of 
resistance. 
ER stress activates ATF4 and elicits an initial pro-survival and secondary pro-
apoptotic response, where the former is suggested to be hijacked by many tumors 
(Urra et al., 2016). One such example is the hijacking of the pro-survival pathway 
upon hypoxia, where ATF4 promotes the transcription of VEGF, while activating 
antioxidant genes (Bi et al., 2005; Rouschop et al., 2013; Urra et al., 2016). Thus, 





tumors to adapt to stressful environments. Still, some PDAC tumors have been 
characterized to express higher levels of factors controlling ER homeostasis and 
conferring ER stress resistance (Milan et al., 2020). Our data supports this 
alternative mechanism whereby increased SOCE in STIM1-amplified tumors leads 
to ER stress resistance and NFAT activation. Interestingly, NFAT promotes the 
transcription of HIF1A in a STIM1-dependent manner in T cells (Vaeth et al., 2017), 
while STIM1 itself has been associated with hypoxic-driven tumorigenesis in 
hepatocarcinoma (Li et al., 2015). STIM1 and thereby SOCE are important 
regulators of melanoma aggressive behavior, controlling cellular oxidative stress 
through redox regulation of NFATc2 (Stanisz et al., 2014; Zhang et al., 2019a). 
Moreover, STIM and ORAI are important regulators of the pathobiology of several 
cancers (Prevarskaya et al., 2011). In PDAC, NFATs have been extensively 
characterized and shown to drive pancreatic cancer development and growth. 
NFATs are central in inflammation-driven pancreatic cancer development 
(Baumgart et al., 2014, 2016) and promote the silencing of CDKN2B in late-stage 
pancreatic intraepithelial neoplasia lesions (Baumgart et al., 2012). Furthermore, 
NFATs have been described to promote cell proliferation and tumor growth by 
fostering MYC expression in pancreatic cancer (Buchholz et al., 2006; König et al., 
2010c; Singh et al., 2010). Taken together, we suggest that rather than hijacking the 
pro-survival pathway of the ER stress response, STIM1-overexpressing tumors 
profit from an alternative STIM1-dependent/ATF4-independent pro-survival 
mechanism. In this case, STIM1 may act as a rheostat balancing between ER stress 
and NFAT activation, making STIM1 an attractive potential therapeutic target. Thus, 
STIM1 may also serve as a potential indicator of NFAT activation and ER stress 
resistance. 
While very little is known about calcium homeostasis in PDAC, calcium signaling is 
key in the development of acute pancreatitis (Raraty et al., 2000) where its 
therapeutic utility has been recently studied. In fact, the ORAI1 inhibitor CM4620 is 
currently being tested in a phase II clinical trial in acute pancreatitis patients 
(NCT04195347) (NCT03401190, 2018; NCT03709342, 2018; NCT04195347, 
2019). Notably, chronic pancreatitis is a known risk factor for the development of 
pancreatic cancer and is characterized by increased inflammation (Saluja et al., 





pancreatitis, it is worth noting that heightened NFAT activity promotes acinar to 
ductal metaplasia and fosters the progression of chronic pancreatitis to pancreatic 
cancer in mouse models (Chen et al., 2015, 2017). Consequently, SOCE inhibitors 
may prevent progression from chronic pancreatitis to PDAC. Hence, it is possible 
that some PDACs display aberrant calcium signaling obtained during previous 
chronic pancreatitis or due to other selective pressures. Therefore, analyzing STIM1 
levels in PDAC could potentially predict tumor sensitivity to stress, while tumors with 
high STIM1 expression might benefit from STIM and ORAI inhibitors. 
In conclusion, this study unravels novel independent molecular properties of 
gemcitabine-resistant tumors in PDAC. Through the amplification of RRM1, tumors 
become resistant to gemcitabine, while STIM1 acts as a rheostat balancing ER 
stress and NFAT activity in a SOCE-dependent manner. Furthermore, the co-
amplification can occur spontaneously in treatment-naïve cancer cells, making 
STIM1 a potential mediator of aberrant NFAT activation and SOCE inhibitors 






2.6 Materials and Methods 
2.6.1 Cell culture 
L3.6pl (Par) (RRID:CVCL_0384) and GemR were cultured in Minimum Essential 
Medium Eagle (Gibco, life technologies); Panc1 (RRID:CVCL_0480), CFPAC-1 
(RRID:CVCL_1119), SJSA (RRID:CVCL_1697), MG63 (RRID:CVCL_0426) in 
Dulbecco’s Modified Eagle’s Medium (Gibco, life technologies); BxPC-3 
(RRID:CVCL_0186) and DLD-1 (RRID:CVCL_0248) in Roswell Park Memorial 
Institute Medium (Gibco, life technologies); and HCT116 (RRID:CVCL_0291) in 
McCoy’s 5A Medium (Gibco, life technologies). All media were supplemented with 
10% FBS (Sigma-Aldrich) and 1% penicillin and streptomycin (Sigma-Aldrich); 
Minimum Essential Medium Eagle was supplemented with 1% L-glutamine (Sigma-
Aldrich). All cells were obtained after 2014 at which time numerous parental cell 
stocks were cryopreserved. Cells were maintained in culture for a maximum of 2-3 
months on average before thawing new stocks. All cells tested negative for 
Mycoplasma using the MycoAlert Mycoplasma Detection Kit (Lonza #LT07-318).  
2.6.2 Establishment of gemcitabine-resistant cells 
GemR were established by treating L3.6pl with increasing concentrations of 
gemcitabine (Sigma-Aldrich #G6432), starting at 4 nM and doubling the 
concentration once cells started to thrive again. This process was continued for 14 
weeks until reaching 64 nM, when cells were considered resistant and maintained 
at this concentration. 
2.6.3 Establishment of stable STIM1 overexpressing cell lines 
HEK293T (RRID:CVCL_0063) cells were transfected with pMD2.G (Addgene 
#12259), psPAX2 (Addgene #12260) and p2K7bsdUBI-mCherry-STIM1 (Addgene 
#114178) or p2K7-bsd-UBI-tagRFP-KDEL (Addgene #114179) using Lipofectamine 
3000 (Invitrogen) following manufacturer’s instructions. The virus was isolated and 
pooled by collecting the media at 24, 48, and 72 hours post-transfection and 
centrifuged at 500x g for 10 min to remove any cellular material. 500,000 L3.6pl, 
BxPC-3 and CFPAC-1 cells were reverse transfected and spin-occulated at 1000x 





normal culture media. After 48 h, the cells were resuspended in appropriate culture 
medium supplemented with 10 ug/mL Blasticidin S Hydrochloride (Millipore 
#203350). Selection was maintained throughout all experiments. 
2.6.4 Transient NFATc2 overexpression 
L3.6pl cells were forward transfected with either a constitutively active NFATc2 
pcDNA3.1 plasmid or an empty pcDNA3.1 vector (both provided by Dr. Singh, UMG, 
Göttingen) using Lipofectamine 3000 (Invitrogen) and following manufacturer’s 
instructions. Protein was harvested 48 h after transfection. 
2.6.5 siRNA transfections 
L3.6pl, GemR and Panc1 cells were reverse transfected with SmartPool siGENOME 
siRNA (Dharmacon) (Table S6) using Lipofectamine RNAiMax (Invitrogen) 
according to manufacturer’s instructions. All experiments were conducted after a 48 
h knockdown. 
2.6.6 Inhibitor treatments 
L3.6pl, GemR and Panc1 cells or transfected cells were treated with 500 nM 
thapsigargin (Focus Biomolecules #10-2105) for 3 h and/or 1 µM CM4620 (Hycultec 
# HY-101942), 1.5 mM EGTA (Sigma-Aldrich), 500 nM Cyclosporine A (Targetmol 
#59865-13-3) for 3.5 h prior to protein and/or RNA harvesting. For 
immunofluorescence, siRNA reverse transfected cells were treated with 500 nM 
thapsigargin (Focus Biomolecules #10-2105) for 40 min. 
2.6.7 Proliferation assay 
L3.6pl, GemR, DLD1 and HCT116 cells in a 96-well plate were seeded, alternatively, 
siRNA reverse transfected cells were used. One day after seeding, cells were 
treated with gemcitabine (Sigma-Aldrich #G6432), thapsigargin (Focus 
Biomolecules #10-2105) or 1 µM CM4620 (Hycultec # HY-101942). After 7 days of 
treatment, cells were fixed with methanol for 15 min, stained with 1% crystal violet 
in 20% ethanol for 15 min and scanned. Cell viability was assessed using cell titer 





absorbance at 590 nm after 7 days. Alternatively, crystal violet was solubilized in 
40% acetic acid and the absorbance measured at 590 nm. IC50 values were 
calculated by assessing the normalized absorbance at 590 nm.  
2.6.8 Protein harvesting and western blot 
Protein was harvested and western blot performed as described (Hamdan and 
Johnsen, 2018; Nagarajan et al., 2014). Briefly, cells were washed with PBS and 
resuspended in RIPA buffer (1X PBS, 1% NP-40, 0.5% Na-deoxycholate and 0.1% 
SDS) with 100 µM β-glycerophosphate, 100 µM N-Ethylmaleimeide, 100 µM 
Pefabloc, 1 µM Aprotinin and 1 µM Leupeptin. Protein extracts were sonicated for 
10 cycles (30 s on/off) using the Bioruptor Pico (Diagenode). Proteins were 
denatured for 10 min at 95 °C in lämmli buffer (375 mM Tris-HCl, 10% SDS, 30% 
glycerol, 0.02% bromophenol blue and 9.3% DTT). Polyacrylamide gels were used 
to separate the proteins, which were then transferred onto nitrocellulose membranes 
and incubated with primary antibodies overnight and secondary antibodies for 1 h. 
The Bio-Rad ChemiDoc imager was used to develop the membranes. The following 
antibodies were used: RRM1 (Cell Signaling #8637, RRID:AB_11217623), STIM1 
(Sigma-Aldrich S6197, RRID:AB_1079007), ATF4 (Cell Signaling #11815, 
RRID:AB_2616025), HA (Roche #3F10, RRID:AB_2314622), GAPDH (Origene 
#TA802519, RRID:AB_2626378), HSC70 (Santa Cruz #sc-7298, 
RRID:AB_627761), anti-rabbit IgG (Jackson ImmunoResearch Labs #211-032-171, 
RRID:AB_2339149) and anti-mouse IgG (Jackson ImmunoResearch Labs #115-
035-174, RRID:AB_2338512).  
2.6.9 RNA extraction and quantitative PCR 
RNA was extracted and qPCR run as described earlier (Hamdan and Johnsen, 
2018; Mishra et al., 2017). Briefly, tissues were homogenized in QIAzol and 
submitted to the same procedure as cells. RNA was harvested using QIAzol 
(Qiagen) and following manufacturer’s instructions. 1 µg of RNA was reverse 
transcribed using M-MuLV reverse transcriptase (NEB) and random nonamer 
primers according to manufacturer’s instructions. The CFX Connect Real Time 
System (Biorad) was used to perform qPCR with an initial denaturation step of 2 min 





levels were normalized to the housekeeping gene GAPDH (primer sequences in 
Table S7). 
2.6.10 Chromatin immunoprecipitation 
ChIP was performed as previously described (Hamdan and Johnsen, 2018; 
Najafova et al., 2017). Briefly, cells were fixed for 20 min with 1% formaldehyde in 
PBS and quenched for 5 min with 1.25 mM Glycine. Cells were scraped, mildly lysed 
and washed once with Nelson Buffer (150 mM NaCl, 20 mM EDTA (pH 8.0), 50 mM 
Tris-HCl (pH 7.5), 0.5% NP-40, 1% Triton X-100 and 20 mM NaF) with 100 µM β-
glycerophosphate, 100 µM N-Ethylmaleimeide, 100 µM Pefabloc, 10 µM 
Iodoacetamide, 1 µM Aprotinin and 1 µM Leupeptin. A stronger lysis was achieved 
with Gomes Lysis Buffer (150 mM NaCl, 1% NP-40, 0.5% Sodium-deoxycholate, 50 
mM Tris-HCl (pH 8.0), 20 mM EDTA (pH 8.0), 20 mM NaF and 0.1% SDS) with 100 
µM β-glycerophosphate, 100 µM N-Ethylmaleimeide, 100 µM Pefabloc, 10 µM 
iodoacetamide, 1 µM Aprotinin and 1 µM Leupeptin. The chromatin was sonicated 
for 30 cycles (30 s on/off) using the Bioruptor Pico (Diagenode) and precleared with 
100 µl Sepharose 4B (GE Healthcare). 1 µg or 10 µl of antibody were added to the 
pre-cleared chromatin extract and incubated overnight. Following, 30 µl of a BSA-
blocked 50% Protein-A Sepharose (GE Healthcare) slurry were incubated with the 
chromatin extracts for 2 h at 4 °C. The complexes were washed once with Gomes 
Lysis Buffer, twice with Gomes Wash Buffer (100 mM Tris-HCl (pH 8.5), 500 mM 
LiCl, 1% NP-40, 1% Sodium deoxycholate, 20 mM EDTA (pH 8.0) and 20 mM NaF), 
twice with Gomes Lysis Buffer and finally twice with TE Buffer (10 mM Tris-HCl (pH 
8.0) and 1 mM EDTA (pH 8.0)). 10 µg of RNAse A in 10 mM Tris-HCl (pH 8.0) were 
incubated with the washed complexes for 30 min at 37 °C. Following, proteins were 
digested overnight at 65 °C by diluting the immunoprecipitated complexes to a final 
10 mM EDTA (pH 8.0), 50 mM Tris-HCl (pH 8.0), 1% SDS and incubating them with 
20 µg Proteinase K. ChIP DNA was eluted from the beads with 10 mM Tris-HCl (pH 
8.0), precipitated with 0.4 M LiCl and linear acrylamide and isolated using 
phenol/chloroform/isomaylic alcohol extraction. ATF4 ChIP was only performed in 
Par treated with 500 nM thapsigargin for 3 h.  
The following antibodies were used: H3K27ac (Diagenode #C15410196, 





was used to probe IP and the enrichment at each site was calculated by normalizing 
the IP values to their respective inputs. Primer sequences used to probe IP 
enrichment at each site can be found in Table S8. 
2.6.11 Publicly available data 
The H3K27ac ChIP-seq and respective inputs in L3.6pl can be found in 
ArrayExpress (RRID:SCR_002964) (E-MTAB-7034). Thapsigargin and 
Gemcitabine sensitivity information from pancreatic cancer cell lines (Sanger 
GDSC1 data set (Iorio et al., 2016)) and STIM1 and RRM1 copy number variation 
information from cancer cell lines (DepMap Public 19Q4 data set (DepMap, 2020)) 
were downloaded from the Dependency Map portal (RRID:SCR_017655) from the 
Broad Institute (Ghandi et al., 2019) and plotted using the LSD package in R. 
Oncoprints with the expression gain rates of STIM1 and RRM1 in pancreatic cancer 
patients were generated by cBioportal for Cancer Genomics 
(RRID:SCR_014555)(Cerami et al., 2012; Gao et al., 2013) using the TCGA 
PanCancer Atlas Studies data set (Press).  
2.6.12 Next generation sequencing 
Sequencing libraries for ChIP-seq and RNA-seq were prepared using the KAPA 
HyperPrep (Roche) or the Microplex Library Preparation V2 (Diagenode) and the 
TruSeq RNA Library Prep V2 (Illumina) kits, respectively. Library quality was 
assessed using a Bioanalyzer 2100 (Agilent). The samples were sequenced on a 
HiSeq4000 (Illumina) at the NGS Integrative Genomics Core Unit (NIG) at the UMG 
or at the Genome Analysis Core at the Mayo Clinic. CASAVA 1.8.2 was used to 
demultiplex the bcl files to fastq files.  
2.6.13 Transcript Profiling 
The high throughput sequencing data in this publication has been deposited in 
NCBI's Gene Expression Omnibus (Edgar et al., 2002) and are accessible through 







2.6.14 RNA-seq analysis 
Fastq files were mapped to the human genome (hg38) using STAR (Dobin et al., 
2013) (version 2.6.0c, RRID:SCR_015899) followed by HTSeq-count (Anders et al., 
2015) (version 0.11.1, RRID:SCR_011867), which was used to obtain the read 
counts. Differential analysis was performed using DESeq2 (RRID:SCR_015687) 
(Love et al., 2014) and the thresholds were set to 0.8 log2FC, basemean >=25 for 
control or treatment and padj <=0.05. Gene Set Enrichment Analysis (GSEA, 
RRID:SCR_003199) (Subramanian et al., 2005) was performed using default 
settings and a gene set permutation type. Normalized read counts for each condition 
obtained from DESeq2 were filtered to contain only expressed genes (normalized 
count value >=30, 10 for PDX data) and used as input files for GSEA. Up and 
downregulated genes of thapsigargin-treated Par compared to vehicle-treated Par 
were identified. The corresponding log2 fold change values from these genes from 
Par, GemR and STIM1-depleted GemR treated with thapsigargin all compared to 
vehicle-treated Par were extracted and used for hierarchical clustering using the 
pheatmap package in R (RRID:SCR_016418). A heatmap was generated with the 
identified 4 gene clusters and the Z scores for all replicates. Pathways associated 
with each cluster were identified using EnrichR (RRID:SCR_001575) (Chen et al., 
2013; Kuleshov et al., 2016). 
2.6.15 ChIP-seq and copy number variation analysis 
Bowtie2 (Langmead and Salzberg, 2012) (version 2.3.4.1, RRID:SCR_005476) with 
a very sensitive read alignment setting was used to map fastq files to the human 
genome (hg38). Bam files for each condition were merged and PCR duplicates 
removed using Samtools (version 1.9, RRID:SCR_002105). Bamcoverage 
(Ramírez et al., 2016) from deeptools (version 3.0.1, RRID:SCR_016366) with 
default settings and RPKM normalization was used to generate initial bigwig files for 
visualization using the Integrative Genomics Viewer (RRID:SCR_011793) 
(Robinson et al., 2011; Thorvaldsdóttir et al., 2013). Final bigwig files were scaled, 
as differences in global background signal intensity were found between conditions. 
The scaling factor for each condition was individually defined as the ratio of the 
median signal intensity of control (vehicle-treated Par) across all TSSs +/- 1kb 





+/- 1kb. Untreated Par and GemR bigwig files were not scaled. ComputeMatrix from 
deeptools with the mode set to reference-point and a window of 1kb up and 
downstream of the region of interest was used to quantify the signal intensity within 
a region and to generate heatmaps and aggregate plots. Peaks were called using 
MACS2 (version 2.1.2, RRID:SCR_013291) with the input file as control, without 
building the model and with a cutoff of 0.05 for broad peak calling. Broad peaks were 
called for H3K27ac, while narrow peaks were called for ATF4. The R package 
Diffbind (RRID:SCR_012918) (Ross-Innes et al., 2012) was used to perform 
differential binding analysis using edgeR. Thresholds were set for gained regions 
(log2 >=1, conc. treatment >=4, FDR <=0.05) as well as lost regions (log2 <=-1, 
conc. control >=4, FDR <=0.05). Enrichment for transcription factor motifs on gained 
and lost regions was determined using HOMER (RRID:SCR_010881) (Heinz et al., 
2010). 
Copy number variation analysis was performed using CNVkit (Talevich et al., 2016) 
for whole genome sequencing and the input files of GemR as treatment and of Par 
as control. Thresholds for amplified and deleted regions were set to log2 >=1 and 
log2 <=-1, respectively. 
2.6.16 Calcium imaging 
Cytosolic calcium levels were assessed using a Zeiss Axiovert S100TV equipped 
with a pE-340fura (CoolLED) LED lightsource, a sCMOS pco.edge camera and a 
Fluar 20x/0.75 objective. siRNA reverse transfected cells were loaded with 1 µM 
Fura-2 AM (Thermo Fisher Scientific #F1221) for 30 min at room temperature in 
growth medium. The measurements were performed in Ringer’s buffer (pH 7.4) 
containing 145 mM NaCl, 4 mM KCl, 10 mM glucose, 10 mM HEPES (4-(2-
hydroxyethyl)-1-piperazineethanesulfonic acid), 2 mM MgCl2 and concentrations of 
CaCl2 as indicated, or 0 mM CaCl2 with 1 mM EGTA. SOCE was induced by addition 
of 1 µM thapsigargin. Ratiometric time-lapse imaging was performed using LED 
excitation at 340 nm (excitation filter: 340/20) and 380 nm (excitation filter: 380/20) 
together with a T400 LP dichroic mirror and 515/80 excitation filter. Data were 
analyzed with VisiView® Software (Visitron Systems GmbH). The obtained 340/380 





= K*(R − Rmin)/(Rmax − R), while the values of K, Rmin, and Rmax were determined 
as described previously (Grynkiewicz et al., 1985).  
2.6.17 Immunofluorescence 
Cells were washed twice with PBS and fixed using 4% Paraformaldehyde in PBS 
for 10 min. Three additional PBS washes were performed prior to permeabilization 
with 0.5% Triton X-100 in PBS for 10 min. Subsequently, cells were washed three 
times with PBS and blocked for 30 min with 3% BSA in PBS. The samples were 
incubated in a 1:100 dilution of the NFATc2 antibody (Abcam #ab2722, 
RRID:AB_303247) in 3% BSA in PBS overnight at 4 °C. After washing with PBS 
twice, a 1:500 dilution of the secondary antibody Alexa 488 donkey anti-mouse 
(Invitrogen #A-21202, RRID:AB_141607) was applied for 1 h at room temperature. 
The samples were washed three times with PBS, incubated with a 1:1000 dilution 
of DAPI in PBS for 30 min, and mounted in mounting media (9.6% (w/v) Mowiol 4-
88, 24% (w/v) Glycerol, 100 mM Tris-HCl (pH 8.5)). Confocal images were acquired 
using a Zeiss LSM 510 Meta microscope (Carl Zeiss AG) and the NFATc2 nuclear 
signal intensity was quantified using Fiji (RRID:SCR_002285) (Schindelin et al., 
2012; Schneider et al., 2012), where DAPI was used to mark the regions of interest 
(ROI). 
2.6.18 Patient-derived xenografts 
For patient-derived xenograft (PDX) model generation, pieces of bulk primary PDAC 
tissue from patients who underwent tumor resection at the UMG were 
subcutaneously transplanted in both flanks of NMRInu/nu mice. Tumors grew until 
their volume exceeded 1cm³ (F1 generation). Upon harvesting of tumors, one 
portion of the tissue was embedded in paraffin as described previously (Chen et al., 
2017), while the other half was subcutaneously transplanted into both flanks of 
another NMRInu/nu mouse for further tumor expansion (F2 generation). For 
gemcitabine/nab-paclitaxel co-treatment, F3-generation PDX-material from 
GöPDX13 was transplanted into both flanks of four NMRInu/nu mice. When tumor 
volumes reached 200mm³, mice were randomized into vehicle (0.9% saline) and 
chemotherapy arms. Gemcitabine (Sigma-Aldrich; 100mg/kg) was administered 
intraperitoneally 2x/week, nab-paclitaxel (Abraxane, Celgene; 30mg/kg) was given 





GöPDX13 material was transplanted into seven NMRInu/nu mice, which were 
randomized into vehicle and gemcitabine (100mg/kg) arms. Here, gemcitabine was 
administered 3x/week. Mice were sacrificed when endpoint criteria (e.g. weight loss 
≥ 20%) were reached (evident upon 3x nab-paclitaxel injections for the 
gemcitabine/nab-paclitaxel study and upon 6 injections in the gemcitabine solo arm) 
and PDX tumors were paraffin-embedded for histological assessment. Animal 
procedures were conducted in accordance with the protocols approved by the 
Institutional Animal Care and Use Committee (33.9-42502-04-17/2407). The 
generation and utilization of PDX models have been approved by the ethical review 
board of the UMG (70112108).  
2.6.19 Immunohistochemistry 
Immunohistochemical analyses of paraffin-embedded primary PDAC patient tissue 
or PDX tumors were performed as described previously (Chen et al., 2017) utilizing 
the Peroxidase Rabbit IgG Vectastain ABC kits (Biozol). The following primary 
antibodies were used: STIM1 (Sigma-Aldrich #S6197, RRID:AB_1079007; 1:900), 
KRT14 (Sigma-Aldrich #HPA023040, RRID:AB_1852201; 1:500) and ATF4 (Novus 
#NBP2-67766, RRID:AB_2877169; 1:100). Representative images were acquired 
using a Zeiss Axio Scope A1 (Carl Zeiss AG) microscope. The area covered by 
signal was measured using Fiji (RRID:SCR_002285) (Schindelin et al., 2012; 
Schneider et al., 2012), where the images were deconvoluted using HDAB Colour 
Deconvolution (Ruifrok and Johnston, 2001) and the signal area in the DAB channel 
measured after setting the threshold. 
2.6.20 Statistics 
GraphPad Prism v5.04 (RRID:SCR_002798) was used for statistical analyses. One-
way ANOVA followed by Newman-Keuls multiple comparison test was used for 
comparisons of more than two conditions. A non-linear regression with a variable 
slope and a bottom constrain between 0 and 2 was used to determine IC50 values, 
which were analyzed using unpaired two-tailed student’s t-test. Linear regressions 
were analyzed using Spearman’s correlation. P<=0.05 were considered statistically 






In this project we investigated the driver and consequences of gemcitabine 
resistance in pancreatic cancer. We identified the amplification of RRM1 as the main 
driver of gemcitabine resistance, and as being accompanied by the amplification of 
its neighboring gene, STIM1. The overexpression of the ER calcium sensor and vital 
SOCE component, STIM1, has proven to elicit ER stress resistance, protecting 
tumor cells from apoptosis. Furthermore, an increase in cytosolic calcium levels 
provoked the activation and translocation of NFATs, a family of transcription factors 
tightly associated with pancreatic cancer development and tumorigenesis. Finally, 
the overexpression of RRM1 did not influence the ER stress response, while higher 
levels of STIM1 did not affect gemcitabine resistance. 
3.1. Overexpression of gemcitabine targets and metabolic enzymes as 
prognostic markers 
In this study (Section 2.4.1), we identify the amplification and overexpression of 
RRM1 as being the main mechanism driving gemcitabine resistance. This is not 
surprising, as several other studies have pointed at the fact that gemcitabine 
resistance can arise due to the regulation of gemcitabine metabolizing enzymes 
and/or targets. In fact, the prognostic value of the expression level of gemcitabine 
metabolizing enzymes has proven to be very promising. In vitro studies as well as 
patient biopsies have shown that the levels of the transporting enzymes hENTs and 
hCNTs and of the kinase dCK correlate with the tumor’s response to chemotherapy 
(Bhutia et al., 2011; Farrell et al., 2009; Giovannetti et al., 2006; Maréchal et al., 
2010, 2012; Mori et al., 2007; Spratlin et al., 2004). Furthermore, gemcitabine 
catabolic enzymes, such as CDA and NT5Cs, have been implicated in gemcitabine 
resistance (Patzak et al., 2019; Weizman et al., 2014). In our hands no great 
difference was seen in the expression levels of these and other gemcitabine 
metabolizing enzymes in parental compared to gemcitabine resistant cells (data not 
shown). Thus, it is possible that the levels of these proteins correspond to the initial 
responsiveness of patients to gemcitabine, but are not the drivers of acquired 
gemcitabine resistance. In order to validate this hypothesis, a wider panel of parental 
and gemcitabine resistant cells lines would have to be established and tested. 





resistance acquisition. Lastly, the levels of these enzymes would be compared in in 
vivo studies as well as biopsies of naïve and treated patients.  
A similar phenomenon is seen regarding the overexpression of RRM1 as a driver of 
gemcitabine resistance. While we and several other groups have reported the 
upregulation of RRM1 upon gemcitabine resistance in in vitro and in vivo studies 
(Bergman et al., 2005; Nakahira et al., 2007; Nakano et al., 2007; Wang et al., 2015; 
Zhou et al., 2019), its prognostic value in patient material remains under debate 
(Akita et al., 2009; Aoyama et al., 2017; Maréchal et al., 2012). This may be 
attributed to the fact that the upregulation of RRM1 may be a gradual process during 
gemcitabine treatment. Consequently, its protein levels in naïve patient biopsies 
may not be indicative of the patient’s likelihood to develop chemotherapy resistance. 
This ability of cancer cells to substantially upregulate genes and adapt to external 
stresses is further supported by the fact that alterations in the tumor’s genomic copy 
number, subtype and chemotherapy response have been observed when 
monitoring PDAC progression (Tiriac et al., 2018). Thus, to draw any conclusions 
on the development of gemcitabine resistance and the response of individual 
patients to treatment, it would be of greatest importance to compare naïve as well 
as treated patient biopsies.  
Moreover, as we also show, it is possible that several PDAC tumors presenting an 
acquired gemcitabine resistance upregulate RRM1 by amplifying it. Even though, 
none of the aforementioned studies has ever identified an amplification of RRM1, 
one study has shown that, in their gemcitabine resistant cell lines, STIM1 and 
TRIM21 were also upregulated (Zhou et al., 2019). Interestingly, these two genes 
fall within our identified amplification region, suggesting that pancreatic cancer cell 
lines from other studies may also amplify a portion of chromosome 11 containing 
RRM1. Remarkably, the amplification of the segment of chromosome 11 has been 
reported in a gemcitabine resistant non-small lung cancer cell line (Tooker et al., 
2007). This further suggests that some genomic amplifications are selected for and 
provide an advantage to the tumor and that our model most likely represents a much 
wider array of gemcitabine resistant tumors. 
Taken together, assessing the levels of gemcitabine transporting and metabolizing 





agent. Still, as the disease progresses, a closer monitoring of RRM1 protein levels, 
as well as, copy numbers may be more indicative of acquired resistance, serving as 
a better prognostic marker. 
3.2. The advantage of (co-)amplifications 
It is common that tumor cells present genomic aberrations, many times amplifying 
or deleting entire segments of their genomes. Such genomic rearrangements are 
mainly due to failures to conventionally resolve double stranded breaks, while also 
being a consequence of major catastrophic events (Korbel and Campbell, 2013; Li 
et al., 2020; Willis et al., 2015). Thus, copy number variations take place rather 
randomly and may be selected for in tumors as they provide the cell with additional 
characteristics. In fact, mutant K-RAS was found to be amplified in many pancreatic 
tumors, while SMAD4 and CDKN2A were frequently deleted. As mentioned 
previously, mutations in K-RAS and silencing of CDKN2A and SMAD4 are key 
events in the development of PanIN lesions to pancreatic cancer (Notta et al., 2016; 
Singhi et al., 2017). Moreover, other genes such as c-MYC, CDK6, NOV, MET, 
SOX9, BRAF, PREX2, ERBB2 and PIK3CA are commonly amplified in pancreatic 
cancer patients (Singhi et al., 2019; Waddell et al., 2015). While, the transcription 
factors GATA6 and FOXA2 are known to be amplified in the classical subtype 
(Chan-Seng-Yue et al., 2020). This suggests that many early pro-tumorigenic 
events take place in the form of genomic aberrations. They shape the cellular 
transcriptome, while also affecting several processes such as DNA damage 
response and cell cycle arrest.  
Not only crucial in the development of cancer, genomic amplifications may affect the 
tumor’s response to chemotherapy and may take place after chemotherapeutic 
treatment. This may be due to the high chromotrypsis and plasticity associated with 
cancer cells. Several studies have described a correlation between the tumor’s 
genetic background and its responsiveness to chemotherapy. For example, PDAC’s 
response to platinum-based agents has been associated with the tumor’s genomic 
stability and mutation frequency on DNA damage responsive genes, such as 
BRCA1 and BRCA2 (Singhi et al., 2019; Waddell et al., 2015). Furthermore, major 
K-RAS genomic imbalances have been correlated with higher chemotherapy 





subtype (Chan-Seng-Yue et al., 2020). In the rare absence of a K-RAS mutation, 
some PDAC tumors have displayed an amplification of EGFR, ERBB2 and AKT 
instead. Tumors with such atypical genomic background presented higher sensitivity 
to tyrosine receptor kinase inhibitors, such as afatinib (Singhi et al., 2019; Tiriac et 
al., 2018). This suggests that the genetic background of cells may highly influence 
their sensitivity to chemotherapy. It further implies that tumors are extremely plastic, 
favoring certain genetic mutations and/or undergoing major genomic 
rearrangements upon a selective pressure.  
Thus, the amplification of chromosome 11 upon gemcitabine acquired resistance, 
as identified in section 2.4.1, serves as another example for such occurrences. It 
may also be a, so far unreported, feature of several studied PDAC tumors and 
should be included in the future characterization of naïve and treated patient 
biopsies. The fact that some naïve cancer cell lines already display the amplification 
of STIM1 and/or RRM1, exemplifies the randomness of such events. The 
maintenance of the amplification, on the other hand, suggests it confers survival 
advantages even to naïve cells. Thus, the reported amplification of RRM1 and 
STIM1 (Section 2.4.3) may serve to gauge how well tumors will respond to 
treatment, as well as how fast they may become resistant to a specific 
chemotherapeutic agent. 
Even though many times the focus lies on the amplification of one specific gene, 
genomic aberrations imply that an entire chromosomal segment is amplified. Thus, 
several other genes, whose functions may have been less studied, are also 
overexpressed. One such examples is the amplification of ERBB2 in breast cancer, 
which extends from chr17:37,818,020 to chr17:37,924,454 and encompasses not 
only ERBB2, but also TCAP, PNMT, PGAP3, MIEN1 and GRB7 (Ferrari et al., 2016; 
Staaf et al., 2010). Later studies revealed that the co-amplification of GRB7 further 
augments the effects of HER2 overexpression.  GRB7 interacts with HER2 directly 
via its SH2-domain, and activates Ras triggering the initiation of the MAPK signaling 
cascade upon EGF signaling (Chu et al., 2010; Janes et al., 1997). On the other 
hand, the overexpression of MIEN1 has been associated with increased migratory 
potential in breast cancer in a HER2-independent manner. In this case, MIEN1 was 
shown to promote migration by triggering downstream Syk-dependent signaling and 





overexpression of co-amplified genes may synergistically promote tumorigenesis or 
endow cells with different oncogenic properties. Our data supports this idea in which 
the amplification of RRM1 confers gemcitabine resistance, while the overexpression 
of STIM1 leads to ER stress resistance and NFAT signaling activation.  
Furthermore, it is possible that other genes co-amplified with RRM1 and STIM1 
provide the cells with additional oncogenic properties or enhance gemcitabine 
resistance and/or ER stress resistance and NFAT activation. The co-amplified 
genes identified on chromosome 11 in section 2.4.1 also encompass ILK and WEE1, 
which have been previously linked to oncogenic pathways. ILK has been shown to 
promote cell proliferation and migration by activating the Akt/mTOR and GSK3β 
pathways, while also fostering the expression of SNAI1 (Hannigan et al., 2005; 
Sawai et al., 2006). Furthermore, ILK inhibition in pancreatic cancer has been 
proven to prevent tumor growth and to synergize with acute gemcitabine treatment 
(Yau et al., 2005). Thus, it is possible that in our case the amplification of ILK 
enhances gemcitabine resistance, while also potentially increasing cell migration. 
The overexpression of WEE1 may also augment gemcitabine resistance in our 
system, as gemcitabine targets DNA Polymerase triggering replication stress, while 
WEE1 is known to protect cells from DNA damage by inducing cell cycle arrest 
(Beck et al., 2012; Sørensen and Syljuåsen, 2012). This way, the upregulation of 
WEE1 could play a cytoprotective role upon gemcitabine treatment. In fact, WEE1 
inhibition in combination with gemcitabine and radiation therapy has shown 
promising results in pancreatic cancer patients (Cuneo et al., 2019; Koh et al., 2018). 
Thus, it would be interesting to test whether gemcitabine resistant cells can be 
sensitized to gemcitabine with ILK or WEE1 inhibitors. If so, tracing the percentage 
of gemcitabine resistant tumors that co-amplify RRM1 and ILK or WEE1 can be of 
great prognostic value.  
In conclusion, characterizing gene amplifications is not only valuable to dissect 
cancer development, but also to better understand how tumors may adapt to 
stresses, such as chemotherapeutic agents. Even though specific gene 
amplifications are regarded as the drivers of a certain cancer type or 
chemotherapeutic resistance mechanism, their co-amplified genes may also 





studies is crucial, while dissecting the interplay between genomic aberrations may 
widen our understanding of cancer and chemotherapy resistance. 
3.3. Are co-amplifications by chance or selected for? 
As described in the previous section, genomic amplifications are a common feature 
in cancer, which take place randomly and may be associated with metastasis and 
chemotherapy response. Furthermore, co-amplifications may reinforce each other 
or confer independent properties to tumors (Section 3.2). Interestingly, some co-
amplifications have been reported to present a high co-occurrence rate, while others 
have been shown to be mutually exclusive, revealing the importance of the selection 
applied on genomic aberration events. Mutual exclusivity can be a result of genomic 
aberration redundancy or synthetic lethality, where cells cannot handle both 
alterations at the same time. On the other hand, co-occurrence of genomic 
aberrations suggests that the alterations complement each other (Deng et al., 2012; 
Sanchez-Vega et al., 2018).  
In PDAC, mutual exclusivity is often seen in the context of K-RAS mutations and 
amplifications. In the absence of an amplified and mutated K-RAS, pancreatic 
cancer tumors frequently amplify ERBB2 and present a higher dependency on 
MAPK and mTOR signaling (Singhi et al., 2019; The Cancer Genome Atlas 
Research Network et al., 2017; Tiriac et al., 2018). Similarly, while deletions of 
SMAD4 are frequent in pancreatic cancer, a tendency has been described for basal 
pancreatic cancer tumors to present an intact SMAD4 copy (Chan-Seng-Yue et al., 
2020). Interestingly, the co-occurrence of SMAD4 loss and GATA6 amplification 
was observed in the classical subtype of pancreatic cancer (Notta et al., 2016). 
Furthermore, FOXA2 has been shown to be amplified in the small fraction of 
classical tumors harboring an intact SMAD4, hinting at a possible mutual exclusivity 
with GATA6 amplification and co-occurrence with intact SMAD4 (Chan-Seng-Yue 
et al., 2020). An even better example of co-occurring genomic aberration is the 
mutation and amplification of K-RAS, accompanied by the deletion of CDKN2A and 
SMAD4 driving pancreatic cancer progression (Notta et al., 2016). This exemplifies 
how different sets of genomic aberrations are selected for during pancreatic cancer 





cells. Thus, even though genomic aberrations are random in origin, they are 
selected for by several internal and external cues.  
Our findings pose a similar scenario in which several genes are co-amplified upon 
the selective pressure of gemcitabine treatment. The co-amplification of RRM1 and 
STIM1 confers the cells with different oncogenic properties, these being 
gemcitabine resistance and ER stress resistance accompanied by NFAT activation, 
respectively. Still, it is possible that the co-amplification of STIM1 is selected for and 
is not just a “passenger” effect arising from the amplification of RRM1 upon 
gemcitabine. This could be rationalized through the impact of STIM1 and calcium 
signaling in NFAT activation and the stress response. It is possible that during an 
initial response to gemcitabine, cells upregulate RRM1 and face major changes in 
their metabolic pathways. RRM1 is responsible for catalyzing the rate limiting step 
in the de novo dNTP synthesis pathway and is thus regarded as a key player in 
metabolic processes (Aye et al., 2014; Kohnken et al., 2015). The upregulation of 
STIM1 in this case could further promote RRM1 activity, by preventing the activation 
of the integrated stress response and thus evading apoptosis and the shutdown of 
energy consuming metabolic processes elicited by RRM1. Moreover, upregulating 
STIM1 could help the cells cope with metabolic changes by promoting the activation 
of NFAT and its downstream targets c-MYC and HIF1a (König et al., 2010b; Singh 
et al., 2010; Vaeth et al., 2017). These factors have been shown to stimulate the 
transcription of several metabolic genes (Dejure and Eilers, 2017; Stine et al., 2015), 
such that STIM1 could aid in the initial metabolic adaptation of the cells. Still, once 
adapted to high levels of RRM1 and STIM1, cells may employ other mechanisms to 
maintain their metabolic processes, such that the effects of the co-amplification may 
become independent. Therefore, it is possible that the co-amplification of RRM1 and 
STIM1 poses another example of genomic aberration co-occurrence in cancer. We 
can speculate that the co-amplification of STIM1 and RRM1 will present a high co-
occurrence rate in gemcitabine resistant PDAC and may serve to monitor tumor 
responsiveness to chemotherapy and stress. 
Expanding this hypothesis, stress elicited by the tumor’s microenvironment may 
promote the amplification of STIM1. In this case, the co-amplification of RRM1 may 
be regarded as a “passenger” effect or as a co-occurrence depending on the source 





STIM1, thriving under stress. Still, while doing so, cells would fail to halt energy-
consuming processes, possibly being faced with the challenge of rewiring their 
metabolic dependencies. Thus, during the adaptation period and depending on the 
source of stress, the cells may profit from the metabolic changes accompanied by 
the upregulation of RRM1. This way, the co-amplification of RRM1 and STIM1 would 
again co-occur and synergize only during the adaptation of the cells to specific 
sources of stress. The fact that naïve cancer cell lines and tumors present a high 
co-occurrence rate of the co-amplification of RRM1 and STIM1 further supports the 
idea. In which the tumor microenvironment may impose a selective pressure on 
tumors thriving under stressful conditions, favoring those with a co-amplification of 
RRM1 and STIM1. Therefore, it would be of great importance to assess STIM1 and 
RRM1 levels in cells and tumors upon a wide array of stresses. This would not only 
prove the hypothesis but also provide evidence as to which stress sources would be 
responsible for selecting for the co-amplification.  
Taken together, even though the properties conferred by the co-amplification of 
RRM1 and STIM1 are independent of each other, they may have both been selected 
for during the adaptation process to gemcitabine treatment. This way, serving as an 
example for genomic aberration co-occurrence in gemcitabine-treated tumors. 
Furthermore, it is highly probable that other sources of stress would also favor the 
co-amplification of STIM1 and RRM1. Thus, even though random in nature, the co-
amplification of RRM1 and STIM1 may be selected for by different stimuli. 
 
3.4. ER stress response: essential or dispensable for the tumor? 
Here we identify the amplification of STIM1 and concomitant increased SOCE as 
responsible for a dampened ER stress response in gemcitabine resistant tumors. 
We further hypothesize that other stresses may also serve as a selective pressure 
for the amplification of STIM1. Still, several studies have pointed at the fact that 
tumors may take advantage of their stressful environment by hijacking the pro-
survival branch of the ISR. In fact, the pro-survival ATF4-triggered response has 
been associated with several tumorigenic processes such as angiogenesis, 
metastasis, genomic instability, and therapeutic resistance (Bi et al., 2005; Dufey et 





One of the best characterized examples is that of hypoxia triggered ER stress 
response and the tumor’s consequent adaptation to oxygen-deprived environments. 
In this case, ATF4 activation by PERK upon ER stress, has been proposed to be 
crucial for the transcription of angiogenic genes. Both, ATF4 and XBP1 have been 
reported to bind the promoter region of VEGFA, while ATF4 has been shown to be 
a driver of VEGFA expression upon stress (Pereira et al., 2014; Wang et al., 2012). 
Furthermore, ATF4 has been shown to interact with and to stabilize HIF1a, 
promoting angiogenesis in bone (Zhu et al., 2013). HIF1a is also a driver of several 
cancers, promoting invasion and metastasis in PDAC (Zhang et al., 2017; Zhao et 
al., 2014). Thus, it is possible that highly hypoxic tumors, such as PDAC, rather profit 
from the activation of the ISR and from ATF4 activity upon hypoxia. 
Following this hypothesis, it is possible that PDAC tumors expressing high STIM1 
levels, may be more vulnerable to hypoxia, as they present a dampened ER stress 
response. At the same time that increased STIM1 and SOCE levels may protect 
pancreatic cancer cells from the pro-apoptotic branch of the ISR, they may impede 
them from hijacking the pro-survival branch upon hypoxia and other ER stresses. 
One could speculate that these tumors would fail to activate ATF4, thus failing to 
upregulate VEGFA and to stabilize HIF1a upon hypoxia. 
On the other hand, STIM1 and SOCE have been shown to promote HIF1a 
expression and stabilization during hepatocarcinogenesis. In this case, upon 
hypoxia, elevated SOCE lead to the activation of CAMKII and consequently of the 
p300 acetyltransferase (Li et al., 2015). p300, in turn, interacts with the 
transactivation domain of HIF1a, stabilizing and preventing the degradation of the 
latter (Yuan et al., 2005). Interestingly, in a feedback mechanism, HIF1a has been 
shown to bind the promoter region of STIM1 increasing its expression upon hypoxia. 
Furthermore, several different tumor types have shown a positive correlation 
between STIM1 and HIF1a levels (Li et al., 2015; Wang et al., 2019). Thus, it is also 
plausible that some tumors rely on the activation of SOCE by STIM1 to cope with 
hypoxia. 
For this reason, STIM1 amplifying cell lines may be able to thrive under hypoxic 
conditions by activating HIF1a through SOCE, circumventing the dampened ER 





hijacking the pro-survival pathway of the ER stress response upon hypoxia may 
become dispensable for the cell. Instead, tumors may employ SOCE-dependent 
alternative mechanisms and pathways to cope with oxygen-deprivation. Thus, 
redundant signaling pathways may aid tumors with very different genetic and 
epigenetic backgrounds to adapt to the same source of stress. This may apply not 
only to hypoxia-induced stress, but also to other external stimuli. 
In order to test the hypotheses above, one would have to first determine whether 
cells expressing high levels of STIM1 present a greater susceptibility to hypoxia or 
not. If the cells rely on the ER stress response to cope with hypoxia, it is plausible 
that STIM1 overexpressing cells display a survival disadvantage under hypoxia. 
Alternatively, if relying on elevated SOCE to cope with oxygen-deprivation, these 
cells may present a similar or improved survival advantage compared to cells 
expressing lower levels of STIM1. Finally, in order to confirm the ER stress or SOCE 
dependency of these cells in response to hypoxia, cells could be deprived from 
STIM1, ATF4 and PERK and their response to hypoxia assessed. In conclusion, 
tumors present different genetic and epigenetic backgrounds, which may affect the 
pathways activated upon stimuli. Even though many cancers rely on the pro-survival 
branch of the ER stress response to overcome several stresses, cells may also 
adapt and employ alternative mechanisms to thrive under the same stimuli and 
conditions. 
3.5. The possible advantages of aberrant NFAT activation 
As identified in section 2.4.5, an alternative pathway activated in STIM1 
overexpressing cells upon heighted SOCE is the NFAT signaling pathway. The 
NFAT family of transcription factors is best described in the immunology field, where 
it regulates T cell activation and differentiation, while also affecting the function of 
other immune cells (Müller and Rao, 2010). Still, NFATs have been reported to be 
crucial in other cell systems as well and their dysregulation associated with several 
diseases, including heart problems and cancer (Dewenter et al., 2017; Mancini and 
Toker, 2009). In the case of cancer, NFATs have been described to promote 
angiogenesis, metastasis and tumor progression (Mancini and Toker, 2009). Thus, 
aberrant NFAT activation in STIM1 overexpressing cells may confer these tumors 





Angiogenesis is a hallmark of cancer, in which tumors upon different stimuli, 
including hypoxia, activate HIF1a, upregulating and secreting VEGF, while also 
reprogramming their metabolism to adapt to oxygen-deprived environments. 
Endothelial cells surrounding the tumor, in turn, can bind VEGF, which stimulates 
their proliferation and fosters angiogenesis (Majmundar et al., 2010). In many 
endothelial cells, the response to VEGF and the subsequent upregulation of 
angiogenic genes, such as COX2, has been proven to be SOCE and NFAT-
dependent (Mancini and Toker, 2009; Suehiro et al., 2014). Interestingly, NFATs 
have also been described to induce HIF1a expression to promote a metabolic 
rewiring in T cells. T cell proliferation has been shown to be dependent on a 
metabolic reprogramming elicited by SOCE and subsequent NFAT and Akt/mTOR 
signaling pathway activation. In this case, NFATs promoted the upregulation of the 
transcription factors HIF1a and IRF4, while Akt/mTOR signaling lead to c-MYC 
activation. Together, NFATs, HIF1a, IRF4 and c-MYC induced the expression of 
various metabolic genes involved in glycolysis, oxidative phosphorylation and 
nucleotide metabolism (Vaeth et al., 2017). Taken together, there is evidence 
suggesting that NFATs control several players involved in angiogenesis and the 
response to hypoxia. Thus, it is possible that in STIM1 overexpressing tumors, 
NFATs may promote the upregulation of HIF1a and the initiation of angiogenesis 
upon hypoxia and other SOCE-promoting stimuli. Furthermore, it is plausible, that 
similar to T cells, NFAT activation upon different stimuli, may rewire the metabolic 
dependencies of STIM1 overexpressing cells. 
Even though, the above speculations have to be tested, an NFAT-dependent 
upregulation of HIF1a could confer STIM1 amplifying cells with an alternative 
pathway to respond to stress signals, which is independent from the ER stress 
response pathway. Furthermore, an NFAT-driven metabolic rewiring upon SOCE 
stimulation, may help the cells cope with several metabolic stresses. Thus, it is 
possible that potential metabolic changes, elicited by the upregulation of RRM1 
during the establishment of gemcitabine resistance, are further accommodated by 
a metabolic reprogramming elicited by aberrant NFAT activation due to STIM1 
upregulation. This would, in turn, favor the co-amplification of RRM1 and STIM1 





Aberrant NFAT activation in STIM1 overexpressing tumors may not only lead to 
increased angiogenesis and a possible metabolic reprogramming, but also to 
heightened metastatic rates. In melanoma, increased NFAT signaling in epithelial 
cells lead to heightened BMP2 secretion, which promoted cancer cell 
dedifferentiation and metastasis. NFAT activity has also been associated with 
increased cell migration and invasion in breast cancer, while being characterized as 
the driver of several metastatic factors in colon cancer (Jauliac et al., 2002; Tripathi 
et al., 2014; Yiu and Toker, 2006). In PDAC, aberrant NFATc1 activation led to 
increased expression of several EMT genes (Hendrikx et al., 2019). By dimerizing 
with SOX2, NFATc1 drove the upregulation of the EMT-promoting transcription 
factors ZEB1, TWIST and SNAI1 (Singh et al., 2015). Thus, it is highly likely that 
cells expressing higher STIM1 and therefore SOCE levels, present a more 
dedifferentiated phenotype and higher metastatic potential.   
Interestingly, NFATs have also been extensively characterized as drivers of 
pancreatic cancer development and growth. Several studies demonstrated that 
NFAT is key for inflammation-driven pancreatic cancer development (Baumgart et 
al., 2014, 2016). The promoter of NFAT itself has also been shown to be methylated 
by EZH2 and consequently silenced in pancreatic acinar cells. This was reversed 
upon KRAS activation during PDAC development, leading to the de-repression and 
concomitant activation of NFATc1 (Chen et al., 2017). Moreover, NFATc2 has been 
shown to promote the silencing of the tumor suppressor CDKN2B further fostering 
tumorigenesis (Baumgart et al., 2012).  NFATs further promote c-MYC expression 
and cell proliferation in pancreatic cancer (Buchholz et al., 2006; König et al., 
2010c). For example, TGFβ has been reported to activate NFAT, which in turn 
displaces SMAD3 allowing TGFβ responsive genes, such as c-MYC, to be 
activated, ultimately promoting tumor growth (Singh et al., 2010). Therefore, it is 
highly likely that STIM1 overexpressing pancreatic cancer cells display a 
tumorigenic and proliferative advantage elicited by aberrant NFAT activation 
compared to STIM1 lowly expressing cells.  
In order to validate all aforementioned hypotheses, functional assays comparing low 
and high STIM1 expressing cells under resting conditions as well as under several 
stresses would have to be conducted. Xenograft experiments could also be 





tumor progression, volume and metastasis occurrence are monitored. Still, even 
though the consequences of an aberrant NFAT activation in STIM1 overexpressing 
cells have to be better characterized, previous studies highly suggest that ectopic 
NFAT activation may confer these cells with important additional tumorigenic 
properties. 
3.6. The benefits and drawbacks of targeting calcium signaling in 
pancreatic cancer 
As described in the sections above, the amplification of STIM1 in pancreatic cancer 
cells upon gemcitabine resistance elicits a shift in calcium signaling and an 
epigenetic reprogramming. The consequent increased SOCE and NFAT activity 
may confer the cells with several additional oncogenic properties, while the 
dampened response to ER stress protects the cells from apoptosis. Therefore, the 
targeting of NFAT and SOCE may prevent the activation of pro-tumorigenic 
processes, while also reestablishing the sensitivity to ER stress.  
NFAT activation can be targeted by inhibiting calcineurin activity employing 
cyclosporine A (CSA) and FK506 (tacrolimus). These compounds are routinely used 
in the clinic as immunosuppressants, preventing organ transplantation rejection, and 
their potential in cancer treatment is still under investigation (Azzi et al., 2013; 
Kaufman et al., 2004). Studies have shown the benefits of using these FDA-
approved drugs in the treatment of different cancer entities. In bladder cancer, both 
CSA and tacrolimus lead to decreased migration and invasion in vitro as well as 
decreased tumor volume in vivo (Kawahara et al., 2015). In breast cancer, 
tacrolimus treatment reduced cancer cell proliferation and migration, while inhibiting 
angiogenesis (Siamakpour-Reihani et al., 2011). Still, the use of these compounds 
for cancer treatment has to be carefully assessed and treatment schedules wisely 
planned. Prolonged exposure to CSA or tacrolimus has been associated with 
increased cancer incidence (Dantal and Soulillou, 2005; Mancini and Toker, 2009), 
while both compounds are also known to elicit severe side effects (Azzi et al., 2013; 
Rezzani, 2004). Furthermore, in our case, where pancreatic cancer cells amplify 
and overexpress STIM1, inhibiting calcineurin with CSA or tacrolimus would solely 





Thus, the SOCE-dependent ER stress resistance observed in these cells would 
most likely perdure. 
In order to target the potential pro-oncogenic properties elicited by aberrant NFAT 
activation, while also sensitizing the cells to ER stress, STIM1 overexpressing 
pancreatic cancer cells could be treated with SOCE inhibitors. Even though, no 
SOCE inhibitor has been approved by the FDA yet, several ones have been 
developed and some are being tested in clinical trials for the treatment of acute 
pancreatitis.  Aberrant calcium signaling is one of the first events leading to the 
development of acute pancreatitis, where increased SOCE leads to early exocytosis 
of zymogens and premature activation of proenzymes in the intracellular space and 
inside acinar cells. Consequently, the pancreas is slowly digested, triggering 
pancreatitis (Raraty et al., 2000; Ward et al., 1995). During preclinical trial studies, 
the SOCE inhibitors GSK7975A and CM128 have shown very promising results in 
treating acute pancreatitis, while also preventing pancreatic acinar cell injury 
(Gerasimenko et al., 2013; Wen et al., 2015). Among SOCE inhibitors, CM4620 
(also known as Auxora) is currently in phase 2 clinical trials for the treatment of acute 
pancreatitis.  
As clinical trials with CM4620 and other SOCE inhibitors evolve, scientists may 
better gauge the impact of SOCE inhibition in the body. It is highly possible that 
SOCE inhibitors lead to the immunosuppression of patients, as SOCE is upstream 
of NFAT activation, and as the immunosuppressants CSA and tacrolimus are known 
repressors of NFAT activity. Furthermore, several important SOCE-dependent 
physiological processes, such as the release of insulin in the pancreas, the 
glomerular hemodynamics in the kidney, the formation of osteoclasts in the bone 
and the differentiation of myoblasts in skeletal muscle, among others, may be 
transiently impaired during SOCE inhibitor treatment (Soboloff et al., 2012). Still, the 
occurrence of these potential side effects will largely depend on the concentration 
and duration of the inhibitor treatment. 
Assuming CM4620 and/or other SOCE inhibitors are approved by the FDA and little 
to mild side effects are detected, SOCE inhibitors may be a suitable candidate to 
treat pancreatic tumors, where STIM1 is overexpressed. Thus, assessing the 





stratify tumors and gauge their sensitivity to stress as well as their suitability for 
SOCE inhibitor treatments. Furthermore, by restoring the cellular sensitivity to ER 
stress, upon SOCE inhibitor treatment, these tumors may be more sensitive to 
alternative chemotherapies, which trigger apoptosis via ER stress. Taken together, 
SOCE inhibition may pose an alternative treatment option for pancreatic cancer 

























Gemcitabine resistance is recurrent in pancreatic cancer and a major factor 
contributing to the low 5-year survival rate faced by PDAC patients. Even though 
gemcitabine resistance itself has been studied extensively before, the molecular 
changes accompanying gemcitabine treatment remained largely unknown. In this 
study, we identify genomic, epigenomic and transcriptomic changes taking place 
upon gemcitabine resistance. We further unravel changes in signaling pathway and 
stress response dependencies upon acquired gemcitabine resistance, and propose 
their targeting as an alternative treatment to gemcitabine (Fig. 32). 
When characterizing gemcitabine resistant cells, two neighboring genes, RRM1 and 
STIM1, were identified as highly amplified and highly upregulated in gemcitabine 
resistant cells compared to parental cells. The role of RRM1 in gemcitabine 
resistance had been characterized previously, and was further validated in our 
experiments as driving resistance in GemR. Still, the amplification of RRM1 has 
never been reported in gemcitabine resistant PDAC tumors and its monitoring during 
treatment may serve to gauge gemcitabine response in patients and to assess the 
need to switch to alternative treatment options.  
The overexpression of STIM1, on the other hand, had not been implicated in 
gemcitabine resistance before and the high co-occurrence rate of its co-
amplification with RRM1 not reported previously. High levels of STIM1 did not 
contribute to gemcitabine resistance in GemR, but elicited an increase in SOCE, 
which triggered an epigenetic and transcriptomic reprogramming. Heightened 
SOCE elicited a dampened ER stress response in GemR compared to parental 
cells, as observed in proliferation assays, transcriptomic studies and by comparing 
the histone mark for active transcription, H3K27ac. The role of SOCE in preventing 
the activation of the ER stress response in cancer is described for the first time in 
this study. Even though a few recent publications have hinted at the interplay 
between SOCE and the ER stress response in diabetes, the exact mechanism by 
which SOCE prevents the activation of the ER stress response remains elusive. 
Thus, our findings open a new field for investigation, where the role of cytosolic 





Increased SOCE not only led to an ER stress resistance and failure to activate the 
stress responsive ATF4, but also triggered NFAT activation. Further 
characterization of the consequences of aberrant NFAT activation in STIM1 
overexpressing cells is needed, but, based on previous studies, it is highly plausible 
that NFATs drive oncogenic programs in these cells. This way, possibly providing 
gemcitabine resistant or STIM1 overexpressing tumors with additional advantages 
to thrive in hostile microenvironments. Furthermore, SOCE is known to also 
stimulate CAMKII leading to the activation of a vast array of transcription factors. 
Thus, it is of great importance to elucidate what other transcription factors are 
activated upon heightened SOCE and what transcriptomic and phenotypic changes 
they elicit in STIM1 overexpressing and gemcitabine resistant tumors. 
Moreover, further investigation revealed that there is a propensity of cancer cells to 
overexpress RRM1 and STIM1 even without treatment. Similarly, different STIM1 
expression levels were observed in treatment naïve pancreatic cancer patient 
specimens and patient-derived xenografts. In this case, STIM1 levels also 
correlated with NFAT activity and ATF4 nuclear localization, further validating our 
findings in vivo. Gemcitabine treatment of patient-derived xenografts further 
promoted the overexpression of STIM1, increased NFAT activity and decreased 
ATF4 nuclear localization. This proves that even though STIM1 may be highly 
expressed in some treatment naïve tumors, an increase in STIM1 levels is selected 
for upon gemcitabine treatment. It further highlights the potential benefits of SOCE 
inhibitors in the treatment of STIM1-overexpressing gemcitabine resistant as well as 
treatment naïve pancreatic tumors. 
Thus, SOCE and NFAT inhibition pose novel treatment options for pancreatic cancer 
patients that present a priori or acquired gemcitabine resistance. Cyclosporine A or 
tacrolimus could be employed to prevent NFAT activation and thus impair any pro-
oncogenic program elicited by increased SOCE. Alternatively, SOCE inhibition 
could not only impair the effects of NFAT activation, but also restore ER stress 
sensitivity in STIM1 overexpressing tumors. This could make gemcitabine resistant 
and STIM1 overexpressing tumors more susceptible to alternative therapeutic 





Taken together, our study unravels molecular changes elicited upon acquired 
gemcitabine resistance. While the amplification of RRM1 drives gemcitabine 
resistance, the amplification of STIM1 leads to a shift in SOCE and calcium 
signaling. Increased SOCE dampens ER stress activation, thus preventing the 
accumulation of the transcription factor ATF4, while promoting the activation of 
NFATs. Therefore, we can conclude that STIM1 acts as a rheostat, fine tuning 
SOCE and consequently balancing between an ATF4-driven ER stress-responsive 
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 Supplemental Material 
Supplemental Material 
Table S1 GSEA of curated gene sets (C2) identified in GemR compared to Par. 
Ranking NAME NES FDR  
1 BROWNE_INTERFERON_RESPONSIVE_GENES 2.11 0.02 
2 SMID_BREAST_CANCER_LUMINAL_A_UP 2.10 0.01 
3 REACTOME_INTERFERON_GAMMA_SIGNALING 2.07 0.01 
4 SANA_RESPONSE_TO_IFNG_UP 2.03 0.02 
5 BOWIE_RESPONSE_TO_EXTRACELLULAR_MATRIX 2.01 0.02 
6 REACTOME_COMPLEX_I_BIOGENESIS 2.00 0.03 
7 REACTOME_INTERFERON_ALPHA_BETA_SIGNALING 1.94 0.06 
8 EINAV_INTERFERON_SIGNATURE_IN_CANCER 1.93 0.06 
9 REACTOME_MITOCHONDRIAL_TRANSLATION 1.93 0.06 
10 STAMBOLSKY_TARGETS_OF_MUTATED_TP53_DN 1.92 0.06 
11 
SATO_SILENCED_BY_METHYLATION_IN_PANCREATIC_
CANCER_2 1.91 0.06 
12 CAVARD_LIVER_CANCER_MALIGNANT_VS_BENIGN 1.91 0.05 
13 MOSERLE_IFNA_RESPONSE 1.89 0.06 
14 NATSUME_RESPONSE_TO_INTERFERON_BETA_DN 1.88 0.06 




_HEAT_PRODUCTION_BY_UNCOUPLING_PROTEINS 1.86 0.07 
17 REACTOME_RESPIRATORY_ELECTRON_TRANSPORT 1.86 0.07 
18 REACTOME_INTERFERON_SIGNALING 1.81 0.11 
19 TOOKER_GEMCITABINE_RESISTANCE_UP 1.81 0.11 
20 BOYLAN_MULTIPLE_MYELOMA_PCA3_DN 1.81 0.11 
21 DER_IFN_BETA_RESPONSE_UP 1.80 0.11 
22 KEGG_HISTIDINE_METABOLISM 1.78 0.14 
23 LEE_LIVER_CANCER_DENA_DN 1.77 0.15 
24 KEGG_DRUG_METABOLISM_CYTOCHROME_P450 1.76 0.16 
25 BOYLAN_MULTIPLE_MYELOMA_D_CLUSTER_DN 1.75 0.16 
26 
KEGG_METABOLISM_OF_XENOBIOTICS_BY_CYTOCHR
OME_P450 1.75 0.17 
27 HELLER_SILENCED_BY_METHYLATION_UP 1.74 0.17 
28 MUELLER_METHYLATED_IN_GLIOBLASTOMA 1.73 0.18 
29 HUANG_FOXA2_TARGETS_DN 1.73 0.18 
30 LANDIS_ERBB2_BREAST_TUMORS_65_DN 1.73 0.18 
31 
REACTOME_METABOLISM_OF_FAT_SOLUBLE_VITAMIN
S 1.71 0.20 





 Supplemental Material 
Table S2 Amplified and deleted regions and genes in GemR compared to Par. 
Chrom
osome 
Start End Gene log2 Depth Probes Weight 







3.22983 3.85219 8 6.72007 
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 Supplemental Material 
Table S3 GSEA of curated gene sets (C2) identified in Par compared to GemR, 
both treated with thapsigargin. 
Ranking NAME NES FDR  
1 KRIGE_AMINO_ACID_DEPRIVATION 2.37 0.00 
2 HELLER_SILENCED_BY_METHYLATION_DN 2.35 0.00 
3 TIEN_INTESTINE_PROBIOTICS_24HR_DN 2.24 0.00 
4 CHEN_HOXA5_TARGETS_9HR_UP 2.22 0.00 
5 BLUM_RESPONSE_TO_SALIRASIB_UP 2.20 0.00 
6 
MCMURRAY_TP53_HRAS_COOPERATION_RESPONSE_U
P 2.18 0.00 
7 HUANG_FOXA2_TARGETS_UP 2.17 0.00 
8 PACHER_TARGETS_OF_IGF1_AND_IGF2_UP 2.12 0.00 
9 RICKMAN_HEAD_AND_NECK_CANCER_A 2.12 0.00 
10 MADAN_DPPA4_TARGETS 2.11 0.00 
11 NAKAMURA_CANCER_MICROENVIRONMENT_DN 2.05 0.01 
12 VALK_AML_CLUSTER_2 2.04 0.01 
13 CUI_GLUCOSE_DEPRIVATION 2.04 0.01 
14 REACTOME_UNFOLDED_PROTEIN_RESPONSE_UPR 2.03 0.01 
15 ZHAN_MULTIPLE_MYELOMA_CD1_VS_CD2_UP 2.02 0.01 
16 TAKEDA_TARGETS_OF_NUP98_HOXA9_FUSION_16D_DN 2.00 0.01 
17 HELLER_HDAC_TARGETS_DN 2.00 0.01 
18 HOLLERN_EMT_BREAST_TUMOR_DN 1.99 0.01 
19 DELPUECH_FOXO3_TARGETS_DN 1.98 0.01 
20 BHATI_G2M_ARREST_BY_2METHOXYESTRADIOL_DN 1.97 0.01 
21 LIN_NPAS4_TARGETS_DN 1.96 0.01 
22 ZHAN_MULTIPLE_MYELOMA_CD1_UP 1.94 0.02 
23 HUNSBERGER_EXERCISE_REGULATED_GENES 1.93 0.02 
24 LIANG_SILENCED_BY_METHYLATION_UP 1.92 0.02 
25 REACTOME_CELL_CELL_JUNCTION_ORGANIZATION 1.91 0.02 
26 POOLA_INVASIVE_BREAST_CANCER_UP 1.90 0.03 
27 REACTOME_TIGHT_JUNCTION_INTERACTIONS 1.90 0.03 
28 REACTOME_PERK_REGULATES_GENE_EXPRESSION 1.89 0.03 
29 MORI_PLASMA_CELL_UP 1.88 0.03 
30 AIGNER_ZEB1_TARGETS 1.88 0.03 
31 REACTOME_CYTOSOLIC_TRNA_AMINOACYLATION 1.86 0.04 
32 NIKOLSKY_BREAST_CANCER_15Q26_AMPLICON 1.85 0.05 
33 REACTOME_INTRA_GOLGI_TRAFFIC 1.84 0.05 
34 CEBALLOS_TARGETS_OF_TP53_AND_MYC_DN 1.83 0.06 
35 VALK_AML_CLUSTER_13 1.81 0.07 
36 WAMUNYOKOLI_OVARIAN_CANCER_GRADES_1_2_UP 1.81 0.07 
37 KEGG_TIGHT_JUNCTION 1.80 0.07 
38 CHIANG_LIVER_CANCER_SUBCLASS_CTNNB1_DN 1.79 0.08 
39 
REACTOME_ATF4_ACTIVATES_GENES_IN_RESPONSE_T
O_ENDOPLASMIC_RETICULUM_STRESS 1.79 0.08 
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41 PLASARI_NFIC_TARGETS_BASAL_UP 1.78 0.08 
42 
GARGALOVIC_RESPONSE_TO_OXIDIZED_PHOSPHOLIPID
S_RED_UP 1.78 0.08 
43 PASQUALUCCI_LYMPHOMA_BY_GC_STAGE_UP 1.78 0.08 
44 CORRE_MULTIPLE_MYELOMA_UP 1.78 0.08 
45 LIU_PROSTATE_CANCER_UP 1.78 0.08 
46 KANG_FLUOROURACIL_RESISTANCE_DN 1.78 0.08 
47 MIKKELSEN_ES_ICP_WITH_H3K4ME3_AND_H3K27ME3 1.77 0.08 
48 TARTE_PLASMA_CELL_VS_B_LYMPHOCYTE_UP 1.77 0.08 
49 
HELLER_HDAC_TARGETS_SILENCED_BY_METHYLATION
_DN 1.76 0.09 
50 LIN_SILENCED_BY_TUMOR_MICROENVIRONMENT 1.76 0.09 
51 CHUANG_OXIDATIVE_STRESS_RESPONSE_UP 1.76 0.08 
52 ANDERSEN_CHOLANGIOCARCINOMA_CLASS2 1.76 0.08 
53 
YAO_TEMPORAL_RESPONSE_TO_PROGESTERONE_CLU
STER_11 1.76 0.09 
54 REACTOME_IRE1ALPHA_ACTIVATES_CHAPERONES 1.76 0.09 
55 FURUKAWA_DUSP6_TARGETS_PCI35_DN 1.76 0.08 
56 KEGG_TYPE_I_DIABETES_MELLITUS 1.75 0.09 
57 HUANG_GATA2_TARGETS_DN 1.74 0.10 
58 PID_SHP2_PATHWAY 1.73 0.11 
59 WESTON_VEGFA_TARGETS 1.73 0.11 
60 REACTOME_SIGNALING_BY_NTRK2_TRKB 1.72 0.12 
61 HANN_RESISTANCE_TO_BCL2_INHIBITOR_DN 1.72 0.12 
62 
COLIN_PILOCYTIC_ASTROCYTOMA_VS_GLIOBLASTOMA_
UP 1.72 0.12 
63 YANG_BREAST_CANCER_ESR1_BULK_DN 1.71 0.12 
64 FISCHER_G2_M_CELL_CYCLE 1.71 0.12 
65 REACTOME_COLLAGEN_CHAIN_TRIMERIZATION 1.71 0.12 
66 KRASNOSELSKAYA_ILF3_TARGETS_DN 1.71 0.12 
67 ZWANG_EGF_INTERVAL_UP 1.70 0.13 
68 HOFMANN_MYELODYSPLASTIC_SYNDROM_RISK_UP 1.70 0.13 
69 NABA_COLLAGENS 1.70 0.13 
70 KIM_LIVER_CANCER_POOR_SURVIVAL_DN 1.69 0.13 
71 NADERI_BREAST_CANCER_PROGNOSIS_UP 1.69 0.14 
72 URS_ADIPOCYTE_DIFFERENTIATION_DN 1.68 0.14 
73 FARMER_BREAST_CANCER_CLUSTER_2 1.68 0.14 
74 KEGG_PRION_DISEASES 1.68 0.14 
75 MURAKAMI_UV_RESPONSE_6HR_UP 1.68 0.14 
76 PID_CMYB_PATHWAY 1.68 0.14 
77 FARMER_BREAST_CANCER_BASAL_VS_LULMINAL 1.68 0.14 
78 BOYAULT_LIVER_CANCER_SUBCLASS_G6_DN 1.67 0.14 
79 SMITH_TERT_TARGETS_UP 1.67 0.14 
80 SU_PLACENTA 1.67 0.15 
81 ROZANOV_MMP14_TARGETS_UP 1.66 0.15 
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83 HOWLIN_CITED1_TARGETS_1_DN 1.66 0.16 
84 LIM_MAMMARY_LUMINAL_PROGENITOR_UP 1.65 0.16 
85 ROSS_AML_WITH_AML1_ETO_FUSION 1.65 0.16 
86 
CHARAFE_BREAST_CANCER_LUMINAL_VS_MESENCHYM
AL_UP 1.65 0.17 
87 WANG_SMARCE1_TARGETS_UP 1.65 0.17 
88 AZARE_NEOPLASTIC_TRANSFORMATION_BY_STAT3_UP 1.65 0.17 
89 MAYBURD_RESPONSE_TO_L663536_UP 1.64 0.17 
90 SMID_BREAST_CANCER_NORMAL_LIKE_UP 1.64 0.17 
91 
PANGAS_TUMOR_SUPPRESSION_BY_SMAD1_AND_SMA
D5_DN 1.64 0.17 
92 NIKOLSKY_BREAST_CANCER_8P12_P11_AMPLICON 1.64 0.16 
93 WALLACE_PROSTATE_CANCER_RACE_UP 1.64 0.16 
94 JIANG_TIP30_TARGETS_DN 1.64 0.16 
95 WESTON_VEGFA_TARGETS_6HR 1.64 0.16 
96 CHIBA_RESPONSE_TO_TSA_DN 1.64 0.16 
97 NIKOLSKY_BREAST_CANCER_8Q23_Q24_AMPLICON 1.64 0.16 
98 
REACTOME_NCAM_SIGNALING_FOR_NEURITE_OUT_GR
OWTH 1.64 0.16 
99 MARKEY_RB1_CHRONIC_LOF_DN 1.64 0.16 
100 ZHAN_MULTIPLE_MYELOMA_PR_UP 1.64 0.16 
101 
HOFFMANN_SMALL_PRE_BII_TO_IMMATURE_B_LYMPHO
CYTE_DN 1.63 0.16 
102 ZWANG_DOWN_BY_2ND_EGF_PULSE 1.63 0.17 
103 
REACTOME_TRANSPORT_OF_MATURE_TRANSCRIPT_TO
_CYTOPLASM 1.63 0.17 
104 KEGG_O_GLYCAN_BIOSYNTHESIS 1.63 0.16 
105 
REACTOME_NOTCH3_INTRACELLULAR_DOMAIN_REGUL
ATES_TRANSCRIPTION 1.63 0.16 
106 PID_ECADHERIN_KERATINOCYTE_PATHWAY 1.63 0.17 
107 REACTOME_PEPTIDE_LIGAND_BINDING_RECEPTORS 1.63 0.17 
108 GROSS_HYPOXIA_VIA_ELK3_DN 1.62 0.17 
109 
REACTOME_DEGRADATION_OF_THE_EXTRACELLULAR_
MATRIX 1.62 0.18 
110 TANG_SENESCENCE_TP53_TARGETS_DN 1.62 0.18 
111 KORKOLA_EMBRYONIC_CARCINOMA_VS_SEMINOMA_UP 1.62 0.18 
112 COLDREN_GEFITINIB_RESISTANCE_UP 1.61 0.18 
113 
SENGUPTA_NASOPHARYNGEAL_CARCINOMA_WITH_LM
P1_DN 1.61 0.18 
114 
REACTOME_COPI_DEPENDENT_GOLGI_TO_ER_RETROG
RADE_TRAFFIC 1.61 0.18 
115 WANG_METHYLATED_IN_BREAST_CANCER 1.61 0.18 
116 SENESE_HDAC1_AND_HDAC2_TARGETS_UP 1.61 0.18 
117 WESTON_VEGFA_TARGETS_3HR 1.61 0.18 
118 REACTOME_SYNDECAN_INTERACTIONS 1.61 0.18 
119 PODAR_RESPONSE_TO_ADAPHOSTIN_UP 1.60 0.19 
120 
REACTOME_DOWNSTREAM_SIGNALING_OF_ACTIVATED
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121 XU_HGF_SIGNALING_NOT_VIA_AKT1_48HR_UP 1.60 0.19 
122 MCCLUNG_CREB1_TARGETS_DN 1.60 0.19 
123 HOELZEL_NF1_TARGETS_UP 1.60 0.19 
124 REACTOME_ECM_PROTEOGLYCANS 1.59 0.19 
125 REACTOME_EGFR_DOWNREGULATION 1.59 0.19 
126 REACTOME_COLLAGEN_DEGRADATION 1.59 0.19 
127 ROVERSI_GLIOMA_COPY_NUMBER_UP 1.59 0.19 
128 MIKKELSEN_MEF_HCP_WITH_H3K27ME3 1.59 0.19 
129 WOOD_EBV_EBNA1_TARGETS_DN 1.59 0.19 
130 TSENG_ADIPOGENIC_POTENTIAL_UP 1.59 0.19 
131 PID_FRA_PATHWAY 1.59 0.19 
132 MOLENAAR_TARGETS_OF_CCND1_AND_CDK4_DN 1.59 0.19 
133 KANG_DOXORUBICIN_RESISTANCE_DN 1.59 0.19 
134 CHARAFE_BREAST_CANCER_LUMINAL_VS_BASAL_UP 1.59 0.19 
135 
REACTOME_NUCLEAR_PORE_COMPLEX_NPC_DISASSE
MBLY 1.58 0.19 
136 REACTOME_COLLAGEN_FORMATION 1.58 0.20 
137 ONDER_CDH1_TARGETS_3_UP 1.58 0.20 
138 LIU_SMARCA4_TARGETS 1.58 0.20 
139 VALK_AML_WITH_FLT3_ITD 1.58 0.20 
140 GRUETZMANN_PANCREATIC_CANCER_DN 1.57 0.21 
141 
SHAFFER_IRF4_TARGETS_IN_PLASMA_CELL_VS_MATUR
E_B_LYMPHOCYTE 1.57 0.21 
142 REACTOME_CELL_JUNCTION_ORGANIZATION 1.57 0.21 
143 ONDER_CDH1_TARGETS_2_DN 1.57 0.21 
144 LANDEMAINE_LUNG_METASTASIS 1.57 0.21 
145 WILLIAMS_ESR1_TARGETS_UP 1.57 0.21 
146 
REACTOME_COLLAGEN_BIOSYNTHESIS_AND_MODIFYIN
G_ENZYMES 1.56 0.21 
147 BILANGES_SERUM_SENSITIVE_VIA_TSC2 1.56 0.22 
148 IIZUKA_LIVER_CANCER_PROGRESSION_G1_G2_DN 1.56 0.22 
149 ANDERSEN_CHOLANGIOCARCINOMA_CLASS1 1.56 0.22 
150 MARCHINI_TRABECTEDIN_RESISTANCE_DN 1.56 0.22 
151 LEE_LIVER_CANCER_MYC_UP 1.56 0.21 
152 REACTOME_MET_ACTIVATES_PTK2_SIGNALING 1.56 0.22 
153 
CHARAFE_BREAST_CANCER_BASAL_VS_MESENCHYMA
L_UP 1.55 0.22 
154 FLORIO_NEOCORTEX_BASAL_RADIAL_GLIA_DN 1.55 0.22 
155 BIOCARTA_ARAP_PATHWAY 1.55 0.22 
156 
REACTOME_FORMATION_OF_THE_CORNIFIED_ENVELO
PE 1.55 0.22 
157 ADDYA_ERYTHROID_DIFFERENTIATION_BY_HEMIN 1.55 0.22 
158 
GARGALOVIC_RESPONSE_TO_OXIDIZED_PHOSPHOLIPID
S_BLACK_UP 1.55 0.22 
159 BOSCO_EPITHELIAL_DIFFERENTIATION_MODULE 1.55 0.22 
160 
REACTOME_TRANSPORT_OF_MATURE_MRNAS_DERIVE
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161 DACOSTA_ERCC3_ALLELE_XPCS_VS_TTD_DN 1.55 0.22 
162 
KEGG_ALANINE_ASPARTATE_AND_GLUTAMATE_METAB
OLISM 1.55 0.22 
163 KATSANOU_ELAVL1_TARGETS_UP 1.54 0.23 
164 GAUSSMANN_MLL_AF4_FUSION_TARGETS_F_DN 1.54 0.23 
165 WANG_RESPONSE_TO_BEXAROTENE_UP 1.54 0.23 
166 GHANDHI_BYSTANDER_IRRADIATION_UP 1.54 0.24 
167 NOJIMA_SFRP2_TARGETS_UP 1.53 0.23 
168 REACTOME_SIGNALING_BY_WNT_IN_CANCER 1.53 0.23 
169 BURTON_ADIPOGENESIS_12 1.53 0.23 
170 
CHIARADONNA_NEOPLASTIC_TRANSFORMATION_CDC2
5_UP 1.53 0.23 
171 REACTOME_SIGNALING_BY_FGFR1 1.53 0.23 
172 KANG_IMMORTALIZED_BY_TERT_UP 1.53 0.24 
173 SMID_BREAST_CANCER_RELAPSE_IN_BONE_DN 1.53 0.23 
174 NABA_CORE_MATRISOME 1.53 0.24 
175 BERNARD_PPAPDC1B_TARGETS_DN 1.53 0.24 
176 MORI_EMU_MYC_LYMPHOMA_BY_ONSET_TIME_DN 1.53 0.24 
177 REACTOME_ION_TRANSPORT_BY_P_TYPE_ATPASES 1.53 0.24 
178 NAGASHIMA_NRG1_SIGNALING_UP 1.52 0.24 
179 BILD_HRAS_ONCOGENIC_SIGNATURE 1.52 0.24 
180 FINETTI_BREAST_CANCER_KINOME_RED 1.52 0.24 
181 SESTO_RESPONSE_TO_UV_C2 1.52 0.24 
182 TERAMOTO_OPN_TARGETS_CLUSTER_7 1.52 0.24 
183 CHO_NR4A1_TARGETS 1.52 0.24 
184 
REACTOME_PLASMA_LIPOPROTEIN_ASSEMBLY_REMOD
ELING_AND_CLEARANCE 1.52 0.24 
185 HOLLERN_MICROACINAR_BREAST_TUMOR_UP 1.52 0.24 
186 
REACTOME_SYNTHESIS_OF_VERY_LONG_CHAIN_FATTY
_ACYL_COAS 1.52 0.24 
187 WENG_POR_TARGETS_GLOBAL_DN 1.52 0.24 
188 NABA_MATRISOME 1.52 0.24 
189 REACTOME_CELL_CELL_COMMUNICATION 1.52 0.24 
190 SHI_SPARC_TARGETS_UP 1.52 0.24 
191 SWEET_KRAS_ONCOGENIC_SIGNATURE 1.52 0.24 
192 GAUSSMANN_MLL_AF4_FUSION_TARGETS_A_DN 1.52 0.24 
193 WANG_CISPLATIN_RESPONSE_AND_XPC_UP 1.52 0.24 
194 REICHERT_MITOSIS_LIN9_TARGETS 1.51 0.24 
195 
TURASHVILI_BREAST_LOBULAR_CARCINOMA_VS_DUCT
AL_NORMAL_UP 1.51 0.24 
196 PID_GLYPICAN_1PATHWAY 1.51 0.24 
197 MARCINIAK_ER_STRESS_RESPONSE_VIA_CHOP 1.51 0.24 
198 ONDER_CDH1_TARGETS_1_DN 1.51 0.24 
199 PID_SYNDECAN_1_PATHWAY 1.51 0.24 
200 
REACTOME_BINDING_AND_UPTAKE_OF_LIGANDS_BY_S
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201 
TURASHVILI_BREAST_DUCTAL_CARCINOMA_VS_DUCTA
L_NORMAL_UP 1.51 0.25 
202 YAMAZAKI_TCEB3_TARGETS_UP 1.51 0.25 
203 REACTOME_KERATINIZATION 1.51 0.25 
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Table S4 Genes comprised in DN-reversed and UP-reversed clusters. 
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Table S5 GSEA of curated gene sets (C2) identified in GemR compared to STIM1-
depleted GemR, both treated with thapsigargin. 
Ranking NAME NES FDR  
1 AMIT_SERUM_RESPONSE_40_MCF10A 2.43 0.00 
2 SMIRNOV_RESPONSE_TO_IR_2HR_UP 2.35 0.00 
3 HORTON_SREBF_TARGETS 2.35 0.00 
4 QI_HYPOXIA 2.32 0.00 
5 DAZARD_RESPONSE_TO_UV_NHEK_UP 2.31 0.00 
6 PICCALUGA_ANGIOIMMUNOBLASTIC_LYMPHOMA_DN 2.27 0.00 
7 SCHMIDT_POR_TARGETS_IN_LIMB_BUD_UP 2.27 0.00 
8 JAEGER_METASTASIS_DN 2.24 0.00 
9 DAZARD_UV_RESPONSE_CLUSTER_G2 2.22 0.00 
10 REACTOME_KERATINIZATION 2.21 0.00 
11 
REACTOME_FORMATION_OF_THE_CORNIFIED_ENVELOP
E 2.20 0.00 
12 NAGASHIMA_NRG1_SIGNALING_UP 2.19 0.00 
13 SMIRNOV_RESPONSE_TO_IR_6HR_DN 2.18 0.00 
14 REACTOME_CHOLESTEROL_BIOSYNTHESIS 2.17 0.00 
15 UZONYI_RESPONSE_TO_LEUKOTRIENE_AND_THROMBIN 2.15 0.00 
16 RASHI_RESPONSE_TO_IONIZING_RADIATION_1 2.15 0.00 
17 NAGASHIMA_EGF_SIGNALING_UP 2.14 0.00 
18 ZWANG_CLASS_3_TRANSIENTLY_INDUCED_BY_EGF 2.14 0.00 
19 AMIT_EGF_RESPONSE_40_HELA 2.13 0.00 
20 
OSWALD_HEMATOPOIETIC_STEM_CELL_IN_COLLAGEN_
GEL_UP 2.12 0.00 
21 CHEN_LVAD_SUPPORT_OF_FAILING_HEART_UP 2.10 0.00 
22 
WANG_BARRETTS_ESOPHAGUS_AND_ESOPHAGUS_CAN
CER_DN 2.06 0.00 
23 CROMER_METASTASIS_DN 2.05 0.00 
24 
BERENJENO_TRANSFORMED_BY_RHOA_REVERSIBLY_D
N 2.04 0.01 
25 SEMENZA_HIF1_TARGETS 2.04 0.01 
26 DELLA_RESPONSE_TO_TSA_AND_BUTYRATE 2.04 0.01 
27 RODRIGUES_NTN1_AND_DCC_TARGETS 2.03 0.01 
28 KEGG_CYTOKINE_CYTOKINE_RECEPTOR_INTERACTION 2.03 0.01 
29 BURTON_ADIPOGENESIS_PEAK_AT_2HR 2.03 0.01 
30 FARDIN_HYPOXIA_11 2.03 0.01 
31 HAHTOLA_MYCOSIS_FUNGOIDES_CD4_UP 2.03 0.01 
32 PEREZ_TP53_AND_TP63_TARGETS 2.02 0.01 
33 INGA_TP53_TARGETS 2.02 0.01 
34 PLASARI_TGFB1_TARGETS_10HR_UP 2.02 0.01 
35 SANSOM_APC_TARGETS_UP 2.00 0.01 
36 HUPER_BREAST_BASAL_VS_LUMINAL_UP 2.00 0.01 
37 WARTERS_IR_RESPONSE_5GY 1.99 0.01 
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39 
REACTOME_REGULATION_OF_CHOLESTEROL_BIOSYNT
HESIS_BY_SREBP_SREBF 1.98 0.01 
40 SASSON_RESPONSE_TO_GONADOTROPHINS_DN 1.98 0.01 
41 AMIT_SERUM_RESPONSE_60_MCF10A 1.98 0.01 
42 GENTILE_UV_RESPONSE_CLUSTER_D8 1.98 0.01 
43 DAZARD_UV_RESPONSE_CLUSTER_G4 1.98 0.01 
44 LE_EGR2_TARGETS_DN 1.97 0.01 
45 
REACTOME_ACTIVATION_OF_GENE_EXPRESSION_BY_S
REBF_SREBP 1.97 0.01 
46 PID_DELTA_NP63_PATHWAY 1.96 0.01 
47 PHONG_TNF_TARGETS_UP 1.96 0.01 
48 ZHOU_INFLAMMATORY_RESPONSE_LIVE_UP 1.96 0.01 
49 BILD_HRAS_ONCOGENIC_SIGNATURE 1.95 0.01 
50 PODAR_RESPONSE_TO_ADAPHOSTIN_DN 1.95 0.01 
51 PEREZ_TP63_TARGETS 1.95 0.01 
52 HOLLERN_SQUAMOUS_BREAST_TUMOR 1.94 0.01 
53 DAUER_STAT3_TARGETS_UP 1.94 0.01 
54 TAKEDA_TARGETS_OF_NUP98_HOXA9_FUSION_6HR_DN 1.94 0.01 
55 PROVENZANI_METASTASIS_DN 1.94 0.01 
56 WILLERT_WNT_SIGNALING 1.94 0.01 
57 SARRIO_EPITHELIAL_MESENCHYMAL_TRANSITION_DN 1.93 0.01 
58 RICKMAN_METASTASIS_DN 1.93 0.01 
59 SCHAEFFER_PROSTATE_DEVELOPMENT_48HR_DN 1.92 0.01 
60 CHOW_RASSF1_TARGETS_DN 1.92 0.02 
61 
TURASHVILI_BREAST_DUCTAL_CARCINOMA_VS_LOBULA
R_NORMAL_DN 1.92 0.01 
62 WARTERS_RESPONSE_TO_IR_SKIN 1.92 0.02 
63 REACTOME_PI3K_AKT_SIGNALING_IN_CANCER 1.91 0.02 
64 BENPORATH_PRC2_TARGETS 1.91 0.02 
65 BROCKE_APOPTOSIS_REVERSED_BY_IL6 1.90 0.02 
66 DORN_ADENOVIRUS_INFECTION_48HR_DN 1.90 0.02 
67 QUINTENS_EMBRYONIC_BRAIN_RESPONSE_TO_IR 1.90 0.02 
68 PHONG_TNF_RESPONSE_VIA_P38_PARTIAL 1.90 0.02 
69 PEART_HDAC_PROLIFERATION_CLUSTER_UP 1.89 0.02 
70 REACTOME_IRS_MEDIATED_SIGNALLING 1.89 0.02 
71 DIRMEIER_LMP1_RESPONSE_EARLY 1.88 0.02 
72 NAKAMURA_METASTASIS 1.88 0.02 
73 DORN_ADENOVIRUS_INFECTION_32HR_DN 1.88 0.02 
74 GESERICK_TERT_TARGETS_DN 1.88 0.02 
75 KEGG_P53_SIGNALING_PATHWAY 1.88 0.02 
76 AMIT_EGF_RESPONSE_60_HELA 1.87 0.02 
77 
RICKMAN_TUMOR_DIFFERENTIATED_WELL_VS_POORLY
_DN 1.87 0.02 
78 FARMER_BREAST_CANCER_CLUSTER_7 1.87 0.02 
79 KOBAYASHI_EGFR_SIGNALING_6HR_DN 1.87 0.02 
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81 
REACTOME_DOWNSTREAM_SIGNALING_OF_ACTIVATED
_FGFR4 1.87 0.02 
82 PODAR_RESPONSE_TO_ADAPHOSTIN_UP 1.87 0.02 
83 ZHANG_ANTIVIRAL_RESPONSE_TO_RIBAVIRIN_DN 1.86 0.02 
84 PID_TCR_CALCIUM_PATHWAY 1.86 0.02 
85 BOYLAN_MULTIPLE_MYELOMA_PCA3_UP 1.86 0.02 
86 DAZARD_UV_RESPONSE_CLUSTER_G1 1.86 0.02 
87 PECE_MAMMARY_STEM_CELL_UP 1.86 0.02 
88 
REACTOME_SIGNALING_BY_TYPE_1_INSULIN_LIKE_GRO
WTH_FACTOR_1_RECEPTOR_IGF1R 1.86 0.02 
89 PID_REG_GR_PATHWAY 1.85 0.02 
90 KEGG_STEROID_BIOSYNTHESIS 1.85 0.02 
91 REACTOME_GAP_JUNCTION_ASSEMBLY 1.85 0.03 
92 PID_NFAT_TFPATHWAY 1.85 0.03 
93 TENEDINI_MEGAKARYOCYTE_MARKERS 1.84 0.03 
94 BROWNE_HCMV_INFECTION_2HR_UP 1.84 0.03 
95 SESTO_RESPONSE_TO_UV_C7 1.84 0.03 
96 MIKKELSEN_NPC_HCP_WITH_H3K4ME3_AND_H3K27ME3 1.84 0.03 
97 BIOCARTA_FCER1_PATHWAY 1.84 0.03 
98 SASSON_RESPONSE_TO_FORSKOLIN_DN 1.83 0.03 
99 MENSE_HYPOXIA_UP 1.82 0.03 
100 GHANDHI_DIRECT_IRRADIATION_UP 1.82 0.03 
101 GU_PDEF_TARGETS_DN 1.82 0.03 
102 
JECHLINGER_EPITHELIAL_TO_MESENCHYMAL_TRANSITI
ON_DN 1.82 0.03 
103 REACTOME_ATTENUATION_PHASE 1.82 0.03 
104 
HOFFMANN_PRE_BI_TO_LARGE_PRE_BII_LYMPHOCYTE_
UP 1.82 0.03 
105 PID_HIF1_TFPATHWAY 1.82 0.03 
106 BENPORATH_EED_TARGETS 1.82 0.03 
107 SABATES_COLORECTAL_ADENOMA_UP 1.82 0.03 
108 
REACTOME_GAP_JUNCTION_TRAFFICKING_AND_REGUL
ATION 1.81 0.03 
109 BASSO_CD40_SIGNALING_DN 1.81 0.03 
110 YAMASHITA_LIVER_CANCER_STEM_CELL_UP 1.81 0.03 
111 BRACHAT_RESPONSE_TO_METHOTREXATE_UP 1.81 0.03 
112 KOBAYASHI_RESPONSE_TO_ROMIDEPSIN 1.81 0.04 
113 MARTORIATI_MDM4_TARGETS_FETAL_LIVER_UP 1.80 0.04 
114 ENK_UV_RESPONSE_EPIDERMIS_DN 1.80 0.04 
115 WONG_ADULT_TISSUE_STEM_MODULE 1.80 0.04 
116 
REACTOME_DOWNSTREAM_SIGNALING_OF_ACTIVATED
_FGFR3 1.80 0.04 
117 HOWLIN_PUBERTAL_MAMMARY_GLAND 1.80 0.04 
118 GROSS_HYPOXIA_VIA_HIF1A_DN 1.80 0.04 
119 WANG_RESPONSE_TO_FORSKOLIN_UP 1.80 0.04 
120 PID_MYC_ACTIV_PATHWAY 1.80 0.04 
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122 ONDER_CDH1_TARGETS_3_DN 1.79 0.04 
123 DAZARD_UV_RESPONSE_CLUSTER_G28 1.79 0.04 
124 BRACHAT_RESPONSE_TO_CISPLATIN 1.79 0.04 
125 FRIDMAN_SENESCENCE_UP 1.79 0.04 
126 REACTOME_HSF1_DEPENDENT_TRANSACTIVATION 1.79 0.04 
127 MARTORIATI_MDM4_TARGETS_NEUROEPITHELIUM_UP 1.79 0.04 
128 NABA_SECRETED_FACTORS 1.79 0.04 
129 AMIT_EGF_RESPONSE_120_HELA 1.79 0.04 
130 
TONKS_TARGETS_OF_RUNX1_RUNX1T1_FUSION_GRAN
ULOCYTE_UP 1.78 0.04 
131 PID_FGF_PATHWAY 1.78 0.04 
132 MA_MYELOID_DIFFERENTIATION_UP 1.78 0.04 
133 KAMIKUBO_MYELOID_MN1_NETWORK 1.78 0.04 
134 
REACTOME_TRANSPORT_OF_VITAMINS_NUCLEOSIDES_
AND_RELATED_MOLECULES 1.78 0.04 
135 KYNG_ENVIRONMENTAL_STRESS_RESPONSE_DN 1.77 0.04 
136 
JECHLINGER_EPITHELIAL_TO_MESENCHYMAL_TRANSITI
ON_UP 1.77 0.04 
137 FAELT_B_CLL_WITH_VH_REARRANGEMENTS_UP 1.77 0.04 
138 BORLAK_LIVER_CANCER_EGF_UP 1.77 0.04 
139 ZWANG_CLASS_2_TRANSIENTLY_INDUCED_BY_EGF 1.77 0.04 
140 SARTIPY_BLUNTED_BY_INSULIN_RESISTANCE_UP 1.77 0.04 
141 ONDER_CDH1_TARGETS_2_DN 1.77 0.04 
142 
SEITZ_NEOPLASTIC_TRANSFORMATION_BY_8P_DELETI
ON_DN 1.77 0.04 
143 ELVIDGE_HYPOXIA_BY_DMOG_UP 1.77 0.04 
144 SCHRAETS_MLL_TARGETS_UP 1.77 0.04 
145 PLASARI_TGFB1_SIGNALING_VIA_NFIC_1HR_DN 1.77 0.04 
146 WANG_METHYLATED_IN_BREAST_CANCER 1.77 0.04 
147 GALINDO_IMMUNE_RESPONSE_TO_ENTEROTOXIN 1.77 0.04 
148 STREICHER_LSM1_TARGETS_DN 1.77 0.04 
149 MEISSNER_BRAIN_HCP_WITH_H3K4ME2_AND_H3K27ME3 1.76 0.04 
150 WINZEN_DEGRADED_VIA_KHSRP 1.76 0.04 
151 BOYLAN_MULTIPLE_MYELOMA_C_DN 1.76 0.04 
152 LEE_TARGETS_OF_PTCH1_AND_SUFU_UP 1.76 0.04 
153 REACTOME_METABOLISM_OF_STEROIDS 1.76 0.04 
154 CHANG_IMMORTALIZED_BY_HPV31_DN 1.76 0.04 
155 REACTOME_INTERLEUKIN_6_FAMILY_SIGNALING 1.76 0.04 
156 GROSS_HYPOXIA_VIA_ELK3_AND_HIF1A_UP 1.76 0.04 
157 WELCSH_BRCA1_TARGETS_DN 1.76 0.04 
158 PID_CD8_TCR_DOWNSTREAM_PATHWAY 1.76 0.04 
159 WINTER_HYPOXIA_UP 1.76 0.04 
160 CONRAD_STEM_CELL 1.75 0.04 
161 LEONARD_HYPOXIA 1.75 0.04 
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163 
TONKS_TARGETS_OF_RUNX1_RUNX1T1_FUSION_HSC_D
N 1.75 0.05 
164 SHIN_B_CELL_LYMPHOMA_CLUSTER_8 1.75 0.05 
165 
REACTOME_DOWNSTREAM_SIGNALING_OF_ACTIVATED
_FGFR2 1.74 0.05 
166 PID_MAPK_TRK_PATHWAY 1.74 0.05 
167 
SHAFFER_IRF4_TARGETS_IN_ACTIVATED_B_LYMPHOCY
TE 1.74 0.05 
168 AMIT_EGF_RESPONSE_40_MCF10A 1.74 0.05 
169 
RICKMAN_TUMOR_DIFFERENTIATED_WELL_VS_MODERA
TELY_DN 1.74 0.05 
170 
REACTOME_INSULIN_RECEPTOR_SIGNALLING_CASCAD
E 1.74 0.05 
171 PID_WNT_SIGNALING_PATHWAY 1.74 0.05 
172 SCHUHMACHER_MYC_TARGETS_UP 1.74 0.05 
173 
GARGALOVIC_RESPONSE_TO_OXIDIZED_PHOSPHOLIPID
S_BLUE_UP 1.74 0.05 
174 KERLEY_RESPONSE_TO_CISPLATIN_UP 1.73 0.05 
175 MULLIGHAN_NPM1_MUTATED_SIGNATURE_1_DN 1.73 0.05 
176 ENGELMANN_CANCER_PROGENITORS_UP 1.73 0.05 
177 CHEN_PDGF_TARGETS 1.73 0.05 
178 PID_P53_DOWNSTREAM_PATHWAY 1.73 0.05 
179 BROWNE_HCMV_INFECTION_30MIN_UP 1.73 0.05 
180 PASINI_SUZ12_TARGETS_DN 1.73 0.05 
181 NEMETH_INFLAMMATORY_RESPONSE_LPS_UP 1.72 0.05 
182 BENPORATH_SUZ12_TARGETS 1.72 0.05 
183 
REACTOME_NEGATIVE_REGULATION_OF_MAPK_PATHW
AY 1.72 0.05 
184 
SATO_SILENCED_BY_DEACETYLATION_IN_PANCREATIC
_CANCER 1.72 0.05 
185 GENTILE_UV_RESPONSE_CLUSTER_D9 1.72 0.05 
186 GENTILE_UV_LOW_DOSE_UP 1.72 0.05 
187 MULLIGHAN_NPM1_SIGNATURE_3_DN 1.72 0.05 
188 
REACTOME_CONSTITUTIVE_SIGNALING_BY_ABERRANT_
PI3K_IN_CANCER 1.72 0.05 
189 KEGG_MELANOMA 1.72 0.05 
190 WINTER_HYPOXIA_METAGENE 1.71 0.05 
191 PLASARI_TGFB1_TARGETS_1HR_UP 1.71 0.05 
192 CAFFAREL_RESPONSE_TO_THC_DN 1.71 0.05 
193 ADDYA_ERYTHROID_DIFFERENTIATION_BY_HEMIN 1.71 0.05 
194 KEGG_FRUCTOSE_AND_MANNOSE_METABOLISM 1.71 0.05 
195 BIOCARTA_ETS_PATHWAY 1.71 0.05 
196 
GRAESSMANN_RESPONSE_TO_MC_AND_SERUM_DEPRI
VATION_DN 1.71 0.05 
197 KIM_WT1_TARGETS_8HR_UP 1.71 0.06 
198 BILD_E2F3_ONCOGENIC_SIGNATURE 1.71 0.06 
199 SMID_BREAST_CANCER_RELAPSE_IN_BONE_DN 1.71 0.06 
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201 BALDWIN_PRKCI_TARGETS_UP 1.70 0.06 
202 BENPORATH_ES_WITH_H3K27ME3 1.70 0.06 
203 
KYNG_ENVIRONMENTAL_STRESS_RESPONSE_NOT_BY_
4NQO_IN_WS 1.70 0.06 
204 FIGUEROA_AML_METHYLATION_CLUSTER_5_DN 1.70 0.06 
205 NAKAMURA_ADIPOGENESIS_EARLY_UP 1.70 0.06 
206 JAATINEN_HEMATOPOIETIC_STEM_CELL_DN 1.70 0.06 
207 AUNG_GASTRIC_CANCER 1.70 0.06 
208 BROWNE_HCMV_INFECTION_8HR_UP 1.70 0.06 
209 CAIRO_PML_TARGETS_BOUND_BY_MYC_UP 1.70 0.06 
210 SCIBETTA_KDM5B_TARGETS_DN 1.70 0.06 
211 KEGG_ACUTE_MYELOID_LEUKEMIA 1.70 0.06 
212 KEGG_PATHOGENIC_ESCHERICHIA_COLI_INFECTION 1.69 0.06 
213 BOQUEST_STEM_CELL_CULTURED_VS_FRESH_UP 1.69 0.06 
214 DASU_IL6_SIGNALING_SCAR_UP 1.69 0.06 
215 PID_SHP2_PATHWAY 1.69 0.06 
216 LIM_MAMMARY_STEM_CELL_UP 1.69 0.06 
217 
TONKS_TARGETS_OF_RUNX1_RUNX1T1_FUSION_MONO
CYTE_DN 1.69 0.06 
218 
ALTEMEIER_RESPONSE_TO_LPS_WITH_MECHANICAL_V
ENTILATION 1.69 0.06 
219 KASLER_HDAC7_TARGETS_1_UP 1.69 0.06 
220 DALESSIO_TSA_RESPONSE 1.69 0.06 
221 NELSON_RESPONSE_TO_ANDROGEN_UP 1.68 0.07 
222 RIZKI_TUMOR_INVASIVENESS_3D_UP 1.68 0.07 
223 SHETH_LIVER_CANCER_VS_TXNIP_LOSS_PAM6 1.68 0.07 
224 KIM_WT1_TARGETS_12HR_UP 1.68 0.07 
225 CEBALLOS_TARGETS_OF_TP53_AND_MYC_UP 1.68 0.07 
226 PID_AP1_PATHWAY 1.68 0.07 
227 WU_CELL_MIGRATION 1.68 0.07 
228 YAMASHITA_LIVER_CANCER_WITH_EPCAM_UP 1.68 0.07 
229 
MATTIOLI_MULTIPLE_MYELOMA_WITH_14Q32_TRANSLO
CATIONS 1.67 0.07 
230 REACTOME_HSF1_ACTIVATION 1.67 0.07 
231 GROSS_HYPOXIA_VIA_ELK3_ONLY_DN 1.67 0.07 
232 MATTIOLI_MGUS_VS_PCL 1.67 0.07 
233 REACTOME_SIGNALING_BY_FGFR4 1.67 0.07 
234 WANG_ESOPHAGUS_CANCER_VS_NORMAL_DN 1.67 0.07 
235 SMID_BREAST_CANCER_LUMINAL_B_DN 1.67 0.07 
236 ELVIDGE_HIF1A_TARGETS_DN 1.67 0.07 
237 
MCMURRAY_TP53_HRAS_COOPERATION_RESPONSE_D
N 1.67 0.07 
238 NAKAYAMA_FRA2_TARGETS 1.67 0.07 
239 LIN_NPAS4_TARGETS_DN 1.67 0.07 
240 REACTOME_SIGNALING_BY_FGFR_IN_DISEASE 1.67 0.07 
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242 SMIRNOV_RESPONSE_TO_IR_6HR_UP 1.66 0.07 
243 
TURASHVILI_BREAST_DUCTAL_CARCINOMA_VS_DUCTAL
_NORMAL_DN 1.66 0.07 
244 AMIT_SERUM_RESPONSE_120_MCF10A 1.66 0.07 
245 
REACTOME_ASSEMBLY_AND_CELL_SURFACE_PRESENT
ATION_OF_NMDA_RECEPTORS 1.66 0.07 
246 REACTOME_SIGNALING_BY_INSULIN_RECEPTOR 1.66 0.07 
247 REACTOME_RAB_GERANYLGERANYLATION 1.66 0.07 
248 TING_SILENCED_BY_DICER 1.66 0.07 
249 DIAZ_CHRONIC_MEYLOGENOUS_LEUKEMIA_DN 1.66 0.07 
250 DOANE_RESPONSE_TO_ANDROGEN_DN 1.66 0.07 
251 BURTON_ADIPOGENESIS_10 1.65 0.07 
252 SAFFORD_T_LYMPHOCYTE_ANERGY 1.65 0.07 
253 DOANE_BREAST_CANCER_ESR1_DN 1.65 0.07 
254 DASU_IL6_SIGNALING_UP 1.65 0.08 
255 LOPEZ_TRANSLATION_VIA_FN1_SIGNALING 1.65 0.08 
256 VALK_AML_CLUSTER_1 1.65 0.08 
257 YANG_BREAST_CANCER_ESR1_LASER_DN 1.65 0.08 
258 
CHIARADONNA_NEOPLASTIC_TRANSFORMATION_KRAS_
CDC25_UP 1.65 0.08 
259 TIAN_TNF_SIGNALING_VIA_NFKB 1.65 0.08 
260 MEISSNER_NPC_HCP_WITH_H3K4ME2_AND_H3K27ME3 1.65 0.08 
261 FOSTER_TOLERANT_MACROPHAGE_DN 1.65 0.08 
262 
HELLER_HDAC_TARGETS_SILENCED_BY_METHYLATION
_UP 1.65 0.08 
263 HILLION_HMGA1_TARGETS 1.64 0.08 
264 BIOCARTA_BCR_PATHWAY 1.64 0.08 
265 
REACTOME_CONSTITUTIVE_SIGNALING_BY_AKT1_E17K_
IN_CANCER 1.64 0.08 
266 WIKMAN_ASBESTOS_LUNG_CANCER_DN 1.64 0.08 
267 
KYNG_ENVIRONMENTAL_STRESS_RESPONSE_NOT_BY_
GAMMA_IN_WS 1.64 0.08 
268 NIKOLSKY_BREAST_CANCER_11Q12_Q14_AMPLICON 1.64 0.08 
269 CHENG_IMPRINTED_BY_ESTRADIOL 1.64 0.08 
270 ZWANG_CLASS_1_TRANSIENTLY_INDUCED_BY_EGF 1.64 0.08 
271 DURAND_STROMA_NS_UP 1.64 0.08 
272 BROWNE_HCMV_INFECTION_12HR_UP 1.64 0.08 
273 NAGASHIMA_NRG1_SIGNALING_DN 1.64 0.08 
274 REACTOME_CELL_CELL_COMMUNICATION 1.64 0.08 
275 PID_P73PATHWAY 1.64 0.08 
276 
TURASHVILI_BREAST_LOBULAR_CARCINOMA_VS_DUCT
AL_NORMAL_DN 1.64 0.08 
277 RAMASWAMY_METASTASIS_DN 1.64 0.08 
278 DOANE_BREAST_CANCER_CLASSES_DN 1.63 0.08 
279 KAN_RESPONSE_TO_ARSENIC_TRIOXIDE 1.63 0.08 
280 
GARGALOVIC_RESPONSE_TO_OXIDIZED_PHOSPHOLIPID
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281 DAZARD_RESPONSE_TO_UV_SCC_UP 1.63 0.08 
282 
REACTOME_NEGATIVE_REGULATION_OF_FGFR4_SIGNA
LING 1.63 0.08 
283 DACOSTA_UV_RESPONSE_VIA_ERCC3_COMMON_UP 1.63 0.08 
284 RASHI_RESPONSE_TO_IONIZING_RADIATION_2 1.63 0.08 
285 
GARGALOVIC_RESPONSE_TO_OXIDIZED_PHOSPHOLIPID
S_MAGENTA_UP 1.63 0.08 
286 REACTOME_FATTY_ACYL_COA_BIOSYNTHESIS 1.63 0.08 
287 REACTOME_METABOLISM_OF_FAT_SOLUBLE_VITAMINS 1.63 0.08 
288 KEGG_LEUKOCYTE_TRANSENDOTHELIAL_MIGRATION 1.62 0.08 
289 REACTOME_SIGNALING_BY_FGFR2_IN_DISEASE 1.62 0.08 
290 WANG_RESPONSE_TO_GSK3_INHIBITOR_SB216763_DN 1.62 0.08 
291 PID_NEPHRIN_NEPH1_PATHWAY 1.62 0.08 
292 MULLIGHAN_NPM1_MUTATED_SIGNATURE_2_DN 1.62 0.09 
293 WEST_ADRENOCORTICAL_TUMOR_UP 1.62 0.09 
294 ROVERSI_GLIOMA_LOH_REGIONS 1.62 0.09 
295 KANG_IMMORTALIZED_BY_TERT_DN 1.62 0.09 
296 BIOCARTA_IL2RB_PATHWAY 1.62 0.09 
297 REACTOME_NEURODEGENERATIVE_DISEASES 1.62 0.09 
298 CHANDRAN_METASTASIS_DN 1.62 0.09 
299 LEE_LIVER_CANCER_SURVIVAL_UP 1.62 0.09 
300 TERAO_AOX4_TARGETS_HG_UP 1.62 0.09 
301 SCHLESINGER_METHYLATED_DE_NOVO_IN_CANCER 1.61 0.09 
302 TRAYNOR_RETT_SYNDROM_UP 1.61 0.09 
303 DACOSTA_UV_RESPONSE_VIA_ERCC3_TTD_UP 1.61 0.09 
304 PID_HDAC_CLASSII_PATHWAY 1.61 0.09 
305 REACTOME_RAF_INDEPENDENT_MAPK1_3_ACTIVATION 1.61 0.09 
306 
KEGG_BIOSYNTHESIS_OF_UNSATURATED_FATTY_ACID
S 1.61 0.09 
307 REACTOME_DOWNSTREAM_SIGNAL_TRANSDUCTION 1.61 0.09 
308 WANG_ESOPHAGUS_CANCER_VS_NORMAL_UP 1.61 0.09 
309 CHIANG_LIVER_CANCER_SUBCLASS_CTNNB1_UP 1.61 0.09 
310 LI_INDUCED_T_TO_NATURAL_KILLER_UP 1.61 0.09 
311 ONO_FOXP3_TARGETS_DN 1.61 0.09 
312 BECKER_TAMOXIFEN_RESISTANCE_DN 1.61 0.09 
313 BROWNE_HCMV_INFECTION_10HR_UP 1.61 0.09 
314 VALK_AML_CLUSTER_6 1.60 0.09 
315 MACAEVA_PBMC_RESPONSE_TO_IR 1.60 0.09 
316 GAL_LEUKEMIC_STEM_CELL_DN 1.60 0.09 
317 CAMPS_COLON_CANCER_COPY_NUMBER_UP 1.60 0.09 
318 REACTOME_GPCR_LIGAND_BINDING 1.60 0.09 
319 PID_HNF3B_PATHWAY 1.60 0.09 
320 ELVIDGE_HIF1A_AND_HIF2A_TARGETS_DN 1.60 0.09 
321 BIOCARTA_NGF_PATHWAY 1.60 0.09 
322 
REACTOME_DEACTIVATION_OF_THE_BETA_CATENIN_TR
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323 TAKEDA_TARGETS_OF_NUP98_HOXA9_FUSION_10D_DN 1.60 0.09 
324 PRAMOONJAGO_SOX4_TARGETS_DN 1.60 0.09 
325 HUMMEL_BURKITTS_LYMPHOMA_UP 1.60 0.09 
326 DACOSTA_UV_RESPONSE_VIA_ERCC3_UP 1.60 0.09 
327 ELVIDGE_HYPOXIA_UP 1.60 0.09 
328 SMID_BREAST_CANCER_BASAL_UP 1.60 0.09 
329 MCDOWELL_ACUTE_LUNG_INJURY_UP 1.60 0.09 
330 
REACTOME_TRANSCRIPTIONAL_REGULATION_OF_PLURI
POTENT_STEM_CELLS 1.60 0.09 
331 BIOCARTA_GPCR_PATHWAY 1.60 0.09 
332 POMEROY_MEDULLOBLASTOMA_PROGNOSIS_DN 1.60 0.09 
333 BRACHAT_RESPONSE_TO_CAMPTOTHECIN_UP 1.60 0.09 
334 SCHAEFFER_PROSTATE_DEVELOPMENT_12HR_UP 1.60 0.09 
335 NAKAMURA_METASTASIS_MODEL_UP 1.59 0.09 
336 BILANGES_RAPAMYCIN_SENSITIVE_GENES 1.59 0.09 
337 DITTMER_PTHLH_TARGETS_DN 1.59 0.09 
338 FISCHER_DIRECT_P53_TARGETS_META_ANALYSIS 1.59 0.09 
339 
REACTOME_NEGATIVE_REGULATION_OF_FGFR3_SIGNA
LING 1.59 0.09 
340 TAKEDA_TARGETS_OF_NUP98_HOXA9_FUSION_16D_UP 1.59 0.09 
341 KANG_CISPLATIN_RESISTANCE_UP 1.59 0.09 
342 BRUINS_UVC_RESPONSE_VIA_TP53_GROUP_C 1.59 0.10 
343 MUELLER_METHYLATED_IN_GLIOBLASTOMA 1.59 0.09 
344 
GARGALOVIC_RESPONSE_TO_OXIDIZED_PHOSPHOLIPID
S_TURQUOISE_UP 1.59 0.10 
345 
REACTOME_TOLL_LIKE_RECEPTOR_TLR1:TLR2_CASCAD
E 1.59 0.10 
346 MASSARWEH_RESPONSE_TO_ESTRADIOL 1.59 0.10 
347 
SMIRNOV_CIRCULATING_ENDOTHELIOCYTES_IN_CANCE
R_UP 1.59 0.10 
348 SHIN_B_CELL_LYMPHOMA_CLUSTER_7 1.59 0.10 
349 LEI_MYB_TARGETS 1.59 0.10 
350 
GRAESSMANN_APOPTOSIS_BY_SERUM_DEPRIVATION_D
N 1.59 0.10 
351 
REACTOME_NONSENSE_MEDIATED_DECAY_NMD_INDEP
ENDENT_OF_THE_EXON_JUNCTION_COMPLEX_EJC 1.59 0.10 
352 XU_GH1_EXOGENOUS_TARGETS_DN 1.59 0.10 
353 MAHAJAN_RESPONSE_TO_IL1A_DN 1.59 0.10 
354 CHAUHAN_RESPONSE_TO_METHOXYESTRADIOL_UP 1.59 0.10 
355 HONRADO_BREAST_CANCER_BRCA1_VS_BRCA2 1.58 0.10 
356 CASORELLI_ACUTE_PROMYELOCYTIC_LEUKEMIA_UP 1.58 0.10 
357 NOJIMA_SFRP2_TARGETS_DN 1.58 0.10 
358 CHUANG_OXIDATIVE_STRESS_RESPONSE_UP 1.58 0.10 
359 REACTOME_SIGNALING_BY_FGFR3 1.58 0.10 
360 
YAO_TEMPORAL_RESPONSE_TO_PROGESTERONE_CLU
STER_8 1.58 0.10 
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362 TAVOR_CEBPA_TARGETS_UP 1.58 0.10 
363 
PAPASPYRIDONOS_UNSTABLE_ATEROSCLEROTIC_PLAQ
UE_DN 1.58 0.10 
364 SCHLINGEMANN_SKIN_CARCINOGENESIS_TPA_UP 1.58 0.10 
365 CROONQUIST_NRAS_SIGNALING_UP 1.58 0.10 
366 KOKKINAKIS_METHIONINE_DEPRIVATION_96HR_UP 1.58 0.10 
367 PID_TAP63_PATHWAY 1.57 0.10 
368 REACTOME_RAF_ACTIVATION 1.57 0.10 
369 JIANG_HYPOXIA_NORMAL 1.57 0.10 
370 SARTIPY_NORMAL_AT_INSULIN_RESISTANCE_UP 1.57 0.10 
371 REACTOME_SIGNALING_BY_INTERLEUKINS 1.57 0.10 
372 REACTOME_CELL_JUNCTION_ORGANIZATION 1.57 0.10 
373 OLSSON_E2F3_TARGETS_UP 1.57 0.10 
374 SASSON_RESPONSE_TO_FORSKOLIN_UP 1.57 0.10 
375 REACTOME_INTERLEUKIN_1_SIGNALING 1.57 0.10 
376 PID_GMCSF_PATHWAY 1.57 0.11 
377 
REACTOME_HSP90_CHAPERONE_CYCLE_FOR_STEROID
_HORMONE_RECEPTORS_SHR 1.57 0.11 
378 WANG_LSD1_TARGETS_UP 1.57 0.11 
379 BENPORATH_MYC_TARGETS_WITH_EBOX 1.56 0.11 
380 IVANOVSKA_MIR106B_TARGETS 1.56 0.11 
381 BURTON_ADIPOGENESIS_9 1.56 0.11 
382 IIZUKA_LIVER_CANCER_PROGRESSION_G2_G3_UP 1.56 0.11 
383 ISSAEVA_MLL2_TARGETS 1.56 0.11 
384 WILCOX_RESPONSE_TO_PROGESTERONE_UP 1.56 0.11 
385 REACTOME_MAPK_FAMILY_SIGNALING_CASCADES 1.56 0.11 
386 BRUNO_HEMATOPOIESIS 1.56 0.11 
387 
CHARAFE_BREAST_CANCER_BASAL_VS_MESENCHYMAL
_UP 1.56 0.11 
388 MARTINEZ_RESPONSE_TO_TRABECTEDIN_UP 1.56 0.11 
389 
REACTOME_POST_CHAPERONIN_TUBULIN_FOLDING_PA
THWAY 1.56 0.11 
390 BIOCARTA_TCR_PATHWAY 1.56 0.11 
391 COULOUARN_TEMPORAL_TGFB1_SIGNATURE_UP 1.56 0.11 
392 GUO_TARGETS_OF_IRS1_AND_IRS2 1.56 0.11 
393 
SHAFFER_IRF4_TARGETS_IN_MYELOMA_VS_MATURE_B
_LYMPHOCYTE 1.56 0.11 
394 KEGG_INSULIN_SIGNALING_PATHWAY 1.56 0.11 
395 MOREAUX_B_LYMPHOCYTE_MATURATION_BY_TACI_UP 1.55 0.11 
396 SHEPARD_CRUSH_AND_BURN_MUTANT_UP 1.55 0.11 
397 SIMBULAN_UV_RESPONSE_NORMAL_DN 1.55 0.11 
398 ABE_VEGFA_TARGETS_30MIN 1.55 0.11 
399 YAGI_AML_WITH_INV_16_TRANSLOCATION 1.55 0.11 
400 BIOCARTA_FMLP_PATHWAY 1.55 0.12 
401 LEE_NEURAL_CREST_STEM_CELL_DN 1.55 0.12 
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403 DELYS_THYROID_CANCER_DN 1.55 0.12 
404 PID_IL12_STAT4_PATHWAY 1.55 0.12 
405 BAE_BRCA1_TARGETS_DN 1.55 0.12 
406 KEGG_MELANOGENESIS 1.55 0.12 
407 EPPERT_HSC_R 1.55 0.12 
408 SHIPP_DLBCL_VS_FOLLICULAR_LYMPHOMA_UP 1.55 0.12 
409 MARZEC_IL2_SIGNALING_UP 1.55 0.12 
410 SMID_BREAST_CANCER_RELAPSE_IN_BRAIN_UP 1.54 0.12 
411 MCCABE_HOXC6_TARGETS_CANCER_UP 1.54 0.12 
412 DOUGLAS_BMI1_TARGETS_UP 1.54 0.12 
413 DELPUECH_FOXO3_TARGETS_UP 1.54 0.12 
414 TAVAZOIE_METASTASIS 1.54 0.12 
415 AMIT_EGF_RESPONSE_240_HELA 1.54 0.12 
416 HOLLEMAN_VINCRISTINE_RESISTANCE_B_ALL_UP 1.54 0.12 
417 TAKAO_RESPONSE_TO_UVB_RADIATION_UP 1.54 0.12 
418 IZADPANAH_STEM_CELL_ADIPOSE_VS_BONE_UP 1.54 0.12 
419 MARTENS_BOUND_BY_PML_RARA_FUSION 1.54 0.12 
420 GRESHOCK_CANCER_COPY_NUMBER_UP 1.54 0.12 
421 ZHAN_MULTIPLE_MYELOMA_MF_UP 1.54 0.12 
422 ZHAN_LATE_DIFFERENTIATION_GENES_UP 1.53 0.12 
423 
PAPASPYRIDONOS_UNSTABLE_ATEROSCLEROTIC_PLAQ
UE_UP 1.53 0.13 
424 MCCLUNG_COCAIN_REWARD_4WK 1.53 0.13 
425 BIOCARTA_VIP_PATHWAY 1.53 0.13 
426 PHONG_TNF_RESPONSE_NOT_VIA_P38 1.53 0.13 
427 MCLACHLAN_DENTAL_CARIES_UP 1.53 0.13 
428 HOFMANN_CELL_LYMPHOMA_UP 1.53 0.13 
429 MORI_EMU_MYC_LYMPHOMA_BY_ONSET_TIME_UP 1.53 0.13 
430 BONCI_TARGETS_OF_MIR15A_AND_MIR16_1 1.53 0.13 
431 
REACTOME_NEGATIVE_REGULATION_OF_FGFR2_SIGNA
LING 1.53 0.13 
432 WEST_ADRENOCORTICAL_TUMOR_MARKERS_UP 1.53 0.13 
433 AMIT_EGF_RESPONSE_240_MCF10A 1.53 0.13 
434 HSIAO_HOUSEKEEPING_GENES 1.53 0.13 
435 REACTOME_INTERFERON_GAMMA_SIGNALING 1.52 0.13 
436 GEISS_RESPONSE_TO_DSRNA_UP 1.52 0.13 
437 MATSUDA_NATURAL_KILLER_DIFFERENTIATION 1.52 0.13 
438 WIERENGA_STAT5A_TARGETS_DN 1.52 0.13 
439 SESTO_RESPONSE_TO_UV_C8 1.52 0.13 
440 STREICHER_LSM1_TARGETS_UP 1.52 0.13 
441 TOMIDA_METASTASIS_DN 1.52 0.13 
442 RIZ_ERYTHROID_DIFFERENTIATION_HBZ 1.52 0.13 
443 BIOCARTA_IGF1_PATHWAY 1.52 0.13 
444 
REACTOME_MISCELLANEOUS_TRANSPORT_AND_BINDIN
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445 
REACTOME_GROWTH_HORMONE_RECEPTOR_SIGNALIN
G 1.52 0.13 
446 
REACTOME_TRANSLOCATION_OF_SLC2A4_GLUT4_TO_T
HE_PLASMA_MEMBRANE 1.52 0.13 
447 STOSSI_RESPONSE_TO_ESTRADIOL 1.52 0.13 
448 HOLLMANN_APOPTOSIS_VIA_CD40_UP 1.52 0.13 
449 YU_BAP1_TARGETS 1.52 0.13 
450 ZHOU_INFLAMMATORY_RESPONSE_FIMA_UP 1.52 0.13 
451 PARK_TRETINOIN_RESPONSE_AND_PML_RARA_FUSION 1.52 0.13 
452 
REACTOME_REGULATION_OF_TP53_EXPRESSION_AND_
DEGRADATION 1.52 0.13 
453 
FULCHER_INFLAMMATORY_RESPONSE_LECTIN_VS_LPS
_UP 1.51 0.13 
454 FRASOR_RESPONSE_TO_ESTRADIOL_UP 1.51 0.13 
455 VALK_AML_CLUSTER_4 1.51 0.13 
456 HOEBEKE_LYMPHOID_STEM_CELL_DN 1.51 0.13 
457 SWEET_LUNG_CANCER_KRAS_DN 1.51 0.13 
458 PID_IL12_2PATHWAY 1.51 0.13 
459 
REACTOME_REGULATION_OF_HSF1_MEDIATED_HEAT_S
HOCK_RESPONSE 1.51 0.13 
460 PID_HIF2PATHWAY 1.51 0.13 
461 AFFAR_YY1_TARGETS_DN 1.51 0.13 
462 KEGG_MAPK_SIGNALING_PATHWAY 1.51 0.13 
463 BIOCARTA_HDAC_PATHWAY 1.51 0.14 
464 LEE_LIVER_CANCER_MYC_E2F1_DN 1.51 0.14 
465 CUI_TCF21_TARGETS_DN 1.51 0.14 
466 CHOW_RASSF1_TARGETS_UP 1.51 0.14 
467 PID_ALK1_PATHWAY 1.51 0.14 
468 COULOUARN_TEMPORAL_TGFB1_SIGNATURE_DN 1.51 0.14 
469 
REACTOME_PREFOLDIN_MEDIATED_TRANSFER_OF_SU
BSTRATE_TO_CCT_TRIC 1.51 0.14 
470 LUI_THYROID_CANCER_CLUSTER_1 1.51 0.14 
471 REACTOME_CARDIAC_CONDUCTION 1.51 0.14 
472 HOOI_ST7_TARGETS_DN 1.51 0.14 
473 
TONKS_TARGETS_OF_RUNX1_RUNX1T1_FUSION_SUSTA
INED_IN_MONOCYTE_UP 1.51 0.14 
474 BIOCARTA_GLEEVEC_PATHWAY 1.51 0.14 
475 UEDA_PERIFERAL_CLOCK 1.51 0.14 
476 PACHER_TARGETS_OF_IGF1_AND_IGF2_UP 1.51 0.14 
477 
YAO_TEMPORAL_RESPONSE_TO_PROGESTERONE_CLU
STER_1 1.51 0.14 
478 SHAFFER_IRF4_MULTIPLE_MYELOMA_PROGRAM 1.50 0.14 
479 SMID_BREAST_CANCER_LUMINAL_A_UP 1.50 0.14 
480 CONCANNON_APOPTOSIS_BY_EPOXOMICIN_UP 1.50 0.14 
481 REACTOME_PLATELET_SENSITIZATION_BY_LDL 1.50 0.14 
482 LINSLEY_MIR16_TARGETS 1.50 0.14 
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484 SHIPP_DLBCL_CURED_VS_FATAL_UP 1.50 0.14 
485 KIM_LIVER_CANCER_POOR_SURVIVAL_UP 1.50 0.14 
486 ELVIDGE_HYPOXIA_DN 1.50 0.14 
487 MOREIRA_RESPONSE_TO_TSA_UP 1.50 0.14 
488 LINDSTEDT_DENDRITIC_CELL_MATURATION_A 1.50 0.14 
489 PID_SMAD2_3NUCLEAR_PATHWAY 1.50 0.14 
490 WANG_RESPONSE_TO_ANDROGEN_UP 1.50 0.14 
491 
TONKS_TARGETS_OF_RUNX1_RUNX1T1_FUSION_SUSTA
INDED_IN_ERYTHROCYTE_UP 1.50 0.14 
492 GENTILE_UV_HIGH_DOSE_UP 1.50 0.14 
493 GUO_HEX_TARGETS_DN 1.50 0.14 
494 PID_IL2_1PATHWAY 1.50 0.14 
495 WIERENGA_STAT5A_TARGETS_GROUP1 1.50 0.14 
496 KEGG_TYPE_II_DIABETES_MELLITUS 1.50 0.14 
497 
GARGALOVIC_RESPONSE_TO_OXIDIZED_PHOSPHOLIPID
S_GREEN_UP 1.50 0.14 
498 GHANDHI_BYSTANDER_IRRADIATION_UP 1.49 0.14 
499 REACTOME_ACTIVATION_OF_BH3_ONLY_PROTEINS 1.49 0.14 
500 SCHAEFFER_PROSTATE_DEVELOPMENT_48HR_UP 1.49 0.14 
501 HORIUCHI_WTAP_TARGETS_DN 1.49 0.14 
502 KEGG_JAK_STAT_SIGNALING_PATHWAY 1.49 0.14 
503 CROMER_TUMORIGENESIS_UP 1.49 0.14 
504 MARZEC_IL2_SIGNALING_DN 1.49 0.14 
505 
REACTOME_SLC_MEDIATED_TRANSMEMBRANE_TRANS
PORT 1.49 0.14 
506 VART_KSHV_INFECTION_ANGIOGENIC_MARKERS_DN 1.49 0.14 
507 TAKEDA_TARGETS_OF_NUP98_HOXA9_FUSION_8D_DN 1.49 0.14 
508 BOYLAN_MULTIPLE_MYELOMA_C_UP 1.49 0.14 
509 HILLION_HMGA1B_TARGETS 1.49 0.14 
510 KAYO_AGING_MUSCLE_UP 1.49 0.14 
511 HUMMERICH_SKIN_CANCER_PROGRESSION_UP 1.49 0.14 
512 LIU_CMYB_TARGETS_UP 1.49 0.14 
513 
REACTOME_CLASS_B_2_SECRETIN_FAMILY_RECEPTOR
S 1.49 0.14 
514 HALMOS_CEBPA_TARGETS_DN 1.49 0.15 
515 
TONKS_TARGETS_OF_RUNX1_RUNX1T1_FUSION_MONO
CYTE_UP 1.49 0.15 
516 AMIT_SERUM_RESPONSE_480_MCF10A 1.49 0.15 
517 CHARAFE_BREAST_CANCER_LUMINAL_VS_BASAL_DN 1.49 0.15 
518 DAVICIONI_MOLECULAR_ARMS_VS_ERMS_DN 1.48 0.15 
519 CONCANNON_APOPTOSIS_BY_EPOXOMICIN_DN 1.48 0.15 
520 REACTOME_CELLULAR_RESPONSE_TO_HEAT_STRESS 1.48 0.15 
521 DELYS_THYROID_CANCER_UP 1.48 0.15 
522 BIOCARTA_IL6_PATHWAY 1.48 0.15 
523 CORRE_MULTIPLE_MYELOMA_DN 1.48 0.15 
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525 CROONQUIST_STROMAL_STIMULATION_UP 1.48 0.15 
526 BURTON_ADIPOGENESIS_8 1.48 0.15 
527 
REACTOME_FORMATION_OF_TUBULIN_FOLDING_INTER
MEDIATES_BY_CCT_TRIC 1.48 0.15 
528 FLORIO_NEOCORTEX_BASAL_RADIAL_GLIA_UP 1.48 0.15 
529 ZHONG_RESPONSE_TO_AZACITIDINE_AND_TSA_UP 1.48 0.15 
530 IGARASHI_ATF4_TARGETS_DN 1.48 0.15 
531 REACTOME_ION_HOMEOSTASIS 1.48 0.15 
532 ONO_AML1_TARGETS_DN 1.48 0.15 
533 KEGG_ENDOCYTOSIS 1.48 0.15 
534 ONDER_CDH1_TARGETS_1_UP 1.48 0.15 
535 KORKOLA_YOLK_SAC_TUMOR 1.48 0.15 
536 PID_AR_NONGENOMIC_PATHWAY 1.48 0.15 
537 FEVR_CTNNB1_TARGETS_UP 1.48 0.15 
538 PEDERSEN_TARGETS_OF_611CTF_ISOFORM_OF_ERBB2 1.48 0.15 
539 KEGG_RIBOSOME 1.48 0.15 
540 KEGG_BASAL_CELL_CARCINOMA 1.47 0.15 
541 TARTE_PLASMA_CELL_VS_PLASMABLAST_DN 1.47 0.15 
542 YAO_HOXA10_TARGETS_VIA_PROGESTERONE_UP 1.47 0.15 
543 REACTOME_SIGNALING_BY_FGFR 1.47 0.15 
544 REACTOME_TOLL_LIKE_RECEPTOR_9_TLR9_CASCADE 1.47 0.15 
545 REACTOME_DISEASES_OF_SIGNAL_TRANSDUCTION 1.47 0.15 
546 SAKAI_CHRONIC_HEPATITIS_VS_LIVER_CANCER_DN 1.47 0.15 
547 
GOTZMANN_EPITHELIAL_TO_MESENCHYMAL_TRANSITIO
N_DN 1.47 0.15 
548 BILBAN_B_CLL_LPL_DN 1.47 0.15 
549 MARSON_FOXP3_TARGETS_DN 1.47 0.15 
550 
ACOSTA_PROLIFERATION_INDEPENDENT_MYC_TARGET
S_UP 1.47 0.15 
551 MONNIER_POSTRADIATION_TUMOR_ESCAPE_DN 1.47 0.15 
552 BEIER_GLIOMA_STEM_CELL_UP 1.47 0.15 
553 BIOCARTA_MEF2D_PATHWAY 1.47 0.16 
554 SMID_BREAST_CANCER_RELAPSE_IN_LUNG_UP 1.47 0.16 
555 KEGG_HEMATOPOIETIC_CELL_LINEAGE 1.47 0.16 
556 
DAVICIONI_RHABDOMYOSARCOMA_PAX_FOXO1_FUSION
_UP 1.47 0.16 
557 PID_EPHRINB_REV_PATHWAY 1.47 0.16 
558 NABA_MATRISOME_ASSOCIATED 1.47 0.16 
559 BIOCARTA_P53_PATHWAY 1.47 0.16 
560 OHGUCHI_LIVER_HNF4A_TARGETS_UP 1.46 0.16 
561 REACTOME_PYRUVATE_METABOLISM 1.46 0.16 
562 HU_ANGIOGENESIS_UP 1.46 0.16 
563 MARSHALL_VIRAL_INFECTION_RESPONSE_DN 1.46 0.16 
564 BIOCARTA_CALCINEURIN_PATHWAY 1.46 0.16 
565 COATES_MACROPHAGE_M1_VS_M2_UP 1.46 0.16 
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567 FARMER_BREAST_CANCER_APOCRINE_VS_BASAL 1.46 0.16 
568 REACTOME_GLYCOLYSIS 1.46 0.16 
569 LI_PROSTATE_CANCER_EPIGENETIC 1.46 0.16 
570 CHANG_IMMORTALIZED_BY_HPV31_UP 1.46 0.16 
571 REACTOME_FGFR2_MUTANT_RECEPTOR_ACTIVATION 1.46 0.16 
572 
REACTOME_CYCLIN_A_B1_B2_ASSOCIATED_EVENTS_D
URING_G2_M_TRANSITION 1.46 0.16 
573 PID_ERBB2_ERBB3_PATHWAY 1.46 0.16 
574 ELVIDGE_HYPOXIA_BY_DMOG_DN 1.46 0.16 
575 
REACTOME_NEGATIVE_REGULATION_OF_THE_PI3K_AKT
_NETWORK 1.46 0.16 
576 GAVIN_FOXP3_TARGETS_CLUSTER_P7 1.46 0.16 
577 WNT_SIGNALING 1.46 0.16 
578 KEGG_GLIOMA 1.46 0.16 
579 RHEIN_ALL_GLUCOCORTICOID_THERAPY_DN 1.46 0.16 
580 
YAO_TEMPORAL_RESPONSE_TO_PROGESTERONE_CLU
STER_5 1.46 0.16 
581 ABBUD_LIF_SIGNALING_1_DN 1.46 0.16 
582 LANDIS_ERBB2_BREAST_TUMORS_65_UP 1.46 0.16 
583 MARTINEZ_RB1_AND_TP53_TARGETS_UP 1.46 0.16 
584 BEGUM_TARGETS_OF_PAX3_FOXO1_FUSION_DN 1.45 0.16 
585 ZHENG_FOXP3_TARGETS_IN_THYMUS_UP 1.45 0.16 
586 SASSON_RESPONSE_TO_GONADOTROPHINS_UP 1.45 0.16 




ANE 1.45 0.16 
589 GAUSSMANN_MLL_AF4_FUSION_TARGETS_E_UP 1.45 0.16 
590 REACTOME_SIGNALING_BY_WNT_IN_CANCER 1.45 0.16 
591 AMIT_EGF_RESPONSE_480_HELA 1.45 0.16 
592 CREIGHTON_ENDOCRINE_THERAPY_RESISTANCE_5 1.45 0.16 
593 ZHENG_BOUND_BY_FOXP3 1.45 0.16 
594 KOHOUTEK_CCNT1_TARGETS 1.45 0.16 
595 MCBRYAN_PUBERTAL_BREAST_4_5WK_UP 1.45 0.16 
596 FUJII_YBX1_TARGETS_UP 1.45 0.16 
597 FARMER_BREAST_CANCER_BASAL_VS_LULMINAL 1.45 0.16 
598 
YAO_TEMPORAL_RESPONSE_TO_PROGESTERONE_CLU
STER_17 1.45 0.17 
599 
SHAFFER_IRF4_TARGETS_IN_PLASMA_CELL_VS_MATUR
E_B_LYMPHOCYTE 1.45 0.17 
600 RIZ_ERYTHROID_DIFFERENTIATION_12HR 1.45 0.17 
601 DAZARD_RESPONSE_TO_UV_SCC_DN 1.45 0.17 
602 RIGGINS_TAMOXIFEN_RESISTANCE_DN 1.45 0.17 
603 YAMAZAKI_TCEB3_TARGETS_DN 1.45 0.17 
604 BIOCARTA_EPO_PATHWAY 1.45 0.17 
605 PID_PDGFRA_PATHWAY 1.45 0.17 
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607 IKEDA_MIR30_TARGETS_UP 1.45 0.17 
608 
REACTOME_MYD88_CASCADE_INITIATED_ON_PLASMA_
MEMBRANE 1.45 0.17 
609 PID_PI3KCI_PATHWAY 1.45 0.17 
610 BIOCARTA_NO1_PATHWAY 1.45 0.17 
611 HINATA_NFKB_TARGETS_KERATINOCYTE_UP 1.44 0.17 
612 SESTO_RESPONSE_TO_UV_C3 1.44 0.17 
613 OZEN_MIR125B1_TARGETS 1.44 0.17 
614 BROWNE_HCMV_INFECTION_1HR_UP 1.44 0.17 
615 
REACTOME_COPI_INDEPENDENT_GOLGI_TO_ER_RETRO
GRADE_TRAFFIC 1.44 0.17 
616 SMITH_TERT_TARGETS_DN 1.44 0.17 
617 PETROVA_PROX1_TARGETS_UP 1.44 0.17 
618 FERRARI_RESPONSE_TO_FENRETINIDE_UP 1.44 0.17 
619 BILBAN_B_CLL_LPL_UP 1.44 0.17 
620 REACTOME_CELL_CELL_JUNCTION_ORGANIZATION 1.44 0.17 
621 ZHANG_RESPONSE_TO_IKK_INHIBITOR_AND_TNF_UP 1.44 0.17 
622 ZHOU_INFLAMMATORY_RESPONSE_LPS_UP 1.44 0.17 
623 REACTOME_BASIGIN_INTERACTIONS 1.44 0.17 
624 BROWNE_HCMV_INFECTION_20HR_UP 1.44 0.17 
625 MARTINEZ_TP53_TARGETS_UP 1.44 0.17 
626 KEGG_WNT_SIGNALING_PATHWAY 1.44 0.17 
627 SAMOLS_TARGETS_OF_KHSV_MIRNAS_DN 1.44 0.17 
628 RIGGI_EWING_SARCOMA_PROGENITOR_UP 1.44 0.17 
629 
REACTOME_WNT_LIGAND_BIOGENESIS_AND_TRAFFICKI
NG 1.44 0.17 
630 
REACTOME_ROS_AND_RNS_PRODUCTION_IN_PHAGOCY
TES 1.44 0.17 
631 SUBTIL_PROGESTIN_TARGETS 1.44 0.17 
632 PID_FRA_PATHWAY 1.44 0.17 
633 RUTELLA_RESPONSE_TO_HGF_UP 1.44 0.17 
634 NAKAYAMA_SOFT_TISSUE_TUMORS_PCA2_UP 1.44 0.17 
635 
REACTOME_INTERLEUKIN_4_AND_INTERLEUKIN_13_SIG
NALING 1.43 0.17 
636 REACTOME_CLASS_A_1_RHODOPSIN_LIKE_RECEPTORS 1.43 0.17 
637 PID_PDGFRB_PATHWAY 1.43 0.17 
638 MIYAGAWA_TARGETS_OF_EWSR1_ETS_FUSIONS_DN 1.43 0.17 
639 
CHIARADONNA_NEOPLASTIC_TRANSFORMATION_KRAS_
DN 1.43 0.17 
640 BIOCARTA_INSULIN_PATHWAY 1.43 0.17 
641 GOLDRATH_IMMUNE_MEMORY 1.43 0.17 
642 HUNSBERGER_EXERCISE_REGULATED_GENES 1.43 0.17 
643 
REACTOME_COOPERATION_OF_PREFOLDIN_AND_TRIC_
CCT_IN_ACTIN_AND_TUBULIN_FOLDING 1.43 0.17 
644 NUTT_GBM_VS_AO_GLIOMA_UP 1.43 0.17 
645 
REACTOME_ACTIVATION_OF_AMPK_DOWNSTREAM_OF_
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646 VERRECCHIA_RESPONSE_TO_TGFB1_C1 1.43 0.18 
647 
REACTOME_DETOXIFICATION_OF_REACTIVE_OXYGEN_
SPECIES 1.43 0.18 
648 SENESE_HDAC3_TARGETS_UP 1.43 0.18 
649 GERY_CEBP_TARGETS 1.42 0.18 
650 FRASOR_RESPONSE_TO_SERM_OR_FULVESTRANT_UP 1.42 0.18 
651 
REACTOME_TP53_REGULATES_TRANSCRIPTION_OF_CE
LL_DEATH_GENES 1.42 0.18 
652 
REACTOME_ACTIVATION_OF_NMDA_RECEPTORS_AND_
POSTSYNAPTIC_EVENTS 1.42 0.18 
653 
REACTOME_DOWNSTREAM_SIGNALING_EVENTS_OF_B_
CELL_RECEPTOR_BCR 1.42 0.18 
654 
REACTOME_FOXO_MEDIATED_TRANSCRIPTION_OF_CEL
L_CYCLE_GENES 1.42 0.18 
655 
RUTELLA_RESPONSE_TO_HGF_VS_CSF2RB_AND_IL4_D
N 1.42 0.18 
656 PID_IL6_7_PATHWAY 1.42 0.18 
657 
KEGG_ALDOSTERONE_REGULATED_SODIUM_REABSOR
PTION 1.42 0.18 
658 BHAT_ESR1_TARGETS_VIA_AKT1_DN 1.42 0.18 
659 ACEVEDO_LIVER_CANCER_DN 1.42 0.18 
660 ALFANO_MYC_TARGETS 1.42 0.18 
661 ZHENG_FOXP3_TARGETS_UP 1.42 0.18 
662 RHEIN_ALL_GLUCOCORTICOID_THERAPY_UP 1.42 0.18 
663 COATES_MACROPHAGE_M1_VS_M2_DN 1.42 0.19 
664 UEDA_CENTRAL_CLOCK 1.42 0.19 
665 
FLECHNER_BIOPSY_KIDNEY_TRANSPLANT_REJECTED_
VS_OK_DN 1.42 0.19 
666 REACTOME_INTERLEUKIN_10_SIGNALING 1.42 0.19 
667 DANG_REGULATED_BY_MYC_DN 1.42 0.19 
668 JIANG_VHL_TARGETS 1.42 0.19 
669 CUI_GLUCOSE_DEPRIVATION 1.41 0.19 
670 ACEVEDO_LIVER_CANCER_WITH_H3K27ME3_UP 1.41 0.19 
671 MIYAGAWA_TARGETS_OF_EWSR1_ETS_FUSIONS_UP 1.41 0.19 
672 VERHAAK_AML_WITH_NPM1_MUTATED_DN 1.41 0.19 
673 
SATO_SILENCED_BY_METHYLATION_IN_PANCREATIC_C
ANCER_2 1.41 0.19 
674 PLASARI_TGFB1_SIGNALING_VIA_NFIC_1HR_UP 1.41 0.19 
675 MITSIADES_RESPONSE_TO_APLIDIN_UP 1.41 0.19 
676 MCBRYAN_PUBERTAL_BREAST_5_6WK_UP 1.41 0.19 
677 MMS_MOUSE_LYMPH_HIGH_4HRS_UP 1.41 0.19 
678 DANG_REGULATED_BY_MYC_UP 1.41 0.19 
679 LI_LUNG_CANCER 1.41 0.19 
680 KEGG_PATHWAYS_IN_CANCER 1.41 0.19 
681 SESTO_RESPONSE_TO_UV_C0 1.41 0.19 
682 BIOCARTA_P53HYPOXIA_PATHWAY 1.41 0.19 
683 SCHUETZ_BREAST_CANCER_DUCTAL_INVASIVE_DN 1.41 0.19 
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685 
REACTOME_TRANSFERRIN_ENDOCYTOSIS_AND_RECYC
LING 1.41 0.20 
686 
REACTOME_ACTIVATION_OF_BAD_AND_TRANSLOCATIO
N_TO_MITOCHONDRIA 1.40 0.20 
687 MOOTHA_GLUCONEOGENESIS 1.40 0.20 
688 UDAYAKUMAR_MED1_TARGETS_DN 1.40 0.20 
689 NIKOLSKY_OVERCONNECTED_IN_BREAST_CANCER 1.40 0.20 
690 VERHAAK_AML_WITH_NPM1_MUTATED_UP 1.40 0.20 
691 BHAT_ESR1_TARGETS_NOT_VIA_AKT1_DN 1.40 0.20 
692 
REACTOME_SIGNALING_BY_THE_B_CELL_RECEPTOR_B
CR 1.40 0.20 
693 BURTON_ADIPOGENESIS_1 1.40 0.20 
694 
REACTOME_MAP3K8_TPL2_DEPENDENT_MAPK1_3_ACTI
VATION 1.40 0.20 
695 PID_S1P_S1P2_PATHWAY 1.40 0.20 
696 SHEDDEN_LUNG_CANCER_POOR_SURVIVAL_A6 1.40 0.20 
697 REACTOME_INTERLEUKIN_1_FAMILY_SIGNALING 1.40 0.20 
698 SANSOM_APC_TARGETS_REQUIRE_MYC 1.40 0.20 
699 WIEDERSCHAIN_TARGETS_OF_BMI1_AND_PCGF2 1.40 0.20 
700 REACTOME_NEPHRIN_FAMILY_INTERACTIONS 1.40 0.20 
701 HAN_JNK_SINGALING_UP 1.40 0.20 
702 KEGG_CELL_ADHESION_MOLECULES_CAMS 1.40 0.20 
703 PID_P38_MK2_PATHWAY 1.40 0.20 
704 CHESLER_BRAIN_HIGHEST_EXPRESSION 1.40 0.20 
705 MILI_PSEUDOPODIA_CHEMOTAXIS_DN 1.40 0.20 
706 
CHIANG_LIVER_CANCER_SUBCLASS_UNANNOTATED_D
N 1.40 0.20 
707 FRIDMAN_IMMORTALIZATION_DN 1.40 0.20 
708 CHIANG_LIVER_CANCER_SUBCLASS_INTERFERON_DN 1.40 0.20 
709 BIOCARTA_IL2_PATHWAY 1.40 0.20 
710 OKUMURA_INFLAMMATORY_RESPONSE_LPS 1.40 0.20 
711 GROSS_HYPOXIA_VIA_ELK3_DN 1.39 0.20 
712 PID_S1P_S1P3_PATHWAY 1.39 0.20 
713 LENAOUR_DENDRITIC_CELL_MATURATION_DN 1.39 0.20 
714 STANELLE_E2F1_TARGETS 1.39 0.20 
715 KEGG_GLYCEROPHOSPHOLIPID_METABOLISM 1.39 0.20 
716 XU_HGF_SIGNALING_NOT_VIA_AKT1_48HR_UP 1.39 0.20 
717 PID_ATF2_PATHWAY 1.39 0.20 
718 SMITH_LIVER_CANCER 1.39 0.20 
719 GYORFFY_DOXORUBICIN_RESISTANCE 1.39 0.20 
720 KEGG_BLADDER_CANCER 1.39 0.20 
721 HOFMANN_MYELODYSPLASTIC_SYNDROM_RISK_UP 1.39 0.20 
722 GENTILE_UV_HIGH_DOSE_DN 1.39 0.20 
723 CHIBA_RESPONSE_TO_TSA_UP 1.39 0.21 
724 POOLA_INVASIVE_BREAST_CANCER_DN 1.39 0.21 
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726 REACTOME_SIGNALING_BY_FGFR2 1.39 0.21 
727 VALK_AML_CLUSTER_11 1.39 0.20 
728 
TONKS_TARGETS_OF_RUNX1_RUNX1T1_FUSION_ERYTH
ROCYTE_UP 1.39 0.21 
729 HADDAD_T_LYMPHOCYTE_AND_NK_PROGENITOR_DN 1.39 0.21 
730 PURBEY_TARGETS_OF_CTBP1_AND_SATB1_UP 1.39 0.21 
731 LEE_LIVER_CANCER_MYC_TGFA_UP 1.39 0.21 
732 REACTOME_METABOLISM_OF_CARBOHYDRATES 1.39 0.21 
733 RICKMAN_HEAD_AND_NECK_CANCER_C 1.39 0.21 
734 LEE_LIVER_CANCER_CIPROFIBRATE_DN 1.39 0.21 
735 BROWNE_HCMV_INFECTION_18HR_UP 1.39 0.21 
736 REACTOME_SEMA4D_IN_SEMAPHORIN_SIGNALING 1.38 0.21 
737 LOPES_METHYLATED_IN_COLON_CANCER_DN 1.38 0.21 
738 KIM_HYPOXIA 1.38 0.21 
739 LIN_SILENCED_BY_TUMOR_MICROENVIRONMENT 1.38 0.21 
740 PEDRIOLI_MIR31_TARGETS_UP 1.38 0.21 
741 REACTOME_TOLL_LIKE_RECEPTOR_4_TLR4_CASCADE 1.38 0.21 
742 PETROVA_ENDOTHELIUM_LYMPHATIC_VS_BLOOD_UP 1.38 0.21 
743 KIM_RESPONSE_TO_TSA_AND_DECITABINE_UP 1.38 0.21 
744 MACLACHLAN_BRCA1_TARGETS_UP 1.38 0.21 
745 BIOCARTA_TNFR1_PATHWAY 1.38 0.21 
746 PID_S1P_S1P1_PATHWAY 1.38 0.21 
747 REACTOME_GLUCOSE_METABOLISM 1.38 0.21 
748 MANALO_HYPOXIA_UP 1.38 0.21 
749 AFFAR_YY1_TARGETS_UP 1.38 0.21 
750 RUTELLA_RESPONSE_TO_CSF2RB_AND_IL4_UP 1.38 0.21 
751 LEE_AGING_MUSCLE_DN 1.38 0.21 
752 DAVICIONI_PAX_FOXO1_SIGNATURE_IN_ARMS_UP 1.38 0.21 
753 HOEBEKE_LYMPHOID_STEM_CELL_UP 1.38 0.21 
754 HOWLIN_CITED1_TARGETS_1_UP 1.38 0.21 
755 ZHANG_GATA6_TARGETS_DN 1.38 0.21 
756 PID_NFAT_3PATHWAY 1.38 0.21 
757 REACTOME_INTERLEUKIN_17_SIGNALING 1.38 0.21 
758 SWEET_KRAS_TARGETS_UP 1.38 0.21 
759 LIAN_LIPA_TARGETS_6M 1.38 0.21 
760 
ACEVEDO_NORMAL_TISSUE_ADJACENT_TO_LIVER_TUM
OR_DN 1.38 0.21 
761 CROMER_TUMORIGENESIS_DN 1.38 0.21 
762 PID_IL1_PATHWAY 1.38 0.21 
763 LUI_TARGETS_OF_PAX8_PPARG_FUSION 1.38 0.21 
764 
GRAESSMANN_RESPONSE_TO_MC_AND_DOXORUBICIN_
UP 1.37 0.22 
765 HUANG_GATA2_TARGETS_DN 1.37 0.22 
766 LI_CISPLATIN_RESISTANCE_DN 1.37 0.22 
767 REACTOME_TRANSCRIPTIONAL_REGULATION_BY_TP53 1.37 0.22 
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769 REACTOME_SIGNALING_BY_NTRK1_TRKA 1.37 0.22 
770 BROWNE_HCMV_INFECTION_48HR_UP 1.37 0.22 
771 WU_HBX_TARGETS_3_UP 1.37 0.22 
772 MEISSNER_BRAIN_HCP_WITH_H3K27ME3 1.37 0.22 
773 DEBIASI_APOPTOSIS_BY_REOVIRUS_INFECTION_UP 1.37 0.22 
774 RORIE_TARGETS_OF_EWSR1_FLI1_FUSION_UP 1.37 0.22 
775 MOOTHA_PGC 1.37 0.22 
776 MEISSNER_NPC_HCP_WITH_H3K4ME3_AND_H3K27ME3 1.37 0.22 
777 MARTINEZ_RB1_TARGETS_UP 1.37 0.22 
778 RUTELLA_RESPONSE_TO_CSF2RB_AND_IL4_DN 1.37 0.22 
779 LEE_EARLY_T_LYMPHOCYTE_DN 1.37 0.22 
780 NOUZOVA_METHYLATED_IN_APL 1.37 0.22 
781 WONG_EMBRYONIC_STEM_CELL_CORE 1.37 0.22 
782 TORCHIA_TARGETS_OF_EWSR1_FLI1_FUSION_DN 1.37 0.22 
783 YOKOE_CANCER_TESTIS_ANTIGENS 1.37 0.22 
784 JOHANSSON_GLIOMAGENESIS_BY_PDGFB_DN 1.37 0.22 
785 GRAHAM_CML_QUIESCENT_VS_NORMAL_DIVIDING_UP 1.37 0.22 
786 PHONG_TNF_RESPONSE_VIA_P38_COMPLETE 1.37 0.22 
787 MODY_HIPPOCAMPUS_NEONATAL 1.37 0.22 
788 ZHENG_GLIOBLASTOMA_PLASTICITY_DN 1.37 0.22 
789 
REACTOME_CHONDROITIN_SULFATE_DERMATAN_SULF
ATE_METABOLISM 1.37 0.22 
790 HOSHIDA_LIVER_CANCER_LATE_RECURRENCE_DN 1.37 0.22 
791 VANTVEER_BREAST_CANCER_METASTASIS_DN 1.37 0.22 
792 TANAKA_METHYLATED_IN_ESOPHAGEAL_CARCINOMA 1.37 0.22 
793 WANG_SMARCE1_TARGETS_DN 1.37 0.22 
794 CHAUHAN_RESPONSE_TO_METHOXYESTRADIOL_DN 1.37 0.22 
795 BAE_BRCA1_TARGETS_UP 1.36 0.22 
796 FARMER_BREAST_CANCER_APOCRINE_VS_LUMINAL 1.36 0.22 
797 BOYAULT_LIVER_CANCER_SUBCLASS_G1_DN 1.36 0.22 
798 BROWN_MYELOID_CELL_DEVELOPMENT_DN 1.36 0.22 
799 LINDSTEDT_DENDRITIC_CELL_MATURATION_C 1.36 0.22 
800 DEBIASI_APOPTOSIS_BY_REOVIRUS_INFECTION_DN 1.36 0.23 
801 MARKS_HDAC_TARGETS_UP 1.36 0.23 
802 QI_HYPOXIA_TARGETS_OF_HIF1A_AND_FOXA2 1.36 0.23 
803 WANG_HCP_PROSTATE_CANCER 1.36 0.23 
804 LANDIS_ERBB2_BREAST_TUMORS_324_UP 1.36 0.23 
805 VERNELL_RETINOBLASTOMA_PATHWAY_DN 1.36 0.23 
806 BONOME_OVARIAN_CANCER_POOR_SURVIVAL_DN 1.36 0.23 
807 TAKEDA_TARGETS_OF_NUP98_HOXA9_FUSION_6HR_UP 1.36 0.23 
808 MULLIGHAN_MLL_SIGNATURE_2_DN 1.36 0.23 
809 REACTOME_SIGNALING_BY_NTRK2_TRKB 1.36 0.23 
810 MATZUK_IMPLANTATION_AND_UTERINE 1.36 0.23 
811 
REACTOME_SEMA4D_INDUCED_CELL_MIGRATION_AND_
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812 
GRAHAM_CML_QUIESCENT_VS_NORMAL_QUIESCENT_U
P 1.36 0.23 
813 LU_IL4_SIGNALING 1.36 0.23 
814 SPIRA_SMOKERS_LUNG_CANCER_UP 1.36 0.23 
815 
YAO_TEMPORAL_RESPONSE_TO_PROGESTERONE_CLU
STER_6 1.36 0.23 
816 BERENJENO_TRANSFORMED_BY_RHOA_UP 1.35 0.23 
817 MARTENS_TRETINOIN_RESPONSE_UP 1.35 0.23 
818 PID_CXCR4_PATHWAY 1.35 0.23 
819 VALK_AML_CLUSTER_2 1.35 0.23 
820 ZAMORA_NOS2_TARGETS_UP 1.35 0.23 
821 WEST_ADRENOCORTICAL_TUMOR_DN 1.35 0.23 
822 PID_TRKR_PATHWAY 1.35 0.23 
823 BASSO_HAIRY_CELL_LEUKEMIA_UP 1.35 0.23 
824 MA_MYELOID_DIFFERENTIATION_DN 1.35 0.23 
825 PID_PI3K_PLC_TRK_PATHWAY 1.35 0.23 
826 LEE_CALORIE_RESTRICTION_NEOCORTEX_DN 1.35 0.23 
827 PASQUALUCCI_LYMPHOMA_BY_GC_STAGE_UP 1.35 0.23 
828 HENDRICKS_SMARCA4_TARGETS_UP 1.35 0.23 
829 ZHAN_MULTIPLE_MYELOMA_CD1_AND_CD2_DN 1.35 0.23 
830 REACTOME_INFLUENZA_INFECTION 1.35 0.23 
831 
IVANOVA_HEMATOPOIESIS_STEM_CELL_AND_PROGENIT
OR 1.35 0.23 
832 ANDERSEN_LIVER_CANCER_KRT19_UP 1.35 0.23 
833 ODONNELL_METASTASIS_DN 1.35 0.23 
834 BIOCARTA_NFAT_PATHWAY 1.35 0.23 
835 PID_HEDGEHOG_2PATHWAY 1.35 0.23 
836 BHAT_ESR1_TARGETS_NOT_VIA_AKT1_UP 1.35 0.23 
837 ZHANG_RESPONSE_TO_IKK_INHIBITOR_AND_TNF_DN 1.35 0.23 
838 COLLER_MYC_TARGETS_UP 1.35 0.23 
839 
RUTELLA_RESPONSE_TO_HGF_VS_CSF2RB_AND_IL4_U
P 1.35 0.24 
840 IWANAGA_CARCINOGENESIS_BY_KRAS_PTEN_DN 1.35 0.24 
841 KEGG_VIRAL_MYOCARDITIS 1.35 0.24 
842 CHIANG_LIVER_CANCER_SUBCLASS_CTNNB1_DN 1.34 0.24 
843 
GARGALOVIC_RESPONSE_TO_OXIDIZED_PHOSPHOLIPID
S_CYAN_UP 1.34 0.24 
844 GAJATE_RESPONSE_TO_TRABECTEDIN_UP 1.34 0.24 
845 WIERENGA_STAT5A_TARGETS_UP 1.34 0.24 
846 VANTVEER_BREAST_CANCER_ESR1_DN 1.34 0.24 
847 ONGUSAHA_TP53_TARGETS 1.34 0.24 
848 KEGG_PROSTATE_CANCER 1.34 0.24 
849 PID_WNT_CANONICAL_PATHWAY 1.34 0.24 
850 CUI_TCF21_TARGETS_UP 1.34 0.24 
851 
ACEVEDO_LIVER_TUMOR_VS_NORMAL_ADJACENT_TISS
UE_DN 1.34 0.24 
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853 LEE_AGING_MUSCLE_UP 1.34 0.24 
854 LEE_LIVER_CANCER_SURVIVAL_DN 1.34 0.24 
855 
SATO_SILENCED_EPIGENETICALLY_IN_PANCREATIC_CA
NCER 1.34 0.24 
856 LEE_LIVER_CANCER_MYC_DN 1.34 0.24 
857 RUIZ_TNC_TARGETS_UP 1.34 0.24 
858 POOLA_INVASIVE_BREAST_CANCER_UP 1.34 0.24 
859 MCBRYAN_PUBERTAL_BREAST_4_5WK_DN 1.34 0.24 
860 
REACTOME_AMINO_ACID_TRANSPORT_ACROSS_THE_P
LASMA_MEMBRANE 1.34 0.24 
861 LANDIS_ERBB2_BREAST_TUMORS_65_DN 1.34 0.24 
862 ONDER_CDH1_TARGETS_1_DN 1.34 0.24 
863 KUMAR_TARGETS_OF_MLL_AF9_FUSION 1.34 0.24 
864 BIOCARTA_CELLCYCLE_PATHWAY 1.34 0.24 
865 SHEN_SMARCA2_TARGETS_DN 1.34 0.24 
866 CERVERA_SDHB_TARGETS_1_UP 1.34 0.24 
867 GROSS_HIF1A_TARGETS_DN 1.34 0.24 
868 AMIT_EGF_RESPONSE_480_MCF10A 1.34 0.24 
869 REACTOME_OTHER_INTERLEUKIN_SIGNALING 1.34 0.24 
870 
BERTUCCI_INVASIVE_CARCINOMA_DUCTAL_VS_LOBULA
R_UP 1.34 0.24 
871 REACTOME_HOST_INTERACTIONS_OF_HIV_FACTORS 1.34 0.24 
872 
TURASHVILI_BREAST_CARCINOMA_DUCTAL_VS_LOBULA
R_UP 1.34 0.24 
873 SEKI_INFLAMMATORY_RESPONSE_LPS_UP 1.34 0.24 
874 
TONKS_TARGETS_OF_RUNX1_RUNX1T1_FUSION_HSC_U
P 1.33 0.24 
875 GEORGES_CELL_CYCLE_MIR192_TARGETS 1.33 0.24 
876 
REACTOME_TRANSCRIPTIONAL_REGULATION_BY_MECP
2 1.33 0.24 
877 REACTOME_FOXO_MEDIATED_TRANSCRIPTION 1.33 0.24 
878 
GRAHAM_CML_QUIESCENT_VS_NORMAL_QUIESCENT_D
N 1.33 0.24 
879 KEGG_B_CELL_RECEPTOR_SIGNALING_PATHWAY 1.33 0.24 
880 ABE_VEGFA_TARGETS_2HR 1.33 0.24 
881 KAYO_CALORIE_RESTRICTION_MUSCLE_UP 1.33 0.24 
882 GAUSSMANN_MLL_AF4_FUSION_TARGETS_G_UP 1.33 0.24 
883 REACTOME_SIGNALING_BY_GPCR 1.33 0.24 
884 SARTIPY_BLUNTED_BY_INSULIN_RESISTANCE_DN 1.33 0.24 
885 FOURNIER_ACINAR_DEVELOPMENT_LATE_2 1.33 0.24 
886 OUILLETTE_CLL_13Q14_DELETION_DN 1.33 0.24 
887 
LIANG_HEMATOPOIESIS_STEM_CELL_NUMBER_LARGE_
VS_TINY_UP 1.33 0.24 
888 CREIGHTON_ENDOCRINE_THERAPY_RESISTANCE_4 1.33 0.24 
889 SCIAN_CELL_CYCLE_TARGETS_OF_TP53_AND_TP73_DN 1.33 0.24 
890 
SHAFFER_IRF4_TARGETS_IN_ACTIVATED_DENDRITIC_C
ELL 1.33 0.25 
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892 WANG_TARGETS_OF_MLL_CBP_FUSION_DN 1.33 0.25 
893 REACTOME_RHO_GTPASES_ACTIVATE_IQGAPS 1.33 0.25 
894 REACTOME_TRANSPORT_OF_SMALL_MOLECULES 1.33 0.25 
895 KEGG_COLORECTAL_CANCER 1.33 0.25 
896 WOOD_EBV_EBNA1_TARGETS_UP 1.33 0.25 
897 BAELDE_DIABETIC_NEPHROPATHY_DN 1.33 0.25 
898 REACTOME_SIGNALING_BY_FGFR2_IIIA_TM 1.33 0.25 
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Table S6 Sequences of siControl and siRNAs used in this study. 
Target Sequences 
Non-targeting 5  D-001210-05: UGGUUUACAUGUCGACUAA 
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Table S7 Gene expression primer sequences. 
Gene Forward primer Reverse primer 
GAPDH ATGGGGAAGGTGAAGGTCG GGGGTCATTGATGGCAACAATA 
RRM1 ACTACTATCCTGTACCAGAGGCAT CTGGGCTTCTGCACTCTCAA 
STIM1 CCTCCTCTCTTGACTCGCCA TATAGGCAAACCAGCAGCCG 
NFATC2 AAGACCACAGATGGACAGCAAA CATGTTGGGCTGGCTCTTGT 
TRIB3 GCCTTTTTCACTCGGACCCA CTTCTTCCTCTCACGGTCAGC 
ERN1 GGCCTCGGGATTTTTGGAAGTA ATTGAGCCTGTCCTCTTGCTG 
DDIT3 GACCTGCAAGAGGTCCTGTC CCAGAGAAGCAGGGTCAAGA 
KDM7A CCTTCACCCCACCAAGAGAC GGACGTTTACCTTTTGTTGCCTG 
KRT14 CAGAGATGTGACCTCCTCCA CTCAGTTCTTGGTGCGAAGG 
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Table S8 Primer sequences used to validate Chromatin Immunoprecipitation 
Site Forward primer Reverse primer 
TRIB3_H3K27ac_pos GCACGCACGCCCCTTA CCGGATCAAAAGGGATCTGACC 
TRIB3_ATF4_pos GCACTGACCAGACGCCC GATCGCACCATCCCCCG 
TRIB3_neg GGAGCTGTGACGGTGATGAG AACCCACAAAGCAGGAGGAA 
ERN1_H3K27ac_pos CGCGAGCTGTCCTCCAC TGCTGCTGACGCTGCTG 
ERN1_ATF4_pos CCCAGGCACACCTACCTACT TCTGATTTGTGGTTGGCAGAAGA 
ERN1_neg GTCCACATGCTTCATGCACTTC TGCCACCATAAATAAAACCAGTGC 
DDIT3_H3K27ac_pos ATTTCCCAAGGGCAACCGA CCTATTGCTTCGGACGACGG 
DDIT3_ATF4_pos CGCTAGGGGGTCGACGTA CCTCCGTGAAGCCTCGTG 
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Akt 
AKT serine/threonine kinase 1.  
AP1 
Activator protein 1.  
ATF3 
Activating transcription factor 3.  
ATF4 
Activating transcription factor 4.  
ATF6 
Activating transcription factor 6.  
ATG5 
Autophagy related 5.  
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Adenosine triphosphate.  
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BRCA1 DNA repair associated.  
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BSA 
Bovine serum albumin.  
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Monoubiquitinated lysine 120 in histone H2B.  
H3 
Histone 3.  
H3K27 
Lysine 27 on histone 3.  
H3K27ac 
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Human concentrative nucleoside transporter 1.  
hCNT3 
Human concentrative nucleoside transporter 3.  
HDAC 
Histone deacetylase.  
HDAC4 
Histone deacetylase 4.  
hENT1 
Human equilibrative nucleoside transporter 1.  
hENT2 
Human equilibrative nucleoside transporter 2.  
HER2 
Human epidermal growth factor receptor 2.  
HIF1a 





 List of Abbreviations 
Heterochromatin protein 1.  
HSF1 
Heat shock factor 1.  
IgG 
Immunoglobulin G.  
IGV 





inhibitor of nuclear factor kappa B kinase subunit.  
ILK 
Integrin linked kinase.  
IP3 
inositol 1,4,5-triphosphate.  
IP3R 
Inositol 1,4,5-triphosphate receptor.  
IRE1 
Inositol requiring enzyme 1.  
IRF4 
Interferon regulatory factor 4.  
ISR 
Integrated stress response.  
JNK 
c-Jun N-terminal kinase.  
JUN 
Jun proto-oncogene, AP1 trtanscription factor subunit.  
KAT 
Lysine acetyltransferase.  
kb 






 List of Abbreviations 
KDM 
Lysine demethylase.  
KDM4C 
Lysine demethylase 4C.  
 
KEAP1 
Kelch-like ECH-associated protein 1.  
KLF4 
Krüppel like factor 4.  
KMT 
Lysine methyltransferase.  
K-RAS 










Microtubule associated protein 1 light chain 3 alpha.  
MAPK 
Mitogen-activated protein kinase.  
MCL-1 
MCL1 apoptosis regulator, BCL2 family member.  
MCU 









 List of Abbreviations 
MET proto-oncogene.  
 
MIEN1 




Mixed lineage leukemia complex.  
MLL3 
Mixed lineage leukemia complex 3.  
MLL4 
Mixed lineage leukemia complex 4.  
M-MuLV 
Moloney-Murine leukemia virus.  
mRNA 
Messenger RNA.  
mTOR 
Mechanistic target of rapamycin kinase.  
MYC 
MYC proto-oncogene.  
n 
Nano (10-9).  
NCLX 
Na+/Ca2+ Li+-permeable exchanger.  
NCX 
plasmalemmal sodium Na+/Ca2+ exchangers.  
NDP 
Nucleotide diphosphate.  
NDPK 
Nucleoside diphosphate kinase.  
NFAT 






 List of Abbreviations 
Nuclear factor of activated T cells 5.  
NFATc1 
Nuclear factor of activated T cells 1.  
NFATc2 
Nuclear factor of activated T cells.  
NFATc3 
Nuclear factor of activated T cells 3.  
NFATc4 
Nuclear factor of activated T cells 4.  
NF-κB 
Nuclear factor kappa B.  
NOV 
Cellular communication netwrok factor 3.  
NRF2 
Nuclear factor erythroid 2-related factor 2.  
NT 
Nucleoside transporter.  
NT5C1A 
Cytosolic 5'-nucleotidase I A.  
NTP 
Nucleotide triphosphate.  
ORAI 
calcium release-activated calcium channel.  
ORAI1 
ORAI calcium release-activated calcium modulators 1.  
ORAI2 
ORAI calcium release-activated calcium modulators 2.  
ORAI3 








 List of Abbreviations 
E1A binding protein p300 and cAMP-response element-binding CREB-binding 
protein.  
p53 
Tumor protein p53.  
padj 
P-value adjusted.  
PanIN 
Pancreatic intraepithelial neoplasm.  
Par 
Parental cell line.  
PBS 
Phosphate buffered saline.  
PD-1 
Programmed cell death protein 1.  
PDAC 
Pancreatic ductal adenocarcinoma.  
PDIA19 
DnaJ heat shock protein family (Hsp40) member C10.  
PDIA5 
Protein disulfide isomerase family A member 5.  
PDIA6 
Protein disulfide isomerase family A member 6.  
peIF2α 
Phosphorylated eukaryotic translation initiation factor 2A.  
PERK 
PKR-like ER kinase.  
PGAP3 
Post-GPI attachment to proteins phospholipase 3.  
pH 
Potentia hydrogenii.  
PIK3CA 
Phosphatidylinositol-4,5-bisphosphate 3-kinase catalytic subunit alpha.  
PIP2 




 List of Abbreviations 
PKC 
Protein kinase C.  
PLC 
Phospholipase C.  
PMCA 




Phosphorylated nuclear factor erythroid 2-related factor 2.  
PP2A 
Protein phosphatase 2A.  
PRC1 
Polycomb repressor complex 1.  
PRC2 
Polycomb repressor complex 2.  
PREX2 
Phosphatidylinositol-3,4,5-triphosphate dependent Rac exchange factor 2.  
PRRX1A 
Paired related homeobox 1a.  
PRRX1B 
Paired related homeobox 1b.  
PS 
Performance Status.  
 
PUMA 




Quantitative polymerase chain reaction.  
RACK1 





 List of Abbreviations 
Ribonucleic acid.  
RNA Pol II 
RNA Polymerase II.  
RNF20 
Ring finger protein 20.  
RNF40 
Ring finger protein 40.  
RNR 
Ribonucleotide reductase.  
ROS 
Reactive oxygen species.  
RRM1 
Ribonucleotide reductase catalytic subunit M1.  
RRM2 
Ribonucleotide reductase regulatory subunit M2.  
RRM2B 
Ribonucleotide reductase regulatory TP53 inducible subunit 2B.  
RTK 
Receptor tyrosine kinase.  
S-1 
Tegafur, gimeracil and oteracil.  
 
S1P 
Site-1 protease.  
S2P 
Site-2 protease.  
SARAF 
SOCE-associated regulatory factor.  
SD 
Standard deviation.  
SDS 






 List of Abbreviations 
SEM 




sarco/endoplasmic reticulum ATPase.  
SETD1A 
SET domain containing 1A, histone lysine methyltransferases.  
SETD1B 
SET domain containing 1B, histone lysine methyltransferases.  
SH2-domain 
Src homology 2 domain.  
siCont 
Control non-targeting siRNA.  
siRNA 
small interfering RNA.  
SMAD3 
SMAD family member 3.  
SMAD4 
SMAD family member 4.  
SNAI1 
Snail family transcriptional repressor 1.  
SOCE 
Store operated calcium entry.  
SOX9 
SRY-box transcription factor 9.  
SPARC 
Secreted protein acidic and cysteine rich.  
SQSTM1 
Sequestosome 1.  
SRF 
Serum response factor.  
STAT3 




 List of Abbreviations 
STIM 
Stromal interaction molecules.  
STIM1 
Stromal interaction molecule 1.  
STIM2 
Stromal interaction molecule 2.  
SUV39H1 
Suppressor of variegation 3-9 homolog 1.  
SUV39H2 
Suppressor of variegation 3-9 homolog 2.  
Syk 




Transcription factor.  
TGFβ 




Transmembrane and coiled-coil domains 1.  
TRAF2 
TNF receptor associated factor 2.  
TRIB3 
Tribbles pseudokinase 3.  
TRIM21 
Tripartite motif containing 21.  
TRP 
Transient receptor potential.  
TRPM4 
Transient receptor potential cation channel subfamily M member 4.  
TRPM5 




 List of Abbreviations 
TRPV5 
Transient receptor potential cation channel subfamily V member 5.  
TRPV6 
Transient receptor potential cation channel subfamily V member 6.  
TS 
Thymidylate synthase.  
TSS 
Transcriptional start site.  
TWIST 




Unfolded protein response.  
VEGF 
Vascular endothelial growth factor.  
VEGFA 
Vascular endothelial growth factor A.  
w/v 
Weight per volume.  
WEE1 
WEE1 G2 checkpoint kinase.  
XBP1 
X-box binding protein 1.  
ZEB1 
Zinc finger E-box binding homeobox 1.  
ΔNp63 
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